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The first section of this dissertation describes the synthesis of five indole-containing compounds 
used in the BoNT LC (botulinum neurotoxin light chain) SAR analysis. Our approach employs a 
Pd(II)-catalyzed cyclization for the formation of indole rings, which are subsequently converted 
to the corresponding amidines or imidazolines. 
The second section describes the extension of the indole synthesis methodology through a 
microwave assisted IMDAF (intramolecular Diels-Alder furan) reaction. This protocol allows for 
a convergent and rapid preparation of 4-mono- and 3,4-disubstituted indoles. This cascade 
process is quite tolerant of functional groups and associated substitution patterns. 
The third part we describes novel routes to the naturally occurring indole alkaloid 
cycloclavine and its unnatural C(5)-epimer. Key features include the rapid construction of the 
heterocyclic core segments by two Diels-Alder reactions. An indole annulation was 
accomplished by a late-stage IMDAF reaction, while the cyclopropa[c]indoline core of 
cycloclavine was derived through a stereoselective intramolecular [4+2] cycloaddition of a 
methylenecyclopropane. 
The fourth section describes an approach towards the total synthesis of cyclopiazonic 
acid. A promising route to this alkaloid was established, including a rapid construction of the 
tricyclic indole-containing core and a stereoselective pyrrolidinone ring formation.     
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1.0  SYNTHESIS OF BOTULINUM NEUROTOXIN A LIGHT CHAIN 
INHIBITORS 
1.1 INTRODUCTION 
Botulinum toxin (BoNT) is a neurotoxin protein produced by the microorganism Clostridium 
botulinum.1,2 Even though it is among the most toxic naturally occurring substances and the most 
toxic protein, it is used in minute amounts in the treatment of muscle spasms as well as in 
cosmetics.3,4 Furthermore, BoNTs have been recognized as potential biological weapons.5 
BoNT was first described at the beginning of the 19th century when it was found that 
some bacteria cause poisoning from poorly conserved meat products. About 80 years later, 
Clostridium botulinum was isolated and later found to play a key role in blocking neuromuscular 
transmission.6 
Seven serologically distinct toxin types have been described (designated A through G) 
with 3 subtypes of type A.1 The toxin is biosynthesized as a single-chain polypeptide of ~150 
kDa and is post-translationally cleaved to form a di-chain molecule. The two-chain polypeptide 
consists of a 100 kDa heavy chain (HC) joined by a disulfide bridge (Cys430-Cys454) to a 50 
kDa light chain (LC) (Figure 1).7 The LC acts as a zinc-dependent endopeptidase and attacks one 
of the fusion proteins at the neuromuscular junction, cleaving components of the SNARE 
complex and inhibiting acetylcholine release. The HC contains two functional domains, each of 
 2 
~50 kDa size. The N-terminal half (HN) is the translocation domain, known to form ion channels 
in lipid bilayers, whereas the C-terminal half (HC) is the ganglioside-binding domain, which has 
an important role in targeting specific axon termini and in internalizing the toxin molecules into 
cholinergic neurons. 
 
Figure 1. BoNT structure (created by PyMOL) 
Following the attachment of the HC to proteins on the surface of axon terminals, the 
toxin is absorbed into the neuron by endocytosis. The LC is then able to leave the endocytotic 
vesicles and reach the cytoplasm (Figure 2).8 Once inside, the LC proteolytically degrades 
SNARE proteins (SNARE: soluble N-ethylmaleimide-sensitive factor-attachment protein 
receptors). Each serotype of BoNT interacts with one of three SNARE proteins (BoNT/A and 
BoNT/E cleave SNAP-25 protein (25 kD synaptosomal associated protein); BoNT/B, /D, /F and 
/G: synaptobrevin; BoNT/C: SNAP-25 and syntaxin). The SNARE-complex is critical for 
 3 
directing acetylcholine vesicles toward the neuromuscular junction and the release of 
neurotransmitters. Once the SNARE-complex is destroyed, the release of neurotransmitter is 
disabled, resulting in paralysis of muscle fibers. 
 
Figure 2. Mechanism of action of botulinum neurotoxins 
(Reproduced from www.biocarta.com with permission) 
Both HC and LC inhibitors of BoNT have previously been developed.2,9 The initial step 
in BoNT poisoning is the binding of the toxin to the neuron. Thus, blocking the interaction 
between BoNT and the cellular receptor can inhibit nerve paralysis. Two approaches can be 
envisioned to accomplish the goal of antagonizing toxin-cell interactions: some molecules can 
coat the toxin and destroy the interaction with the cell receptor while others can bind directly to 
the cellular receptor, also blocking the binding of toxin. In the former case, polysialylated 
 4 
gangliosides were observed to be potential ligands for BoNT/A, while some lectines were found 
to compete with BoNT for the cellular binding site. 
The lethal effects of BoNT poisoning involve the inhibition of the synaptic signal transfer 
at the neuro-muscular junction. Upon endocytosis, the BoNT molecule undergoes a structural 
rearrangement inside the acidic compartment of the vesicle. Thus, compounds that neutralize 
acidic media can lengthen the time necessary for the protein to reach the cytosol. For example, 
the polyether ionophores nigericin and monensin were found to increase the membrane 
permeability to H+ and thus act as proton shunts neutralizing the pH gradient.10 Unfortunately, 
higher concentrations of these antibiotics also block synapses.9 It has also been shown that many 
antimalarial drugs (aminoquinolines) are effective in antagonizing the BoNT/A-induced 
neuromuscular blockade.11 
The site-specific SNARE hydrolysis is catalyzed by the BoNT/A LC, and thus another 
possibility for BoNT inhibition is to limit metalloprotease activity. Several small molecules were 
identified as inhibitors of LC metalloprotease.2 Gussio and coworkers conducted a high-
throughput screening of the National Cancer Institute Diversity Set, which provided a series of 4-
aminoquinolines and led to the identification of several potent BoNT A inhibitors (michellamine 
B (1-1), Q2-15 (1-2) and NSC 357756 (1-3); Figure 3).12 Given the presence of a critical zinc ion 
in the LC active site, it was speculated that the hydroxamate zinc-binding functionality, when 
coupled to a suitable scaffold to impart specificity, would provide potent BoNT inhibitors.9,13 
Indeed, 2,4-dichlorocinnamic hydroxamate 1-4 (Figure 3) was shown to be a good LC 
metalloprotease inhibitor.13 Further analysis identified indole based analogs 1-5 – 1-7, quinolinol 
1-8, chiral hydroxamic acid 1-9, as well as pyrrole and thiophene containing hydroxamic acids 
(1-10 and 1-11) as very potent BoNT/A LC inhibitors.14     
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Figure 3. Small molecule inhibitors of BoNT/LC 
Detailed conformational analysis together with molecular docking studies provided a 
model for a common pharmacophore for LC/A inhibitors.12,15 This pharmacophore was further 
improved by the docking study of the peptide mimic inhibitor 1-12 developed by Schmidt and 
coworkers (Figure 4).16 Comparing to the previous pharmacophore A, the newly proposed 
pharmacophore B contains two new components (F and G). This hypothesis revealed several 
new hits in NCI’s Open Repository, which were assayed against LC/A. Among the four 
 6 
pharmacophore components (A-C and F), which were occupied by the most potent inhibitors 
shown in Figure 5, component C was proposed to wedge between the side chain phenyls of Phe-
162 and Phe-193. Component F was believed to be involved in hydrogen bonding with Glu-54 
and Glu-63 of LC/A. While NCSs 341909 and 308574 (1-13 and 1-14, respectively, Figure 6) 
showed cytotoxicity in concentrations as low as 1-5 µM, NCS 240898 (1-5) was well tolerated at 
concentrations as high as 40 µM. Furthermore, 1-5 showed dose-dependent protection of SNAP-
25 cleavage. Thus, it was chosen as a lead for a structure-activity relationship (SAR) study, with 
the goal to find a more potent LC/A inhibitor. 
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Figure 4. Proposed new pharmacophore model for LC/A 
A: Components A and B represent two planar moieties, one of which contains heteroatom; C and D are two 
hydrophobic substituents, E is a positive ionizable substituent. B: The peptide mimic inhibitor (2-mercapto-3-
phenylpropionyl-RATKML) was mapped to the common pharmacophore A. Components F and G represent 
potential new binding sites (distance unit: Å). C: for comparison, 1-2 (Q2-15) mapped to the common 
pharmacophore. (Reproduced with permission from the American Society for Biochemistry and Molecular Biology: 
this research was originally published in the Journal of Biological Chemistry. Burnett, J. C. et al. Inhibition of 
Metalloprotease of Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule that is Active 
in Primary Neurons. The Journal of Biological Chemistry. 2007; 282:5004-5014. © the American Society for 
Biochemistry and Molecuar Biology.) 
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Figure 5. Non-peptidic BoNT/A LC inhibitors: Ki values and query mappings 
1 = distances taken from planar centroids; 2 = total length of the compounds 
(Reproduced with permission from the American Society for Biochemistry and Molecular Biology: this research 
was originally published in the Journal of Biological Chemistry. Burnett, J. C. et al. Inhibition of Metalloprotease of 
Botulinum Serotype A from a Pseudo-peptide Binding Mode to a Small Molecule that is Active in Primary Neurons. 
The Journal of Biological Chemistry. 2007; 282:5004-5014. © the American Society for Biochemistry and 
Molecuar Biology.) 
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Figure 6. Structures of proposed BoNT/A LC inhibitors 
 9 
1.2 RESULTS AND DISCUSION 
1.2.1 BoNT/A LC Inhibitor Library Design 
Compound 1-5 (NCS 240898) and its nitrogen analog 1-16 (NCS 377363, Figure 7) both 
exhibited 70-75% inhibition of BoNT/A LC activity at 20 µM concentration of P[167-206], the 
carboxy-terminal 40 residues of SNAP-25. It was hypothesized that it would be possible to 
improve this inhibitory activity further by modifications of the aromatic backbone: introducing 
either an indole (compounds 1-17 – 1-20, Figure 7), with amidine or imidazoline functionalities 
at position 5 or 6, or a thiooxadiazole moiety (1-21). Based on this information, the Wipf group 
decided to investigate the structure-activity relationship (SAR) of indole amidine type BoNT/A 
inhibitors and ultimately to identify more potent compounds using 1-5 and 1-16 as lead 
structures. 
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Figure 7. Proposed BoNT/A LC inhibitors and synthetic targets for SAR 
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1.2.2 First Generation Approach toward Analogs 1-17 – 1-20  
The general features of our initial synthesis are illustrated in retrosynthetic format in Scheme 1. 
Although the structure of compounds 1-17 – 1-20 is quite simple, an important initial design clue 
for synthetic routes toward their polyaromatic framework was provided by the fact that amidine 
or imidazoline derivatives can be obtained from the corresponding nitriles,17,18 thus having 
compounds 1-22 and 1-23 as their synthetic precursors. In the forward direction, treating nitriles 
1-22 and 1-23 with hydrochloric acid in ethanol followed by treatment of the intermediate 
imidates with either ethylenediamine in the presence of catalytic amounts of sulfur or gaseous 
ammonia would be expected to afford the desired imidazolines or amidines, respectively. 
N
H
N
H
R1
R2
1-17: R1 = Am, R2 = H
1-18: R1 = H, R2 = Am
1-19: R1 = Im, R2 = H
1-20: R1 = H, R2 = Im
N
H
N
H
R3
R4
1-22: R3 = CN, R4 = H
1-23: R3 = H, R4 = CN
Pd(II) assisted cyclization
N
H H2N
R3
R4
1-24: R3 = CN, R4 = H
1-25: R3 = H, R4 = CN
N
H H2N
R3
R4I+
1-26 1-27: R3 = CN, R4 = H
1-28: R3 = H, R4 = CN
N
H
CHO
FGI
CHO
NH2
NH2
CHOBr
+
Sonogashira coupling
Pd(II) assisted cyclization
Sonogashira coupling
1-29 1-30
1-31
1-32  
Scheme 1. Retrosynthetic analysis in the first generation approach 
The synthetic challenge was now reduced to the preparation of intermediates 1-22 and 1-
23. Although a large variety of methods for indole synthesis are known,19,20 we decided to install 
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these heterocycles in two separate steps by a Sonogashira coupling followed by a Pd(II)-
mediated cyclization. Retrosynthetic cleavage of the more substituted indole led us to 
intermediates 1-24 and 1-25, which could easily be prepared from commercially available 
aminoiodobenzonitriles 1-27 and 1-28. Through standard functional group manipulations, it is 
conceivable that intermediate alkyne 1-26 could be derived from aldehyde 1-29. Another 
sequence of Sonogashira coupling-Pd(II)-assisted cyclization led to the commercially available 
p-bromobenzaldehyde (1-31) and aminoalkyne 1-32.  
Based on the retrosynthetic analysis presented above, the synthesis of compounds 1-17 – 
1-20 commenced with the preparation of the intermediate 1-32 through a Sonogashira reaction 
using 2-iodoaniline (1-33) and TMS-protected acetylene 1-34 as starting materials (Scheme 2). 
The intermediate 1-35 was deprotected in a subsequent step and provided the aminoalkyne 1-32 
in 88% overall yield.21 When a solution of aminoalkyne 1-32, 
bis(triphenylphosphino)palladium(II) chloride and cuprous iodide in acetonitrile was treated with 
p-bromobenzaldehyde, intermediate 1-30 was formed in only 10% yield. We believe that the 
initial reaction of unprotected aniline 1-32 and p-bromobenzaldehyde is faster and thus 
suppresses the Sonogashira coupling. 
I
NH2
TMS+
1-33 1-34
Pd(PPh3)2Cl2 (2 mol%)
CuI (20 mol%), Et3N
CH3CN, rt; 96%
NH2
TMS
1-35
K2CO3, CH3OH
rt; 92%
NH2
1-32
Br CHO
Pd(PPh3)2Cl2 (5 mol%)
CuI (20 mol%), Et3N
CH3CN, rt to 70 °C; 10%
CHO
NH2
1-30  
Scheme 2. Synthesis of the intermediate 1-30 
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During the course of the synthesis of aldehyde 1-29, we turned our attention to a well 
documented one-pot reaction for installing indole moiety.22,23 Subjecting N-acylated aniline 1-36 
and alkyne 1-37 to Sonogashira reaction conditions should in principle give the N-
acylatedaminoalkyne, which subsequently undergoes intramolecular cyclization resulting in N-
acylated indole formation (Scheme 3).24  Unfortunately, instead of leading to the desired indole 
1-29, the reaction was very sluggish and only decomposition of the starting material was 
observed upon heating the reaction mixture at 80 °C. 
I
NH2
1-33
AcCl, Et3N
Et2O
0 °C to rt; 95%
I
NHAc
1-36
CHO
1-37
Pd(PPh3)2Cl2 (5 mol%)
CuI (10 mol%), TMG
dioxane, 80 °C
X
N
H
CHO
1-29  
Scheme 3. Attempted domino copper-catalyzed indole formation 
Surmising that a more acidic N-H bond might favor the cyclization reaction generating, 
under basic conditions, a stronger nitrogen nucleophile, Cacchi and coworkers recently described 
a similar strategy for domino indole formation using N-trifluoroacetyl protected 2-iodoanilines 
(Scheme 4).25 
I
NHC(O)CF3
[Cu(phen)(PPh3)2]NO3 (10 mol%)
CuI (5 mol%), K3PO4
toluene, 110 °C; 57-96%
N
H
Ar
Ar
 
Scheme 4. 2-Arylindole formation from o-iodotrifluoroacetanilide 
Treating o-iodotrifluoroacetanilide 1-38 with alkyne 1-37 in toluene, using cuprous 
iodide and triphenylphosphine in the presence of K3PO4, furnished aldehyde 1-29 in 74% yield 
(Scheme 5). 
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I
NH2
1-33
(CF3CO)2O, Et3N
THF, -15 °C to rt; 91%
I
NHC(O)CF3
1-38
CHO
1-37
CuI (25 mol%)
Ph3P, K3PO4
toluene, 110 °C
74%
N
H
CHO
1-29
 
Scheme 5. Tandem copper-catalyzed Sonogashira reaction-indole formation 
Initial attempts to convert 1-29 to the corresponding alkyne using Corey-Fuchs 
homologation26,27 led to 3-bromo-substituted indole 1-39, suggesting that perhaps the bromine, 
generated in situ, acted as an excellent electrophile (Scheme 6). 
N
H
CHO
1-29
CBr4, PPh3
Et3N, CH2Cl2
0 °C to rt
N
H
Br
Br
Br
Br
N
H
1-39
Br
Br
Br
O
P(OCH3)2
O
N2
K2CO3, CH3OH
10%
N
H
1-26
 
Scheme 6. Functionalization of aldehyde 1-29 
In contrast, subjecting aldehyde 1-29 to the Ohira-Bestmann modification of the 
Seyferth-Gilbert reaction conditions led to only a 10% isolated yield of the desired alkyne 1-26.28 
However, using N-Boc-protected indole in the Ohira-Bestmann reaction furnished alkyne 1-40 in 
a good yield (Scheme 7). 
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N
H
CHO
1-29
1. Boc2O, pyr, DMAP
    THF, rt; 98%
2. K2CO3, CH3OH; 82%
O
P(OCH3)2
O
N2
N
Boc
1-40
 
Scheme 7. Synthesis of intermediate 1-40 
For the attachment of the second indole fragment, alkyne 1-40 was treated with 3-iodo-4-
trifluoroacetamidobenzonitrile 1-41 under Sonogashira conditions to provide directly the desired 
cyclized product 1-42, albeit in modest yield (Scheme 8). Interestingly, while alkyne 1-40 
smoothly cyclized under Sonogashira reaction conditions, the previously attempted reaction 
between iodoaniline 1-36 and alkyne 1-37 (Scheme 3) was very sluggish. Importantly, the 
installation of the cyano group increased the acidity of the p-acetamide, considerably influencing 
the cyclization reaction. 
N
Boc
1-40
I
F3C(O)CHN
CN
1-41
Pd(PPh3)2Cl2 (6 mol%)
CuI (9 mol%), Et3N
THF, 60 °C; 42%
N
Boc
N
H
CN
1-42  
Scheme 8. Synthesis of bis-indole 1-42 
During the planning stages of this synthesis, the task of removing the Boc-protecting 
group in 1-42 was not anticipated to be problematic. Unfortunately, the seemingly 
straightforward deprotection of 1-42 proved to be a very difficult transformation. Many of the 
conventional protocols, including TFA in THF,29 TFA (neat),29 TFA/thioanisole,30 
NaOMe/MeOH,31 TMSI,32 led to decomposition of the starting material, or in the case of  
thermal deprotection with SiO2 under high vacuum33 to a very small conversion (10%). 
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1.2.3 Second Generation Approach towards Analogs 1-17 – 1-20 
Encouraged by our success in the palladium (II)-assisted indole cyclization, we turned our 
attention to a related approach that bypassed an indole protection/deprotection step. We planned 
to achieve the construction of both indoles in a single step. Thus, our goal was to synthesize a 
bis-alkyne intermediate with two amino groups in ortho-positions, enabling a tandem metal-
assisted cyclization. 
As shown in the retrosynthetic analysis (Scheme 9), our modified approach commenced 
with a cleavage of the bis-indole motif in nitriles 1-22 and 1-23, providing the bis-aminoalkynes 
1-43 and 1-44.34 These intermediates could be constructed through a double Sonogashira 
coupling, starting with p-(trimethylsilylethynyl)phenylacetylene 1-45.35 
N
H
N
H
R1
R2
1-17: R1 = Am, R2 = H
1-18: R1 = H, R2 = Am
1-19: R1 = Im, R2 = H
1-20: R1 = H, R2 = Im
N
H
N
H
R3
R4
1-22: R3 = CN, R4 = H
1-23: R3 = H, R4 = CN
Pd(II) assisted cyclization
NH2 H2N
R4
R3
1-43: R3 = CN, R4 = H
1-44: R3 = H, R4 = CN
NH2 H2N
R4
R3
I+
1-27: R3 = CN, R4 = H
1-28: R3 = H, R4 = CN
1-46
NH2
I + TMS
1-45
Sonogashira coupling Sonogashira coupling
 
Scheme 9. Second-generation approach: retrosynthetic analysis 
The second-generation approach towards BoNT LC inhibitors 1-17 – 1-20 commenced 
with the exploration of the literature protocol for the essential building block 1-45 from either 
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1,4-diiodobenzene or 1,4-dibromobenzene through a sequence of two Sonogashira reactions and 
the subsequent elimination of acetone (Scheme 10).35 
X X
Pd(PPh3)2Cl2 (1 mol%)
CuI (0.1 mol%), Et3N
70 °C
OH
X
OH
1-47: X = Br, 42%
1-48: X = I, 48%
TMS
Pd(PPh3)2Cl2 (10 mol%)
CuI (1 mol%), Et3N,
THF, rt
TMS
OH
1-49: from 1-47, 76%
         from 1-48, 98%
TMS
1-45
NaOH (0.1 equiv)
toluene, 110 °C
96%
 
Scheme 10. Synthesis of building block 1-45 
Fragment 1-45 was subsequently coupled with 2-iodoaniline under Sonogashira reaction 
conditions in acetonitrile to afford intermediate 1-50 (Scheme 11). Upon treatment of 1-50 with 
K2CO3 in methanol, the terminal alkyne was deprotected, furnishing 1-46, which set the stage to 
introduce the cyano-substituted benzene. Treatment of 1-46 with regioisomeric benzonitriles 1-
27 and 1-28 provided the bis-aminoalkynes 1-43 and 1-44 in 88% and 95% yield, respectively. 
Exposure of 1-43 and 1-44 to 20 mol% of bis(benzonitrile)palladium(II) chloride in DMF at 80 
°C provided 1-22 and 1-23 in 79% and 54% yield, respectively.36 
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TMS
1-45
NH2
I
Pd(PPh3)2Cl2 (5 mol%)
CuI (10 mol%), Et3N
CH3CN, 82 °C; 40%
NH2
TMS
1-50
K2CO3
CH3OH
rt; 60%
NH2
1-46
Pd(PPh3)2Cl2 (5 mol%)
CuI (10 mol%), Et3N
CH3CN, 82 °C
H2N
R4
R3
I
1-27: R3 = CN, R4 = H
1-28: R3 = H, R4 = CN
NH2 H2N
R4
R3
1-43: R3 = CN, R4 = H; 88%
1-44: R3 = H, R4 = CN; 95%
Pd(PhCN)2Cl2 (20 mol%)
DMF, 80 °C N
H
N
H
R3
R4
1-22: R3 = CN, R4 = H; 79%
1-23: R3 = H, R4 = CN; 54%  
Scheme 11. Synthesis of advanced intermediates 1-22 and 1-23 
 In order to convert bis-indole building blocks into the corresponding amidines (1-17, 1-
18) or imidazolines (1-19, 1-20; Scheme 12), the nitriles were treated with gaseous HCl in 
ethanol at room temperature for 24 h, furnishing the imidate esters.17 These intermediates were 
not isolated, but by treatment with gaseous ammonia in ethanol, they were directly converted to 
the corresponding amidines 1-17 and 1-18.17,37  
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H
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H
N
H
NH
NH2
1-17
N
H
N
H1-19
N
H
N
1. HCl, EtOH
2. NH3, EtOH
61% (overall)
ethylenediamine
S8, µW; 56%
N
H
N
H
N
H
N
H1-18
N
H
N
H1-20
1. HCl, EtOH
2. NH3, EtOH
39% (overall)
ethylenediamine
S8, µW; 47%
CN
NH
NH2
N
H
N
1-22
1-23
 
Scheme 12. Completion of synthesis of BoNT/A LC inhibitors 1-17 - 1-20 
Among several methods described in literature for imidazoline preparation from the 
corresponding nitriles,38-41 we focused our attention on the reaction with ethylenediamine in the 
presence of elemental sulfur, because of both the simplicity of the method and the easy work-up 
procedure. Accordingly, nitriles 1-22 and 1-23 were converted to imidazolines 1-19 and 1-20 
under microwave conditions in 56% and 47% yield, respectively.18 
1.2.4 Synthesis of a Thiooxooxadiazole Analog 1-21 
As mentioned previously, the BoNT LC contains a Zn2+ ion in its active site, which is shown to 
be critical for its proper function. In order to make a suitable inhibitor of BoNT toxin, one can 
imagine that binding a Zn2+ ion by a small molecule would impact the catalytic activity of the 
toxin. Accordingly, we hoped that installing the thioxooxadiazole fragment onto an indole 
scaffold, together with an amidine subunit, would provide a potent BoNT inhibitor. The 
thioxooxadiazole fragment, possessing a soft sulfur atom, was considered to interact with the soft 
Zn2+ ion, thus diminishing the BoNT activity.42 
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With the goal of introducing the amidine function at the last stage of our synthesis, the 
direct precursor to compound 1-21 was nitrile 1-51 (Scheme 13). The synthesis of the 
thioxooxadiazole was known43 and thus the conversion of 1-51 into 1-21 was considered to be a 
feasible process. Subsequent functional group manipulation should lead to intermediate ester 1-
52. For 1-52, the retrosynthetic disconnections mirror those applied to the synthesis of analogs 1-
17–1-20. 
N
H
O
1-21
O
NHN
S
NH
H2N
amidine 
formation
thiooxooxadiazole
synthesis
N
H
O
1-51
O
NH2HN
NC
N
H
O
1-52
CO2Et
NC
indole
synthesis
NH2
O
CO2Et
NC
1-53
Sonogashira
coupling
O
CO2Et
NH2
NC I +
1-28 1-54
I OHTMS + +
Sonogashira
coupling
Br
CO2Et
 
Scheme 13. Retrosynthetic analysis of 1-21 
The synthesis of thioxooxadiazole analog 1-21 (Scheme 14) commenced with O-
alkylation of the commercially available 4-iodophenol with ethyl bromoacetate in the presence of 
NaI and K2CO3, providing ether 1-55 in 63% yield. A Sonogashira reaction with TMS-protected 
acetylene, followed by K2CO3 mediated cleavage of the TMS group, afforded 1-54 in 60% 
overall yield. A second Sonogashira coupling provided intermediate 1-53 in quantitative yield. 
The Pd(II)-mediated indole cyclization furnished the intermediate 1-52, with both nitrile and 
ester functionalities, which were to be converted to amidine and thioxooxadiazole motifs, 
respectively. 
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The thioxooxadiazole ring was readily synthesized by a two-step protocol. Conversion of 
the ester into the corresponding hydrazide 1-51 was achieved through a reaction with hydrazine 
monohydrate44 followed by a cyclization in DMSO using carbon disulfide, providing 
intermediate 1-56 in 80% overall yield.43 The construction of the final amidine was 
accomplished by a two-step procedure: formation of the imidate ester and subsequent conversion 
to the amidine. Upon treating the intermediate imidate ester with gaseous ammonia in ethanol, 
target compound 1-21 was obtained in 56% overall yield from 1-56. 
Br
CO2Et
I OH
K2CO3, NaI
3-pentanone
63%
O
CO2Et
I
1-55
1. TMS-acetylene
    Pd(PPh3)2Cl2 (5 mol%)
    CuI (10 mol%)
    Et3N, THF
2. K2CO3, MeOH
    60% (overall)
O
CO2Et
1-54
Pd(PPh3)2Cl2 (5 mol%)
CuI (10 mol%), Et3N
CH3CN; 100%
NH2
NC I
1-28
NH2
O
CO2Et
NC
1-53
N
H
O
1-52
CO2Et
NC
Pd(PhCN)2Cl2 (20 mol%)
DMF, 80 °C; 63%
1. N2H4•H2O, EtOH
2. CS2, KOH, MeOH
    DMSO; 80% (overall) NH
O
1-56
O
NHN
S
NC
1. HCl, EtOH
2. NH3, EtOH
56% (overall)
N
H
O
1-21
O
NHN
S
NH
H2N
 
Scheme 14. Synthesis of analog 1-21 
1.2.5 Biological Evaluation of Analogs 1-19 – 1-21 
Biological evaluation42 of compounds 1-19 – 1-21 and their comparison with other 
analogs previously synthesized in our group2 revealed interesting binding properties. According 
 21 
to the binding hypothesis, a 3-zone pharmacophore model was developed by Nuss and Bavari.45 
The zones can be defined as such: 
Zone 1 is an aromatic planar component and one component of positive charge. 
Zone 2 is also an aromatic planar component and a second component of positive charge. 
Zone 3 is an aromatic planar component, which is hypothesized to occupy the BoNT/A 
LC S1’ site, and is linked to the positively charged component of Zone 2 by a methylene tether. 
Results from in vitro testing of mono-imidazoline analogs 1-19 and 1-20 (at 20 M 
concentration) indicated 26.6 (± 5.8)% and 27.4 (± 8.5)% inhibition, respectively. With respect 
to the 3-Zone pharmacophore (Figure 8), neither compound possesses the Zone 2 cationic 
charge. Moreover, neither compound occupies Zone 3. 
N
H
N
H
1-19
N
H
N
Zone 2 Zone 1Zone 3
No Zone 2 positive ionizable component
Missing Zone 3 The positive-ionizale component
is in an unfavorable position
N
H
N
H
1-20
N
H
N
Zone 2 Zone 1Zone 3
Missing Zone 3
No Zone 2 positive ionizable component
 
Figure 8. 3-Zone pharmacophore model for compounds 1-19 and 1-20 
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Compound 1-21, a fragment of NCS240898 containing a 5-thioxo-4,5-dihydro-1,3,4-
oxadiazole (thioxooxadiazole) component, contains sulfur which might coordinate the Zn2+ ion. 
However, Zn2+ coordination with a constrained thioxooxadiazole ring is not trivial given the very 
narrow geometric window required for the Zn-S coordinate bond (distance approx. = 2.3 Å, and 
angle approx. = 106 - 109°).45 No activity was observed for this compound even at 20 M 
concentration. According to the 3-Zone pharmacophore (Figure 9), the sulfur atom of the 
thioxooxadiazole ring is unable to interact with the Zn2+ ion within the defined geometric 
parameters. Other factors that are likely contributing to the inactivity of this compound include 
no Zone 2 positive charge and the absence of a Zone 3 component. 
N
H
O
1-15
O
HN N
S
NH
NH2
Zone 2 Zone 1Zone 3
No Zone 3 component
No Zone 2 positive ionizable component
Zn2+
Zone 2A
 
Figure 9. 3-Zone pharmacophore model for compound 1-21  
(Zone 2A added to indicate the necessary position of the Zn2+ coordinating substituent) 
1.3 CONCLUSIONS 
On the basis of a BoNT SAR analysis, we synthesized analogs 1-17 – 1-21, employing a Pd(II) 
catalyzed cyclization for the formation of indole rings. Cyclization of both indole rings in 
analogs 1-17 – 1-20 (second generation approach mentioned above) offers an elegant access to 
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the bis-indole core containing two differently substituted indole rings. Amidines 1-17, 1-18 and 
1-21, as well as imidazolines 1-19 and 1-20, were derived from the corresponding nitriles. No 
activity of the nitriles 1-22 and 1-23 was observed, suggesting that a strongly basic amidine or 
imidazoline moiety is indeed required, either for hydrogen-bonding or ionic interactions with the 
receptor site at the BoNT A LC.2 Finally, the absence of activity after the introduction of the 
thioxooxadiazole moiety (analog 1-21) through a phenyloxymethylene linker at position 2 on the 
indole ring implies that the binding event is probably highly directional. 
1.4 EXPERIMENTAL PART 
General: All moisture-sensitive reactions were performed under an atmosphere of N2. Glassware 
was flame dried prior to use. Reactions carried out at -78 °C employed a dry ice/acetone bath. 
THF and Et2O were dried by distillation over Na/benzophenone ketyl, Et3N was distilled from 
CaH2, and CH2Cl2 and toluene were purified using an alumina filtration system. Unless 
otherwise stated, solvents and reagents were used as received. Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F254 plates (250 m layer thickness, 
particle size 0.040-0.055 mm, 230-240 mesh) and visualization was accomplished with a 254 nm 
UV light and/or by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 
95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of 
conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O244H2O and 0.2 
g of Ce(SO4)2 in 100 mL of a 3.5 M H2SO4 solution), or a KMnO4 solution (1.5 g of KMnO4 and 
1.5 g of K2CO3 in 100 mL of a 0.1 % NaOH solution). Flash chromatography on SiO2 was used 
to separate and purify the reaction crude mixtures. Microwave reactions were performed on a 
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Biotage Initiator microwave reactor. 1H and 13C NMR were recorded on a Bruker Avance 300 
instrument. Chemical shifts () were reported in parts per million with the residual solvent peak 
used as an internal standard. 1H NMR spectra were run at 300, 400 or 500 MHz, and are 
tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, sept = septet, 
m = multiplet, br = broad, app = apparent), number of protons, and coupling constant(s). 13C 
NMR were obtained using a proton-decoupled pulse sequence with a d1 of 3 sec, and are 
tabulated by observed peak. LC/MS analyses were obtained from a Helwett Packard Series 1100 
MSD. RP HPLC was performed on a Gilson Series 215, using C18 column, Bio-rad 
Laboratories, 250 x 4.6 mm. Mass spectra were obtained on a Micromass Autospec double 
focusing instrument. Infrared spectra were measured on a Nicolet AVATAR 360 FT-IR E.S.P. 
spectrometer (KBr or neat) or Smiths Detection IdentifyIR FT-IR spectrometer (ATR). 
N
H
N
H
NH
NH2
 
2-(4-(1H-Indol-2-yl)phenyl)-1H-indole-5-carboximidamide (1-17). A suspension of nitrile 1-
22 (5.0 mg, 0.015 mmol) in ethanol (0.1 mL) was treated with gaseous HCl for 20 min at room 
temperature, and the mixture was stirred for 3 d. The solvent was removed under reduced 
pressure to afford crude imidate ester, which was used directly in the next step. A suspension of 
the intermediate imidate ester (6.0 mg, 0.015 mmol) in ethanol (0.5 mL) was cooled to 0 °C and 
treated with gaseous ammonia for 20 min. The solution was stirred for 24 h at room temperature. 
Solvent was removed under reduced pressure and the solid material was purified on RP HPLC 
(C18 column, acetonitrile/1% TFA in water, 7/3), and recrystalized from MeOH, which afforded 
1-17 (3.2 mg, 61% overall yield) as a yellow solid: Mp 198-203 °C (decomp.); IR (ATR) 3410, 
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3127, 1660, 1446, 788 cm-1; 1H NMR (300 MHz, MeOD)  8.10 (d, 1 H, J = 1.2 Hz), 7.89 (app 
s, 4 H), 7.59 (d, 1 H, J = 8.7 Hz), 7.54 (d, 1 H, J = 8.7 Hz), 7.53 (d, 1 H, J = 8.4 Hz), 7.38 (d, 1 H 
J = 8.1 Hz), 7.09 (dt, 1 H, J = 7.2, 1.2 Hz), 7.04 (s, 1 H), 6.99 (t, 1 H, J = 6.9 Hz), 6.87 (s, 1 H); 
13C NMR (75 MHz, MeOD)  140.8, 140.6, 137.7, 137.2, 132.7, 130.2, 129.2, 125.5, 125.2, 
121.6, 120.8, 120.3, 119.9, 119.2, 118.6, 11.5, 110.7, 99.5, 98.9; MS (ESI) m/z 350 ([M+H]+, 9), 
333 (100); HRMS (ESI) m/z calcd for C23H18N4 [M+H]+ 350.1531, found 350.1530. 
N
H
N
H
NH
NH2
 
2-(4-(1H-Indol-2-yl)phenyl)-1H-indole-6-carboximidamide (1-18). A suspension of nitrile 1-
23 (26.3 mg, 0.0750 mmol) in ethanol (1.0 mL) was treated with gaseous HCl for 10 min at room 
temperature and the mixture was stirred for 24 h. The solvent was removed under reduced 
pressure to afford crude imidate ester, which was used directly in the next step. A suspension of 
the intermediate imidate ester in ethanol (1.0 mL) was cooled to 0 °C and treated with gaseous 
ammonia for 10 min. The solution was stirred for 24 h at room temperature. Solvent was 
removed under reduced pressure and the solid material was purified on RP HPLC (C18 column, 
acetonitrile/1% TFA in water, 7/3), and recrystalized from MeOH, which afforded 1-18 (10.7 
mg, 39% overall yield) as a yellow solid: Mp 198 °C (decomp.); IR (ATR) 3425, 3285, 2218, 
1452, 1301, 822 cm-1; 1H NMR (300 MHz, MeOD)  7.92-7.88 (m, 5 H), 7.73 (d, 1 H, J = 8.4 
Hz), 7.54 (d, 1 H, J = 7.8 Hz), 7.44 (dd, 1 H, J = 8.4, 1.8 Hz), 7.40 (d, 1 H J = 8.4 Hz), 7.10 (dt, 
1 H, J = 6.9, 0.9 Hz), 7.02 (s, 1 H), 7.00 (t, 1 H, J = 6.9 Hz), 6.89 (s, 1 H); 13C NMR (75 MHz, 
MeOD)  144.2, 139.3, 138.7, 138.2, 135.5, 134.5, 131.7, 130.7, 127.4, 126.8, 123.2, 122.0, 
121.4, 120.8, 119.8, 112.8, 112.3, 100.7, 100.6; MS (TOF MS ESI) m/z 351 [M+H]+ (100), 334 
(8); HRMS (TOF MS ESI) m/z calcd for C23H18N4 [M+H]+ 351.1610, found 351.1592. 
 26 
N
H
N
H
N
H
N
 
2-(4-(1H-Indol-2-yl)phenyl)-5-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole (1-19). To a 
solution of nitrile 1-22 (5.7 mg, 0.017 mmol) in ethylenediamine (2.0 mL) was added sulfur (0.9 
mg, 0.03 mmol) and the reaction mixture was heated in the microwave for 20 min at 130 °C. To 
the reaction mixture was added water and the precipitate was filtered through a Buchner funnel, 
and rinsed with water (3 x 5 mL). The solid residue was purified by RP HPLC (C18 column, 
acetonitrile/1% TFA in water, 7/3) to afford 1-19 (3.6 mg, 56%) as a yellow solid: Mp 198-201 
°C (decomp.); IR (neat) 3413, 3221, 2927, 1598, 1442, 1301, 792 cm-1; 1H NMR (300 MHz, 
DMSO-d6)  12.26 (s, 1 H), 11.61 (s, 1 H), 10.29 (s, 1 H), 8.26 (s, 1 H), 8.00-8.03 (m, 4 H), 7.66, 
7.62 (AB, 2 H, J = 8.1), 7.54 (d, 1 H, J = 7.5 Hz), 7.41 (d, 1 H, J = 8.1 Hz), 7.23 (s, 1 H), 7.11 (t, 
1 H, J = 7.2 Hz), 7.01-7.07 (m, 2 H), 4.01 (s, 4 H); 13C NMR (75 MHz, DMSO-d6)  165.9, 
140.3, 140.2, 137.3, 137.0, 131.9, 129.8, 128.6, 128.4, 125.8, 125.4, 121.8, 121.2, 120.1, 119.5, 
113.0, 112.0, 111.3, 100.0, 99.3, 44.2; MS (TOF MS ESI) m/z 377 [M+H]+ (100), 365 (8), 139 
(10); HRMS (TOF MS ESI) m/z calcd for C25H20N4 [M+H]+ 377.1766, found 377.1774. 
N
H
N
H
N
H
N
 
2-(4-(1H-Indol-2-yl)phenyl)-6-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole (1-20). To a 
solution of nitrile 1-23 (25.0 mg, 0.0660 mmol) in ethylenediamine (2.0 mL) was added sulfur 
(1.0 mg, 0.028 mmol). The reaction mixture was heated in a microwave reactor for 30 min at 130 
°C. To the reaction mixture was added water, and the precipitate was filtered through a Buchner 
funnel and rinsed with water (3 x 5 mL). The solid residue was dried in vacuo to afford 1-20 
(10.2 mg, 47%) as a yellow solid: Mp 197.6-198.3 C (decomp.); IR (KBr) 3421, 2925, 2360, 
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2340, 1601, 1451, 790 cm-1; 1H NMR (300 MHz, DMSO-d6)  11.84 (s, 1 H), 11.60 (s, 1 H), 
7.99 (app s, 4 H), 7.91 (s, 1 H), 7.50-7.60 (m, 3 H), 7.42 (d, 1 H, J = 7.8 Hz), 7.12 (t, 1 H, J = 7.2 
Hz), 6.96-7.07 (m, 3 H), 3.67 (s, 4 H); 13C NMR (75 MHz, DMSO-d6)  165.5, 141.5, 137.3, 
137.0, 136.3, 132.3, 131.9, 130.0, 128.6, 126.1, 125.4, 121.8, 120.1, 119.5, 119.1, 111.7, 111.3, 
99.5, 99.3, 45.8; MS (TOF MS ESI) m/z 377 ([M+H]+, 100), 290 (14); HRMS (TOF MS ESI) 
m/z calcd for C25H20N4 [M+H]+ 377.1766, found 377.1766. 
N
H
O O
NHN
S
NH
H2N
 
2-(4-((5-Thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methoxy)phenyl)-1H-indole-6-carboximi-
damide (1-21). A suspension of nitrile 1-56 (7.5 mg, 0.021 mmol) in ethanol (0.5 mL) was 
treated with gaseous HCl for 10 min at room temperature and the mixture was stirred for 24 h. 
The solvent was removed under reduced pressure to afford crude imidate ester, which was used 
directly in the next step. A suspension of the intermediate imidate ester in ethanol (0.2 mL) was 
treated with gaseous ammonia for 10 min. The solution was stirred for 24 h at room temperature. 
Solvent was removed under reduced pressure and the solid material was purified on RP HPLC 
(C18 column, acetonitrile/1% TFA in water, 7/3), and recrystalized from MeOH, which afforded 
1-21 (4.2 mg, 56% overall yield) as a yellow solid: Mp 232-234 °C (decomp.); IR (ATR) 3351, 
3086, 3030, 1660, 1606, 1455, 1124, 1312 cm-1; 1H NMR (300 MHz, DMSO-d6)  12.07 (bs, 1 
H), 9.19 (bs, 2 H), 8.63 (bs, 2 H), 7.89 (d, 2 H, J = 8.7 Hz), 7.86 (s, 1 H), 7.70 (d, 1 H, J = 8.4 
Hz), 7.42 (d, 1 H, J = 8.4 Hz), 7.19 (d, 2 H, J = 8.7), 6.97 (s, 1 H), 5.13 (s, 2 H); 13C NMR (75 
MHz, DMSO-d6)  166.3, 157.9, 142.1, 135.9, 133.0, 127.1, 124.4, 119.9, 119.6, 118.8, 115.4, 
111.8, 98.3, 59.9. 
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2-(4-(1H-Indol-2-yl)phenyl)-1H-indole-5-carbonitrile (1-22). To a solution of 1-43 (15.0 mg, 
0.0450 mmol) in DMF (0.5 mL) was added Pd(PhCN)2Cl2 (3.4 mg, 0.0088 mmol). The mixture 
was heated to 80 C for 30 min, cooled to room temperature, treated with water (1 mL), and 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (1 x 20 
mL), brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (50% THF/hexanes) afforded 1-22 (11.8 mg, 79%) as a yellow solid: 
Mp 198 C (decomp.); IR (KBr) 3432, 2220, 1616, 790 cm-1; 1H NMR (300 MHz, acetone-d6)  
11.28 (bs, 1 H), 10.75 (bs, 1 H), 8.05 (s, 1 H), 8.00 (app s, 4 H), 7.61 (d, 1 H, J = 8.4 Hz), 7.59 
(d, 1 H, J = 8.1 Hz), 7.44 (d, 1 H, J = 8.4 Hz), 7.43 (d, 1 H, J = 8.1 Hz), 7.16-7.06 (m, 2 H), 
7.01-6.92 (m, 2 H); 13C NMR (75 MHz, acetone-d6)  139.9, 138.9, 137.3, 137.0, 131.8, 129.8, 
128.6, 128.4, 125.8, 125.4, 124.3, 121.8, 120.7, 120.1, 119.5, 112.4, 111.3, 101.5, 99.4, 99.3; MS 
(EI) m/z 333 (M•+, 100), 262 (67), 183 (53), 68 (37); HRMS (EI) m/z calcd for C23H15N3 
333.1266, found 333.1276. 
N
H
N
H CN  
2-(4-(1H-Indol-2-yl)phenyl)-1H-indole-6-carbonitrile (1-23). A solution of 1-44 (130.0 mg, 
0.3899 mmol) and Pd(PhCN)2Cl2 (31.0 mg, 0.0808 mmol) in DMF (3.9 mL) was heated to 80 C 
for 1 h. After cooling the reaction mixture to room temperature, water (5 mL) was added and the 
mixture was extracted with EtOAc (5 x 10 mL). The combined organic layers were washed with 
water (1 x 20 mL) and brine, dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (50% THF/hexanes) afforded 1-23 (70.1 mg, 54%) as a 
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yellow solid: Mp 192 C (decomp.); IR (KBr) 3431, 2359, 2340, 2218, 1617, 1353 cm-1; 1H 
NMR (300 MHz, DMSO-d6)  12.18 (bs, 1 H), 11.60 (bs, 1 H), 8.00 (app s, 4 H), 7.84 (s, 1 H), 
7.71 (d, 1 H, J = 8.1 Hz), 7.55 (d, 1 H, J = 7.8 Hz), 7.41 (d, 1 H, J = 8.1 Hz), 7.34 (d, 1 H, J = 8.1 
Hz), 7.09-7.14 (m, 2 H), 6.98-7.03 (m, 2 H); 13C NMR (75 MHz, DMSO-d6)  141.6, 137.3, 
137.0, 135.9, 132.1, 131.9, 129.7, 128.6, 126.1, 125.4, 122.3, 121.9, 121.0, 120.7, 120.2, 119.5, 
115.8, 111.3, 102.6, 99.7, 99.4; MS (EI) m/z 333 (M•+, 33), 205 (100), 91 (57); HRMS (EI) m/z 
calcd for C23H15N3 333.1266, found 333.1256. 
HO2C
NO2
I
 
4-Iodo-3-nitrobenzoic acid. A solution of 4-iodobenzoic acid (10.0 g, 40.3 mmol) in a mixture 
of conc. H2SO4 (50 mL) and conc. HNO3 (10 mL) was stirred for 20 h at room temperature. The 
reaction mixture was poured into ice water (100 mL) and filtered through a Buchner funnel. The 
solid residue was dissolved in THF, concentrated under reduced pressure and azeotropically 
dried with toluene (50 mL). The yellow residue was dissolved in THF (200 mL), dried (Na2SO4), 
and filtered through a pad of Celite/Florisil (1/1; v/v). After concentration under reduced 
pressure, the residue was dissolved in water (300 mL), extracted with EtOAc (3 x 150 mL), dried 
(Na2SO4), and concentrated under reduced pressure to afford 4-iodo-3-nitrobenzoic acid (11.8 g, 
100%) as a yellow solid: Mp 212.2-215.3 C; IR (ATR) 3086, 2834, 1685, 1521, 1353, 1297 cm-
1; 1H NMR (300 MHz, acetone-d6)  8.42 (d, 1 H, J = 1.8 Hz), 8.32 (d, 1 H, J = 8.1 Hz), 7.97 
(dd, 1 H, J = 8.1, 1.8 Hz); 13C NMR (75 MHz, acetone-d6)  165.6, 154.8, 143.4, 134.5, 133.2, 
126.5, 92.7; MS (EI) m/z 293 (M•+, 100), 92 (61), 74 (53); HRMS (EI) m/z calcd for C7H4INO4 
292.9185, found 292.9174. 
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4-Iodo-3-nitrobenzonitrile. A solution of 4-iodo-3-nitrobenzoic acid (2.57 g, 8.77 mmol) in 
THF (25 mL) and DMF (0.3 mL) was cooled to 0 °C and oxalyl chloride (1.4 mL, 16 mmol) was 
added dropwise. The reaction mixture was stirred at room temperature for 1 h. Solvent was 
removed in vacuo. The residue was re-dissolved in THF (30 mL), treated with gaseous ammonia 
for 5 min and stirred for 1 h at room temperature. After addition of ether (30 mL), the mixture 
was filtered through Celite/Florisil (1/1; v/v). The filtrate was concentrated in vacuo and 
dissolved in pyridine (25 mL) under an atmosphere of dry nitrogen. After addition of mesyl 
chloride (1.5 mL, 19 mmol), the mixture was stirred for 30 h at room temperature, treated with 
ether (20 mL), transferred to a separatory funnel with aq NaHSO4 (2M solution, 150 mL), and 
extracted with ether (3 x 75 mL). The combined organic layers were washed with aq NaHSO4 
(2M solution, 50 mL), water (100 mL), brine, and dried (Na2SO4). Purification by 
chromatography on SiO2 (5% Et2O/toluene) gave 4-iodo-3-nitrobenzonitrile (2.08 g, 87%) as a 
yellow powder: Mp 121.0-124.2 C; IR (ATR) 3086, 2233, 1705, 1526, 1342, 840 cm-1; 1H 
NMR (300 MHz, acetone-d6)  8.42 (d, 1 H, J = 8.4 Hz), 8.40 (d, 1 H, J = 2.4 Hz), 7.83 (dd, 1 H, 
J = 8.4, 2.1 Hz); 13C NMR (75 MHz, acetone-d6)  143.1, 135.9, 133.2, 128.2, 116.2, 113.4, 
92.5; MS (EI) m/z 274 (M•+, 100), 228 (73), 101 (75), 75 (51); HRMS (EI) m/z calcd for 
C7H3IN2O2 273.9239, found 273.9233. 
NH2
NC I
 
3-Amino-4-iodobenzonitrile (1-28). To a solution of 4-iodo-3-nitrobenzonitrile (2.00 g, 7.29 
mmol) in EtOH (20 mL) was added glacial acetic acid (20 mL), iron powder (2.29 g, 41.0 mmol) 
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and conc. HCl (0.3 mL). The reaction mixture was heated at reflux for 4 h, cooled to room 
temperature, and treated with Na2CO3 slowly until gas stopped evolving. The reaction mixture 
was extracted with EtOAc (3 x 35 mL) and the combined organic layers were washed with 
water, brine and dried (Na2SO4). Purification by chromatography on SiO2 (50% EtOAc/hexanes) 
furnished 1-28 (1.56 g, 87%) as a white solid: Mp 122-124.8 C; IR (ATR) 3395, 3315, 2223, 
1586, 1463, 1301 cm-1; 1H NMR (300 MHz, acetone-d6)  7.59 (d, 1 H, J = 8.7 Hz), 7.05 (d, 1 H, 
J = 2.7 Hz), 6.77 (dd, 1 H, J = 8.7, 3.0 Hz), 5.34 (bs, 2 H); 13C NMR (75 MHz, acetone-d6)  
150.1, 140.7, 121.3, 121.0, 120.3, 120.1, 79.7; MS (EI) m/z 244 (M•+, 100), 118 (72), 91 (63), 63 
(59); HRMS (EI) m/z calcd for C7H5IN2 243.9497, found 243.9488. 
NH2 H2N
CN
 
4-Amino-3-((4-((2-aminophenyl)ethynyl)phenyl)ethynyl)benzonitrile (1-43). To a solution of 
1-46 (15.2 mg, 0.0700 mmol) in MeCN (0.5 mL) were added PdCl2(PPh3)2 (2.8 mg, 0.0040 
mmol), CuI (1.4 mg, 0.0073 mmol), Et3N (50 L, 0.35 mmol) and 4-amino-3-iodobenzonitrile 
(1-27) (17.1 mg, 0.0701 mmol). The resulting mixture was heated at reflux for 2 h, and filtered 
through a pad of Celite/Florisil (1:1; v/v). The pad was washed with Et2O (3 x 5 mL) and the 
filtrate was concentrated under reduced pressure. Purification by chromatography on SiO2 (10 to 
20 to 30% EtOAc/hexanes) afforded 1-43 (15.2 mg, 65%) as a pale yellow solid: Mp 184-186 C 
(decomp.); IR (KBr) 3460, 3395, 3324, 2360, 2340, 2216, 1621, 1510, 833 cm-1; 1H NMR (300 
MHz, acetone-d6)  7.67 (d, 1 H, J = 1.8 Hz), 7.56-7.66 (m, 4 H), 7.44 (dd, 1 H, J = 8.4, 1.8 Hz), 
7.31 (dd, 1 H, J = 7.5, 0.9 Hz), 7.13 (dt, 1 H, J = 8.4, 1.2 Hz), 6.93 (d, 1 H, J = 8.7 Hz), 6.81 (d, 
1 H, J = 8.1 Hz), 6.62 (dt, 1 H, J = 7.2, 0.9 Hz); 13C NMR (75 MHz, acetone-d6)  153.8, 150.6, 
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137.2, 134.3, 133.0, 132.5, 132.3, 131.0, 124.8, 123.3, 120.0, 117.5, 115.2, 115.1, 107.8, 107.3, 
99.5, 95.9, 94.6, 89.7, 86.8; MS (EI) m/z 333 (M•+, 18), 117 (45), 91 (94), 88 (100), 81 (73); 
HRMS (EI) m/z calcd for C23H15N3 333.1266, found 333.1259. 
NH2 H2N
CN
 
3-Amino-4-((4-((2-aminophenyl)ethynyl)phenyl)ethynyl)benzonitrile (1-44). To a solution of 
1-46 (100.8 mg, 0.4639 mmol) in MeCN (3.5 mL) was added PdCl2(PPh3)2 (16.8 mg, 0.0239 
mmol), CuI (8.0 mg, 0.042 mmol), Et3N (320 L, 2.30 mmol) and 3-amino-4-iodobenzonitrile 
(1-28) (112.5 mg, 0.4610 mmol). The resulting mixture was heated at reflux for 4 h and filtered 
through a pad of Celite/Florisil (1:1; v/v). The pad was washed with Et2O (3 x 10 mL) and the 
filtrate was concentrated under reduced pressure. Purification by chromatography on SiO2 (30% 
EtOAc/hexanes) afforded 1-44 (146.1 mg, 95%) as a yellow solid: Mp 178-180 C; IR (KBr) 
3412, 3333, 2360, 2340, 2215, 1616, 1515, 753 cm-1; 1H NMR (300 MHz, acetone-d6)  7.56-
7.66 (m, 4 H), 7.47 (d, 1 H, J = 7.8 Hz), 7.29 (d, 1 H, J = 7.5 Hz), 7.09-7.14 (m, 2 H), 6.95 (dd, 1 
H, J = 7.8, 1.2 Hz), 6.80 (d, 1 H, J = 8.1 Hz), 6.62 (t, 1 H, J = 6.9 Hz); 13C NMR (75 MHz, 
acetone-d6)  150.7, 150.6, 133.8, 132.9, 132.5, 132.2, 131.0, 125.0, 123.1, 121.1, 119.5, 117.5, 
117.4, 115.1, 113.6, 111.8, 107.2, 97.8, 94.6, 89.8, 87.5; MS (TOF MS ESI) m/z 334 [M+H]+ 
(100); HRMS (TOF MS ESI) m/z calcd for C23H15N3 [M+H]+ 334.1344, found 334.1319. 
TMS
 
((4-Ethynylphenyl)ethynyl)trimethylsilane (1-45).35 A solution of 1-49 (3.50 g, 13.6 mmol) in 
toluene (200 mL) was treated with finely powdered NaOH (90.0 mg, 2.25 mmol), heated at 
reflux for 2 h, and stirred at room temperature overnight. Solvent was removed under reduced 
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pressure and the residue was purified by chromatography on SiO2  (hexanes) to furnish 1-45 
(2.60 g, 96%) as a white solid: 1H NMR (300 MHz, CDCl3)  7.48 (app s, 4 H), 3.44 (s, 1 H), 
0.24 (s, 9 H); MS (EI) m/z 199 (M•+, 31), 183 (36), 91 (100). 
NH2  
((4-Ethynylphenyl)ethynyl)trimethylsilane (1-46). To a solution of 1-50 (1.16 g, 4.00 mmol) 
in MeOH (60 mL) and THF (100 mL) was added K2CO3 (2.20 g, 16.0 mmol). The reaction 
mixture was stirred at room temperature for 2 h, filtered through a pad of Celite/Florisil (1/1; 
v/v), and washed with ether. The filtrate was concentrated in vacuo to afford 1-50 (0.50 g, 60%) 
as a white solid which was used in the next step without further characterization: 1H NMR (300 
MHz, acetone-d6)  7.60-7.49 (m, 4 H), 7.29 (dd, 2 H, J = 7.8, 1.5 Hz), 7.12 (dt, 1 H, J = 8.7, 1.5 
Hz), 6.79 (dd, 1 H, J = 8.1, 0.6 Hz), 6.61 (dt, 1 H, J = 7.5, 1.2 Hz), 5.20 (bs, 2 H), 3.81 (s, 1 H); 
MS (EI) m/z 217 (M•+, 100), 289 (78), 274 (100), 137 (8); HRMS (EI) m/z calcd for C19H19NSi 
289.1287, found 289.1285. 
I
OH  
4-(4-Iodophenyl)-2-methylbut-3-yn-2-ol (1-48). To a solution of 1,4-diiodobenzene (10.2 g, 
30.3 mmol) in THF (100 mL) under an atmosphere of dry nitrogen were added Pd(PPh3)2Cl2 
(0.42 g, 0.61 mmol) and CuI (0.23 g, 1.2 mmol). The reaction mixture was stirred at room 
temperature for 5 min, treated with triethylamine (10.6 mL, 75.8 mmol) and 2-methyl-3-butyne-
2-ol (2.9 mL, 30 mmol), stirred overnight, filtered through a pad of Celite/Florisil (1/1; v/v), and 
washed with ether. The filtrate was concentrated under reduced pressure and the residue was 
purified by chromatography on SiO2 (10% EtOAc/hexanes) to provide 1-48 (4.11 g, 48%) as a 
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white solid: Mp 86-88 C; IR (KBr) 3410, 2981, 2360, 2340, 1481, 1372, 1274, 1159, 820 cm-1; 
1H NMR (300 MHz, CDCl3)  7.64 (d, 2 H, J = 8.4 Hz), 7.13 (d, 2 H, J = 8.4 Hz), 2.17 (s, 1 H), 
1.62 (s, 6 H); 13C NMR (75 MHz, CDCl3)  137.4, 133.1, 122.3, 95.2, 94.1, 81.2, 65.6, 31.4; MS 
(EI) m/z 286 (M•+, 35), 272 (12), 271 (100), 144 (25), 115 (25); HRMS (EI) m/z calcd for 
C11H11OI 285.9855, found 285.9867. 
TMS
OH  
2-Methyl-4-(4-((trimethylsilyl)ethynyl)phenyl)but-3-yn-2-ol (1-49). To a solution of 1-48 
(4.00 g, 14.0 mmol) in THF (45 mL) were added Pd(PPh3)2Cl2 (0.20 g, 0.28 mmol) and CuI 
(0.10 g, 0.56 mmol). The reaction mixture was stirred at room temperature for 5 min, treated 
with triethylamine (4.9 mL, 35 mmol) and ethynyltrimethylsilane (2.1 mL, 15 mmol), stirred for 
2 h at room temperature, filtered through a pad of Celite/Florisil (1/1; v/v), and washed with 
ether. The filtrate was concentrated under reduced pressure and the residue was purified by 
chromatography on SiO2 (10% EtOAc/hexanes) to provide 1-48 (3.50 g, 98%) as a white solid: 
Mp 108 C; IR (KBr) 3281, 2981, 2960, 2359, 2156, 1249, 864, 834 cm-1; 1H NMR (300 MHz, 
CDCl3)  7.73-7.63 (m, 4 H), 2.06 (s, 1 H), 1.54 (s, 6 H), 0.20 (s, 9 H); 13C NMR (75 MHz, 
CDCl3)  131.8, 131.4, 123.0, 122.8, 104.5, 96.1, 95.6, 81.8, 65.6, 31.4, -0.1; MS (EI) m/z 256 
(M•+, 23), 242 (21), 241 (100), 183 (14), 68 (28); HRMS (EI) m/z calcd for C16H20OSi 256.1283, 
found 256.1289. 
NH2
TMS
 
2-((4-((Trimethylsilyl)ethynyl)phenyl)ethynyl)benzenamine (1-50). To a solution of 1-45 
(2.12 g, 10.7 mmol) in CH3CN (70 mL) under an atmosphere of nitrogen were added 
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Pd(PPh3)2Cl2 (0.38 g, 0.53 mmol) and CuI (0.22 g, 1.1 mmol). The reaction mixture was stirred 
for 5 min at room temperature, treated with triethylamine (7.5 mL, 53 mmol) and 2-iodoaniline 
(2.34 g, 10.7 mmol), heated at reflux for 2 h, cooled to room temperature, filtered through a pad 
of Celite/Florisil (1/1; v/v), and washed with ether. The filtrate was concentrated in vacuo and 
then purified by chromatography on SiO2 (5% EtOAc/hexanes) to furnish 1-50 (1.16 g, 40%) as a 
white solid: Mp 99-101 C; IR (KBr) 3385, 3294, 2960, 2361, 2151, 1612, 1250, 865, 837, 761 
cm-1; 1H NMR (300 MHz, acetone-d6)  7.58-7.45 (m, 4 H), 7.29 (d, 1 H, J = 7.5 Hz), 7.11 (t, 1 
H, J = 8.1 Hz), 6.79 (d, 1 H, J = 8.4 Hz), 6.61 (t, 1 H, J = 7.2 Hz), 5.19 (bs, 2 H), 0.24 (s, 9 H); 
13C NMR (75 MHz, acetone-d6)  150.6, 132.9, 132.7, 132.2, 131.0, 125.0, 123.5, 117.4, 115.1, 
107.2, 105.6, 96.6, 94.5, 89.7, 0.0; MS (EI) m/z 289 (M•+, 78), 274 (100), 137 (8); HRMS (EI) 
m/z calcd for C19H19NSi 289.1287, found 289.1285. 
N
H
O O
NH2HN
NC  
2-(4-(6-Cyano-1H-indol-2-yl)phenoxy)acetohydrazide (1-51). To a suspension of 1-52 (112.1 
mg, 0.3500 mmol) in EtOH (14.2 mL) was added hydrazine monohydrate (0.50 mL, 10 mmol) 
and the reaction mixture was stirred at room temperature for 20 h. Solvent was removed under 
reduced pressure and the crude product was dried in vacuo overnight to give 1-52 (107.0 mg, 
100%) as a grey solid: Mp 270-272 C (decomp.); IR (KBr) 3423, 3302, 3168, 2216, 1685, 1248 
cm-1; 1H NMR (300 MHz, DMSO-d6)  12.03 (s, 1 H), 9.38 (bs, 1H), 7.85 (d, 2 H, J = 9.0 Hz), 
7.78 (s, 1 H), 7.65 (d, 1 H, J = 8.4 Hz), 7.31 (dd, 1 H, J = 8.4, 0.9 Hz), 7.09 (d, 2 H, J = 8.7 Hz), 
6.95 (s, 1 H), 4.55 (s, 2 H), 4.35 (bs, 2 H); 13C NMR (75 MHz, DMSO-d6)  166.5, 158.1, 141.9, 
135.7, 132.1, 127.0, 124.2, 122.2, 120.8, 120.6, 115.5, 115.2, 102.0, 98.4, 66.3; MS (EI) m/z 306 
(M•+, 30), 234 (100), 61 (33); HRMS (EI) m/z calcd for C17H14N4O2 306.1117, found 306.1116. 
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N
H
O
CO2Et
NC  
Ethyl 2-(4-(6-cyano-1H-indol-2-yl)phenoxy)acetate (1-52). A solution of 1-53 (115.1 mg, 
0.3593 mmol) in DMF (3.6 mL) was treated with Pd(PhCN)2Cl2 (28.1 mg, 0.0733 mmol), heated 
at reflux for 1.5 h, and cooled to room temperature. EtOAc (10 mL) and water (10 mL) were 
added and the product was extracted with EtOAc (3 x 10 mL), dried (Na2SO4) and concentrated 
in vacuo. Purification by chromatography on SiO2 (30% EtOAc/hexanes) provided 1-52 (71.8 
mg, 63%) as a white solid: Mp 195 C (decomp.); IR (KBr) 3367, 2211, 1752, 1495, 1261 cm-1; 
1H NMR (300 MHz, acetone-d6)  11.17 (bs, 1 H), 7.86 (d, 2 H, J = 8.7 Hz), 7.78 (s, 1 H), 7.70 
(d, 1 H, J = 8.4 Hz), 7.31 (dd, 1 H, J = 8.2, 1.3 Hz), 7.08 (dt, 2 H, J = 9.0, 1.9 Hz), 6.95 (s, 1 H),  
4.80 (s, 2 H), 4.22 (q, 2 H, J = 7.2 Hz), 1.26 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, acetone-d6) 
 169.3, 159.6, 143.1, 137.1, 133.6, 128.0, 125.8, 123.4, 121.8, 121.3, 116.4, 116.2, 104.3, 99.7, 
65.9, 61.6, 14.6; MS (EI) m/z 320 (M•+, 100), 233 (72); HRMS (EI) m/z calcd for C19H16N2O3 
320.1161, found 320.1154. 
NH2
O
CO2Et
NC
 
Ethyl 2-(4-((2-amino-4-cyanophenyl)ethynyl)phenoxy)acetate (1-53). A solution of 1-54 
(101.0 mg, 0.4585 mmol) in CH3CN (2.5 mL) was treated with Pd(PPh3)2Cl2 (16.8 mg, 0.0239 
mmol) and CuI (10.4 mg, 0.0546 mmol). The resulting mixture was stirred for 5 min at room 
temperature, treated with triethylamine (0.25 mL, 2.5 mmol) and 1-28 (124.2 mg, 0.5089 mmol), 
heated at reflux for next 1 h, cooled to room temperature, and filtered through Celite/Florisil 
(1/1; v/v). The pad was washed with ether. The filtrate was concentrated in vacuo and the residue 
was purified by chromatography on SiO2 (20% EtOAc/hexanes) to afford 1-53 (159.2 mg, 
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100%) as a white solid: Mp 131-132 C; IR (KBr) 3460, 3368, 2223, 1725, 1621, 1549, 1514, 
1238 cm-1; 1H NMR (300 MHz, acetone-d6)  7.58-7.53 (m, 2 H), 7.42 (d, 1 H, J = 8.1 Hz), 7.12 
(d, 1 H, J = 1.5 Hz), 6.99 (dt, 2 H, J = 9.0, 2.0 Hz), 6.93 (dd, 1 H, J = 7.8, 1.5 Hz), 5.61 (bs, 2 H),  
4.79 (s, 2 H), 4.22 (q, 2 H, J = 7.2 Hz), 1.25 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, acetone-d6) 
 169.1, 159.6, 150.5, 134.0, 133.5, 120.1, 119.7, 117.3, 116.4, 116.0, 115.8, 113.0, 98.2, 84.6, 
65.8, 61.7, 14.5; MS (TOF MS ESI) m/z 321 [M+H]+ (100); HRMS (TOF MS ESI) m/z calcd for 
C19H16N2O3 [M+H]+ 321.1239, found 321.1232. 
O
CO2Et
 
Ethyl 2-(4-ethynylphenoxy)acetate (1-54). To a solution of 1-55 (0.50 g, 1.6 mmol) in THF (3 
mL) were added Pd(PPh3)2Cl2 (21.0 mg, 0.0299 mmol) and CuI (12.0 mg, 0.0630 mmol). The 
resulting mixture was stirred for 5 min at room temperature, treated with triethylamine (0.34 mL, 
2.5 mmol) and ethynyltrimethylsilane (0.24 mL, 1.7 mmol), stirred at room temperature for 1 h, 
and filtered through Celite/Florisil (1/1; v/v). The pad was washed with ether. The filtrate was 
concentrated in vacuo and the crude material was dissolved in MeOH (5 mL). After the addition 
of K2CO3 (330.1 mg, 2.450 mmol), the mixture was stirred at room temperature for 2 h. The 
product was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The solid residue was purified by 
chromatography on SiO2 (1% EtOAc/hexanes) to afford 1-54 (171.1 mg, 60%) as a white solid: 
Mp 78.0-80.5 C; IR (ATR) 3235, 1744, 1508, 1217 cm-1; 1H NMR (300 MHz, CDCl3)  7.44 
(d, 2 H, J = 9.0 Hz), 6.86 (d, 2 H, J = 9.0 Hz), 4.63 (s, 2 H), 4.28 (q, 2 H, J = 7.2 Hz), 3.01 (s, 1 
H), 1.30 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3)  168.5, 158.1, 133.6, 115.5, 114.6, 
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83.3, 76.2, 65.3, 61.5, 14.1; MS (EI) m/z 204 (M•+, 100), 131 (48); HRMS (EI) m/z calcd for 
C12H12O3 204.0786, found 204.0777. 
O
CO2Et
I
 
Ethyl 2-(4-iodophenoxy)acetate (1-55). To a solution of 4-iodophenol (5.00 g, 22.7 mmol) in 3-
pentanone (100 mL) was added NaI (0.68 g, 4.5 mmol) followed by K2CO3 (9.42 g, 68.1 mmol) 
and ethyl bromoacetate (10.0 mL, 90.8 mmol). The reaction mixture was heated at reflux for 12 
h, cooled to room temperature, and extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with water, brine, dried (Na2SO4), and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (1% EtOAc/hexanes) gave 1-55 (4.40 g, 63%) as a 
white solid: Mp 57.2-59.6 C; IR (ATR) 3067, 2972, 2929, 1739, 1211, 822 cm-1; 1H NMR (300 
MHz, CDCl3)  7.58 (dt, 2 H, J = 9.0, 2.0 Hz), 6.69 (dt, 2 H, J = 9.0, 2.0 Hz), 4.59 (s, 2 H), 4.27 
(q, 2 H, J = 7.2 Hz), 1.30 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3)  168.5, 157.7, 138.3, 
117.0, 84.0, 65.4, 61.5, 14.1; MS (EI) m/z 306 (M•+, 100), 233 (36), 203 (25), 106 (18), 86 (44), 
84 (73); HRMS (EI) m/z calcd for C10H11IO3 305.9753, found 305.9742. 
N
H
O O
NHN
S
NC  
2-(4-((5-Thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methoxy)phenyl)-1H-indole-6-carbonitrile 
(1-56). To a solution of 1-51 (15.8 mg, 0.0516 mmol) in DMSO (0.5 mL) was added a solution 
of KOH (4.9 mg, 0.050 mmol) in MeOH (0.5 mL), followed by the addition of CS2 (0.25 mL). 
The reaction mixture was heated at reflux for 24 h, quenched with aq HCl (1M, 10 mL), and 
extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with water (20 
mL), brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by 
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chromatography on SiO2 (10 to 50% EtOAc/hexanes) gave 1-56 (13.4 mg, 80%) as a white solid: 
Mp 141 C; IR (ATR) 3583, 3325, 2217, 1460, 1245, 821 cm-1; 1H NMR (300 MHz, DMSO-d6) 
 14.71 (bs, 1 H), 12.05 (s, 1 H), 7.89 (d, 2 H, J = 8.4 Hz), 7.79 (s, 1 H), 7.66 (d, 1 H, J = 8.4 
Hz), 7.32 (d, 1 H, J = 8.1 Hz), 7.20 (d, 2 H, J = 8.4 Hz), 6.98 (s, 1 H), 5.34 (s, 2 H); 13C NMR 
(75 MHz, DMSO-d6)  178.0, 159.5, 157.4, 141.7, 135.7, 132.0, 127.2, 125.0, 122.2, 120.7, 
115.6, 115.5, 102.3, 98.7, 59.6; MS (EI) m/z 348 (M•+, 13), 234 (100), 233 (36); HRMS (EI) m/z 
calcd for C18H12N4O2S 348.0681, found 348.0691. 
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2.0  MICROWAVE ASSISTED INTRAMOLECULAR-DIELS-ALDER-FURAN 
APPROACH TO UNPROTECTED 4-MONOSUBSTITUTED AND 3,4-DISUBSTITUTED 
INDOLES 
2.1 INTRODUCTION 
2.1.1 Importance of Indole Containing Compounds 
The indole ring is a ubiquitous motif in nature and is found in a wide array of naturally occurring 
alkaloids. Functionalized indoles, along with their dihydro and tetrahydro derivatives, have been 
of interest to organic chemists for many years due to the large number of natural products and 
biologically active compounds that contain these heterocycles.46,47 Some natural indoles are 
simple monosubstituted derivatives, such as plant growth regulator indole-3-acetic acid 2-1 
(Figure 10),48 while others have more complex substitution pattern. Most indole alkaloids are 
derived from the amino acid (S)-tryptophan 2-2 and some of them, such as serotonin 2-3, are 
involved in important biological processes and metabolic pathways. A relatively uniform fraction 
of ~4% of all pharmaceuticals, high-throughput screening samples, and natural products, contain 
an aromatic or partially saturated indole core.49-52 Many indole-containing compounds are 
important drugs, such as naturally occurring vincristine 2-4,53 ambiguine A isonitrile 2-5,54 and 
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lysergic acid 2-6, as well as synthetic drugs such as imitrex 2-7,55 zorfan ODT 2-8,56 cialis 2-9,57 
requip 2-10,58 and the phosphoinositide 3-kinase inhibitor 2-1151 (Figure 10). 
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Figure 10. Representative indole-containing natural and synthetic products (indole outlined in red) 
For over a hundred years, the synthesis of indoles has been a major area of focus for 
synthetic chemists, and many methods for indole preparation have been developed.59 In some 
cases, however, specific substitution patterns remain difficult to obtain by standard indole-
forming reactions.60 Thus, the search for efficient protocols for the formation of 
substituted/functionalized indole scaffolds remains an important topic in the areas of synthetic 
and medicinal chemistry.61 
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2.1.2 Methods for Indole Synthesis 
The most nucleophilic position of the indole ring is the C3 position. It is therefore relatively easy 
to prepare 3-substituted indoles by an electrophilic aromatic substitution reaction on an existing 
indole nucleus. For indoles with other substitution patterns, however, it is often necessary to 
assemble the ring system. Two general approaches have been outlined. The first approach is 
based on an aniline with a free ortho-position, while the second approach utilizes an ortho-
alkylated aniline.19 
2.1.2.1 Fischer Indole Synthesis 
The Fisher indole synthesis provides a simple, efficient method for the transformation of 
enolizable N-arylhydrazones into indoles.62 In many cases, the indolization reaction is carried out 
by simple heating of the ketone or aldehyde and the arylhydrazine with an appropriate acid, 
without isolation of the hydrazone intermediate. The catalysts that successfully lead to 
indolization include strong acids (e.g., PTSA, PPA, HCl, H2SO4), weak acids (e.g., pyridinium 
chloride, acetic acid), solid acids (e.g., montmorillionite KSF clay, Zeolite Y, ion exchange 
resins) and Lewis acids (e.g., PCl3, ZnCl2).63  
Advantages of the Fisher indole synthesis include the tolerance of a wide range of  
functional groups and the use of relatively readily available starting materials.64 One 
disadvantage is that unsymmetrical ketones can lead to mixtures of indoles if both substituents 
have enolizable -protons. Arylhydrazones of methyl alkyl ketones, however, normally give 2-
methylindoles, implying that the cyclization takes place at the more substituted alkyl group. 
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The mechanism of the Fisher indole synthesis is believed to involve a [3,3]-sigmatropic 
rearrangement of an ene-hydrazine tautomer 2-13 to a bis-iminobenzylketone 2-14 (Scheme 15). 
Cyclization and aromatization with loss of ammonia provides the indole product 2-17.65 
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Scheme 15. Mechanism of the Fischer indole synthesis 
2.1.2.2 Bartoli Synthesis 
Bartoli et al. have described the reaction of substituted nitroarenes with an excess of 
vinyl Grignard reagents at low temperature to afford substituted indoles upon aqueous work-
up.66,67 The highest yields were obtained with ortho-substituted nitroarenes, while the absence of 
the ortho-substituent leads to very low yields of the desired indole. 
The mechanism of the Bartoli reaction (Scheme 16) is believed to also involve a [3,3]-
sigmatropic rearrangement as the key step.68 The sequence begins with the addition of Grignard 
reagent 2-19 to the oxygen atom of the nitro group, followed by a rapid conversion to the 
intermediate nitrosoarene 2-21. This intermediate is more reactive than the starting nitroarene 2-
18 and quickly reacts with a second equivalent of Grignard reagent to give the O-alkenyl 
hydroxylamine 2-22, which undergoes a [3,3]-sigmatropic rearrangement. The rearranged 
product 2-23 then undergoes an intramolecular attack followed by deprotonation by the third 
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equivalent of Grignard reagent. Finally, an acidic work-up yields the 7-substituted indole 2-25 in 
moderate to good yields. 
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Scheme 16. Bartoli indole synthesis 
2.1.2.3 Gassman Indole Synthesis 
Another method based on ortho-cyclization uses a [3,2]-sigmatropic rearrangement of a 
sulfonium ylide. The starting material for the Gassman synthesis is an N-chlorinated aniline 2-
27, which is converted to sulfonium salt 2-29 by reaction with the -keto sulfide 2-28, thereby 
providing the additional carbon aroms needed to construct the indole core (Scheme 17).69,70 In 
the cyclization step, a weak N-S bond (E = 111 kcal mol-1) is broken and a strong C-C bond (E = 
145 kcal mol-1) is formed. Upon rearomatization and intramolecular nucleophilic attack, indole 
2-32 is formed. The methylthio group can be removed in a subsequent step by reduction with 
Raney Ni.71 
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Scheme 17. Gassman indole synthesis 
2.1.2.4 Leimgruber-Batcho Indole Synthesis 
One of the most important and commonly used methods for the preparation of 2,3-
unsubstituted indoles is the Leimgruber-Batcho indole synthesis.72 The classical Leimgruber-
Batcho reaction involves the condensation of an appropriately substituted o-nitrotoluene 2-33 
with N,N-dimethylformamide dimethyl acetal (Scheme 18) to give the intermediate -
(dimethylamino)-2-nitrostyrene 2-34. Reductive cyclization leads to substituted indoles 2-35. 
The increased acidity of the methyl group of the o-nitrotoluene allows the isolation of the 
remarkably stable intermediate 2-34. In an improved procedure, the formation of 2-34 uses an 
excess of pyrrolidine.72,73  
The Leimgruber-Batcho reaction is capable of tolerating a large number of substituents, 
and this method has been extensively used for the construction of both natural products and 
pharmaceutically important compounds.20,74 
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Scheme 18. Leimgruber-Batcho reaction 
2.1.2.5 Fukuyama’s Radical Approach to Indole 
Fukuyama and coworkers have reported a mild method for indole synthesis employing a 
radical cyclization.75 In this efficient and useful method 2-alkenylthioanilide was subjected to tri-
n-butyltin hydride and AIBN in toluene at 80 °C for 5 min, resulting in clean formation of the 
desired indole. It was also shown that using Et3B as a radical initiator gave excellent results in 
this procedure.  
The sequence is believed to begin with the addition of tin radical to thioamide 2-36 
(Scheme 19) to form either a C-sp3 2-38 or an imidoyl radical species 2-39. Both radical species 
could in principle undergo a cyclization to furnish the 2,3-disubstituted indole 2-40.75 
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Scheme 19. Fukuyama reaction 
The ease of preparation of the indole precursors, the mild cyclization conditions and the 
compatibility with various substituents at the 2- and 3- positions, as well as on the benzene group 
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make this method a very powerful addition to existing indole syntheses. It has already been 
utilized in numerous synthesis, including aspidophytine,76 vinblastine77 and strychnine.78 
2.1.2.6 Palladium-Mediated Processes for Indole Synthesis 
The palladium-catalyzed cyclization of 2-alkynylanilines 2-42 and the one-pot annulation 
of 2-haloanilines 2-41 with terminal alkynes have received considerable attention for the 
construction of indoles.22,23,79,80 In both cases, the preparation of indoles requires reductive 
elimination of either an indolylpalladium intermediate, leading to substituted indoles 2-43, or an 
acylindolylpalladium species, giving 3-acylindoles 2-44 (Scheme 20). 
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Scheme 20. Palladium-assisted reactions for indole synthesis 
It was reported recently by Larock that 2-iodoanilines and disubstituted alkynes undergo 
one-pot Pd-catalyzed coupling to furnish 2,3-disubstituted indoles.81 The reaction commences 
with the oxidative addition of the Pd(0) catalyst into the C-I bond to form intermediate 2-44. 
Upon ligand exchange, intermediate 2-46 undergoes a carbopalladation process followed by 
reductive elimination to give substituted indoles 2-48 (Scheme 21).82 
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Scheme 21. Larock indole synthesis 
2.1.3 Intramolecular Diels-Alder Furan (IMDAF) Reaction 
The intramolecular Diels-Alder furan cycloaddition (IMDAF), popularized by Padwa83-87 and 
others, represents a particularly interesting method for indole preparation, and it has successfully 
been applied to the synthesis of a variety of indolines. This process involves the regioselective 
intramolecular cycloaddition of 2-aminofurans to various dienophiles.86 
To establish the viability of the IMDAF sequence, Padwa and coworkers prepared several 
2-amidofurans containing olefinic tethers from the reaction of N-tert-butylfuranyl carbamate 
with various alkenyl halides in the presence of base.84 As outlined in Scheme 22, the IMDAF 
reaction of alkenyl-substituted furanyl carbamates proceeds via a cycloaddition/rearrangement 
cascade. It was shown that the initially formed oxabicyclic intermediate 2-50 undergoes a 
nitrogen-assisted ring opening followed by the loss of a proton to produce aza-bicyclic ketones 
2-52 – 2-54. Early studies by the Padwa group showed that when a 2-substituted olefin was used, 
the thermal reaction provided rearranged hexahydroindolinones 2-52 – 2-54. On the other hand, 
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unsubstituted alkenyl tethers furnished dihydroindoles 2-55 and 2-56 by the thermally promoted 
loss of a water molecule. 
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Scheme 22. Intramolecular Diels-Alder reaction of 2-amidofurans 
A remarkable rate enhancement was noticed with substrates that contain an sp2 center 
within the tether. These reactions proceed at lower temperature, and often lead to the isolation of 
the oxabicyclic intermediates (Scheme 23). The presence of the rigid amide moiety is believed to 
place the alkenyl dienophile in a much closer position to the furanyl -system, thereby lowering 
the energy gap between the ground state and the reactive conformers. 
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Scheme 23. Effect of the carbonyl group present in the tether 
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The Padwa group successfully applied this methodology for a number of alkaloids 
containing a hydroindole subunit. The synthesis of the Amaryllidaceae alkaloid mesembrine 2-66 
(Scheme 24) utilized a thermolysis of amidofuran 2-63 to establish the required quaternary 
center present in the natural product. A similar strategy was also used in the synthesis of 
dendrobine (2-70), where the key IMDAF reaction involved a cycloaddition of the amidofuran 
unit with a trisubstituted unactivated olefin, and provided the highly functionalized tricyclic 
ketone 2-69 in 74% yield. Further functional group transformations provided the desired alkaloid 
dendrobine.88 
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Scheme 24. Padwa's IMDAF approach to mesembrine and dendrobine 
Previous work in our group focused on extending the use of 2-aminofuranes for indole 
synthesis.89 Such a process would be readily possible by the strategic placement of a second, 
easily dehydrated oxygen functionality. To achieve this goal, it was envisioned that allylic 
alcohols bearing the N-Boc-protected 2-furanylaminomethyl fragment could be employed as 
starting materials. In contrast to Padwa’s work where dehydration of the 6-membered ring of the 
indole-like fragment was an undesired reaction pathway,84 our methodology utilizes an extensive 
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aromatization and introduces an additional hydroxyl group leading to the pyrrole portion of the 
target heterocycle.90 
Appropriate furanyl olefins were envisioned to arise from an alkyllithium addition to ,-
unsaturated aldehydes. Due to the instability of alkyllithium reagents, a stannane precursor was 
selected, which can be transmetalated in situ by treatment with n-BuLi.91 The stannane reagent 
was synthesized by a series of routine transformations (Scheme 23).92 The tributylstannyl anion, 
generated by treatment of tributyltin hydride with LDA, was quenched with paraformaldehyde to 
afford alcohol 2-71. Iodination of this alcohol with NIS/PPh3 furnished the corresponding iodide 
2-72, which was subsequently coupled with N-Boc-protected 2-aminofuran 2-7386 in the 
presence of sodium hydride to yield stannane 2-74. 
n-Bu3SnH
LDA
(CH2O)n
97%
n-Bu3Sn OH
NIS/Ph3P
74%
n-Bu3Sn I
O NHBoc NaH, DMF
87%
O NBoc
Snn-Bu3
n-Bu3Sn I
2-71 2-72
2-73
2-72
2-74  
Scheme 25. Furanyl stannane reagent preparation 
With the stannane in hand, conditions for the addition to ,-unsaturated aldehydes were 
explored. Treatment of 2-74 with n-buthyllitium in THF for 15 min at -78 °C, followed by the 
addition of cinnamaldehyde provided the expected addition product 2-75 in 68% yield after 3 h 
(Scheme 24). 
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Snn-Bu32-74
n-BuLi, THF
-78 °C, 15 min
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3 h; 68%
O NBoc
2-75
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Scheme 26. Transmetallation and alkylation of cinnamaldehyde 
Unfortunately, heating alcohol 2-75 in toluene at reflux led to gradual decomposition 
instead of the desired Diels-Alder reaction. Microwave conditions, however, proved to be very 
efficient. When 2-75 was heated in o-dichlorobenzene for 20 min at 180 °C, complete 
consumption of the starting material was observed, and the desired 4-phenylindole (2-76, Table 
1, entry 1) was isolated in 79% yield. Additionally, this process proceeded with complete Boc-
deprotection.93,94  
It is clear that the microwave heating is essential for the success of the IMDAF reaction. 
The introduction of microwave energy into a chemical reaction can lead to much higher heating 
rates than those that can be achieved conventionally.95 In contrast to conventional heating, which 
involves a slow heat transfer from an external heating source, microwave irradiation is 
transferred directly by interaction of the radiation with dipoles of solvent and/or reaction 
components.48,96  
Table 1. Scope of the microwave-assisted IMDAF reactiona 
Entry Substrate Product 
Yield 
(%) 
1 
O NBoc OH
Ph
 
2-75 
N
H
Ph
 
2-76 
79 
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2 
O NBoc OH
CH3
 
2-77 
N
H
CH3
 
2-78 
76 
3 
O NBoc OH
F
 
2-79 
N
H
F
 
2-80 
83 
4 
O NBoc OH
OCH3
 
2-81 
N
H
OCH3
 
2-82 
69 
5 
O NBoc OH
CO2CH3
 
2-83 
N
H
CO2CH3
 
2-84 
77 
6 O NBoc OH
Ts
N
 
2-85 
N
H
NTs
 
2-86 
71 
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7 OH
N
BocOH
N
BocO
O
 
2-87 
HN NBoc HN NH  
2-88                             2-89 
61 
(1.75:1) 
8 
O NBoc OH  
2-90 
N
H  
2-91 
69b 
aAll reactions were carried out by heating a solution of alcohol in o-dichlorobenzene in a microwave reactor for 20 
min at 180 °C. The reaction mixture was concentrated and purified by chromatography on SiO2 (1% 
EtOAc/hexanes). bThe product 2-91 was isolated as a mixture of geometric isomers (E:Z = 7:1) 
Of particular importance is the degree of structural diversity that can be accessed during 
this process.90 As seen in Table 1, both electron rich p-anisyl (2-81) and electron poor p-
fluorophenyl (2-79) substrates were suitable for cyclization. Carboxylic ester 2-83 was tolerated 
without diminishing reactivity or yield. Incorporation of an additional double bond in allylic 
alcohol 2-90 led to clean formation of 4-alkenyl substituted indole 2-91 in a 7:1 ratio of E:Z 
isomers. When symmetric bisfuran 2-87 was subjected to the Diels-Alder cascade process, 
diannulated products 2-88 and 2-89 were isolated in a 7:4 ratio, with no monocyclization being 
observed. 
The straightforward construction of 4-substituted indoles presented here presumably 
proceeds as shown in Scheme 27. The addition of the alkyllithium reagent to the ,-unsaturated 
carbonyl compound 2-92 furnishes allylic alcohol 2-93. Upon heating, allylic aclohol 2-93 
undergoes a [4+2] cycloaddition resulting in the formation of the tricyclic intermediate 2-94 
bearing an alkyl or an aryl substituent at position 4. The nitrogen atom adjacent to the 5,7-ether 
facilitates the opening of the ether bridge in intermediate 2-94 to give iminium ion 2-95. The 
completion of the sequence requires deprotonation at position 3’, water elimination, and Boc-
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deprotection. This results in the formation of the N-unprotected 4-substituted indole 2-97. 
Alternatively, the tricyclic intermediate 2-94 could undergo an N-O Boc-group transfer, leading 
to the amide 2-98. Upon opening of the oxygen bridge followed by a proton transfer, elimination 
of water and CO2 from the intermediate 2-100 leads to the formation of indole 2-97. 
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Scheme 27. Proposed mechanism for the indole formation 
2.1.4 Uhle’s Ketone  
Uhle’s ketone (2-106, Scheme 28) is a tricyclic compound structurally related to lysergic acid 
derivatives, and is a key intermediate in the synthesis of many pharmacologically active 
compounds.97 It was first synthesized by Uhle in 1949 in 8 steps from 2-chloro-6-nitrotoluene.98 
Several attempts to improve the preparation of Uhle’s ketone have been described,99-101 but the 
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increasing importance of the synthesis of pharmacologically active compounds requires new 
efficient and simple ways for the synthesis of this important precursor. 
For the synthesis of Uhle’s ketone, indoline derivatives or 4-substituted indole derivatives 
are usually employed as starting materials. While the direct cyclization at the 4-position of indole 
would offer an elegant way for the closure of the C ring of Uhle’s ketone, the much greater 
nucleophilicity of the 2-position leads to the corresponding isomeric compounds.97 To overcome 
this problem, Uhle prepared -(4-carboxy-3-indole)-propionic acid 2-105 (Scheme 28), starting 
from 2-chloro-6-nitrotoluene 2-101.98 This reaction sequence introduces a carboxylic moiety at 
the indole 4-position through a nucleophilic substitution of chloride with copper(I) cyanide, 
while the indole ring is derived from the nitro group and the previously introduced three-carbon 
unit. After subjecting 2-105 to KCN and acetic anhydride under reflux for 20 h, Uhle obtained 
the corresponding ketone 2-106 in 80% yield. 
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2-104 2-105 Uhle's ketone (2-106)  
Scheme 28. Uhle's approach to 2-106 
In 1972 Bowman and coworkers improved Uhle’s approach to 2-106 (Scheme 29).102 The 
chloroanthranilic acid 2-107 was first diazotized103 and then coupled with ethyl 2-
oxocyclopentanecarboxylate (2-108). Azocyclopentane 2-109 was subjected to hydrolysis to 
obtain hydrazono-triacid monoester 2-110, which upon heating with BF3 in acetic acid at 90 °C 
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for 4 h furnished indole 2-111 in 81% yield. Finally, selective decarboxylation of indole-2-
caboxylic acid under basic conditions in the autoclave at 240 °C provided dicarboxylic acid 2-
105 in 67% yield. As in the Uhle’s original procedure, initial formation of a mixed anhydride 
with Ac2O and a subsequent cyclization using KCN as a base, followed by an intramolecular 
decarboxylation of an intermediary formed -ketoester provided 2-106 in 80% yield. 
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Scheme 29. Bowman's synthesis of Uhle's ketone 2-106 
Teranishi and coworkers published a facile synthesis of Uhle’s ketone using a 
regioselective Friedel-Crafts cyclization.97 In this work, a trimethylacetyl group was used to 
inhibit a cyclization at the 2-position, thus favoring the Friedel-Crafts reaction at the 4-position 
of the indole ring (Scheme 30). N-Protection of 3-(indole-3-yl)propionic acid (2-112) with 
trimethylacetyl chloride (2-113) and n-BuLi in THF at -78 °C provided 2-114 in 91% yield. This 
acid was converted into the corresponding chloride with thionyl chloride, and directly used in the 
Friedel-Crafts reaction. Treatment of 2-114 with AlCl3 (4.0 equiv) and propionyl chloride (4.0 
equiv) in 1,2-dichloroethane at 15 °C for 1 h gave a mixture of 2-115 and 2-116 in 76% yield 
and a 92:8 ratio. Subsequent removal of the trimethylacetyl group with a catalytic amount of 
sodium methoxide in methanol at 15 °C for 10 min gave Uhle’s ketone (2-106) in 95% yield. 
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Scheme 30. Teranishi's approach to 2-106 
2.2 RESULTS AND DISCUSSIONS 
2.2.1 IMDAF Cascade Process toward Indoles 
Based on previous work in our group,89 our initial goal was to extend the IMDAF methodology 
towards the synthesis of indoles that possess alkyl groups in the 4-position. Accordingly, we 
synthesized allylic alcohols with iso-propyl (2-117) or 2-methylcyclopropyl (2-118) substituents 
(Figure 11). We then subjected them to the previously described microwave conditions in order 
to generate 4-alkyl substituted indoles. 
OH
N
Boc
O
OH
N
Boc
O
2-117 2-118  
Figure 11. New precursors for the IMDAF reaction 
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The general strategy presented in Scheme 26 permits the construction of compounds 2-
117 and 2-118. Starting with the previously synthesized aldehydes 2-119104,105 and 2-120,104 the 
addition of the lithiated 2-74 in THF at -78 °C furnished alcohols 2-117 and 2-118 in 36% and 
65% yield, respectively (Scheme 31). 
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n-BuLi, THF, -78 °C
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O
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65%
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N
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O
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Scheme 31. Synthesis of allylic alcohols 2-117 and 2-118 
Exposing alcohols 2-117 and 2-118 to microwave conditions in o-dichlorobenzene for 20 
min at 180 °C gave an incomplete conversion of the starting alcohols. Optimized conditions for 
this reaction, i.e. irradiation for 30 min at 180 °C under microwave conditions, led to complete 
consumption of starting materials and provided the corresponding indoles 2-121 and 2-122 in 
36% and 48% yield, respectively (Scheme 32). In spite of the lower yield observed for 2-121, the 
successful use of a cyclopropane-substituted compound in this reaction sequence is noteworthy. 
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Scheme 32. IMDAF reaction on substrates 2-117 and 2-118 
We were also interested in expanding the scope of this reaction to 3,4-disubstituted 
indoles derived analogously from addition of the lithiated analog of 2-74 to ,-unsaturated 
ketones. Treatment of the lithiated analog of 2-74 with 5 equiv of 2-cyclohexene-1-one (2-123) 
accomplished the formation of tert-alcohol 2-124 in 51% yield (Scheme 33). Exposure of 2-124 
to the standard microwave conditions provided the cyclohexane-annulated indole 2-125 in 84% 
yield. Importantly, the tricyclic core 2-125 is representative of the core heterocycle of many 
Ergot alkaloids (Figure 12). 
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Scheme 33. Synthesis of 3,4-disubstituted indole 2-125 
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Figure 12. Representative ergot alkaloids containing the tricyclic core 2-125 (outlined in red) 
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Notably, the presence of a hydrogen substituent at position 3 in intermediate 2-95 
(Scheme 27) was shown to be crucial for the completion of the sequence since the elimination of 
that hydrogen atom furnishes a cyclohexadiene intermediate, which easily rearomatizes to give 
the desired indole 2-97. With an alkyl group at position 3, aromatization is impossible in the 
absence of more forcing conditions. For example, when allylic alcohol 2-129 was synthesized 
from S-(+)-carvone (2-130) (Scheme 34), standard microwave conditions did not lead to indole 
product. Instead, gradual decomposition of the starting material was observed. 
O NBoc
Snn-Bu32-74
n-BuLi, THF, -78 °C
 
then OH
N
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74%
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Scheme 34. Control experiment with allylic alcohol 2-129 
2.2.2 Attempts toward the Synthesis of 7-Azaindoles 
Successful implementation of the IMDAF cascade process in the synthesis of indoles with 
different substitution patterns at positions 3 and 4 led us to a hypothesis that a similar strategy 
could be used in the synthesis of other heterocycles. Possible modifications in the structure of the 
original allylic alcohols and the corresponding products are shown in Figure 13. 
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Figure 13. Summary of possible modifications to the original allylic alcohol 
The incorporation of nitrogen at positions 3, 4, and 5 of the furan moiety would, in 
principle, allow us to synthesize 7-, 6-, and 5-azaindoles, respectively. The replacement of the 
oxygen atom with another heteroatom is not of any importance, since this heteroatom is being 
removed from the molecule in the late stage of this cascade process (Scheme 27). Finally, 
replacement of the N-atom from the tether with O or S, would lead us to 4-substituted 
benzo[b]furan or benzo[b]thiophene. 
7-Azaindoles have recently attracted the interest of the chemical community and form a 
part of many biologically active compounds.106 Differently acylated azaindole compounds have 
been reported to have analgesic and anti-inflammatory activities.107 Azaindole derivatives were 
also found to possess blood pressure lowering activity, acting as effective coronary, vasodilator, 
cardiovascular, and hypotensive agents.  
In order to test our hypothesis and apply our method to the synthesis of 7-azaindoles, we 
decided to start with the preparation of an allylic alcohol derived from 2-aminothiophene. As 
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shown in Scheme 35, we planned to synthesize the allylic alcohol 2-132 through a previously 
described sequence. N-Boc protection of 2-aminothiazole and subsequent alkylation with the 
known iodide 2-72 should provide the required tin reagent 2-133. Transmetallation of 2-133 with 
n-BuLi, and coupling with ,-unsaturated aldehyde should yield the desired alcohol 2-132. 
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Scheme 35. Retrosynthetic plan towards 7-azaindoles through the IMDAF cascade reaction 
2-Aminothiazole was prepared from bromoacetaldehyde diethylacetal 2-136 and thiourea 
2-137 in 56% yield, and subsequently N-Boc protected in 80% yield.108 As previously 
described,86 alkylation of 2-135 with 2-72 provided the required tin reagent 2-133 (Scheme 36). 
Attempts to add a lithiated 2-72 to trans-cinnamaldehyde (2-139) provided alcohol 2-141 instead 
of the desired allylic alcohol 2-140. Apparently, the intermediary anion 2-142 is basic enough to 
deprotonate the thiazole 5-position, and this proton exchange occurs faster than the addition of 
the electrophile. A similar observation was reported by Caldwell et al.109 
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Scheme 36. Coupling of 2-133 and trans-cinnamaldehyde 
To circumvent this problem, we envisioned that the desired allylic alcohol could be 
obtained from the corresponding ketone, which could be derived from 2-135 and bromoketone 2-
145 (Scheme 37). Thus, we brominated (E)-4-phenyl-3-butene-2-one 2-144 in a two-step 
procedure used by Iwasawa to obtain 2-145 in 90% yield.110 Alkylation of thiazole 2-135 with 
bromide 2-145 under basic conditions gave the corresponding ketone in 79% yield.111 Finally, 
ketone 2-146 was reduced with NaBH4 in MeOH to provide the desired allylic alcohol 2-140 in 
72% yield. Unfortunately, microwave irradiation of the solution of 2-140 in o-dichlorobenzene at 
180 °C for 20 min did not provide the desired 7-azaindole, and only starting material was 
recovered. 
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Scheme 37. Attempts toward 4-phenyl-7-azaindole (2-147) 
The low reactivity of thiazoles in the Diels-Alder reaction is probably due to their high 
aromaticity, i.e. delocalization of the -molecular orbitals that should participate in this [4+2] 
cycloaddition.112 Comparison of the bond order uniformity (i.e. the bond order deviation from an 
ideal bond order distribution in a ring) in few common dienes reveals the inherent stability of 
thiazoles in this process (Table 2). Large bond order deviation of a diene indicates more 
localized -electrons, and consequently the higher reactivity of the diene in the Diels-Alder 
reaction. Similarly, the smaller bond order deviation of 1,3-thiazole (0.985) relative to 
cyclopentadiene (1.986), furan (1.290), and 1,3-oxazole (1.296) indicates stronger delocalization 
of -electrons that participate in the [4+2] cycloaddition, and therefore lower reactivity.113     
Table 2. Comparison of the bond order deviations for different dienes with the AM1 semiempirical method using 
Chem-3D Plus 
Diene SBOa ABOb BDOc 
cyclopentadiene 6.763 1.353 1.986 
furane 6.738 1.348 1.290 
1,3-oxazole 6.712 1.342 1.296 
1,3-thiazole 6.824 1.365 0.985 
aSBO – sum of ring bond orders; bABO – average bond order; cBDO – sum of bond order deviation from the 
average ring bond order 
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2.2.3 Synthesis of Uhle’s Ketone through IMDAF Cascade Reaction 
Once we discovered a quick way to access tricycle 2-125 through the IMDAF cascade process, 
we hypothesized that other functionalized 2-cyclohexene-1-ones could also be used as starting 
materials in this reaction. As previously mentioned, Uhle’s ketone is a valuable building block in 
the synthesis of ergot-alkaloids, and thus attracted our attention as a potential synthetic target in 
order to demonstrate the utility of our methodology. 
Implementing the IMDAF reaction for the construction of the indole moiety requires 
alcohol 2-148 as a precursor to Uhle’s ketone (Scheme 38). We initially chose to use 
monoprotected diketone 2-149, to avoid potential alkyl-group migration and aromatization due to 
the inherent reactivity and instability of the corresponding unprotected dione. Furthermore, the 
preparation of 2-148 would be simpler and could be achieved by the addition of the lithium 
reagent to 2-149. The ,-unsaturated ketone 2-149 could be derived from the commercially 
available 2-150 using the Saegusa-Ito protocol to install the necessary unsaturation. 
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Scheme 38. Proposed route towards Uhle's ketone using the IMDAF reaction 
Indeed, formation of the TMS-enol ether of 2-150 under standard conditions, and 
treatment of this intermediate with Pd(OAc)2 in CH3CN for 20 h, afforded the desired ,-
unsaturated ketone 2-149 in 54% yield.114,115 When 2-74 was transmetallated with n-BuLi and 
then added to a solution of 2-149 in THF at -78 °C, clean alcohol 2-148 was isolated in 69% 
yield. When 2-148 was heated under microwave irradiation in trifluorotoluene at 185 °C for 1 h, 
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2-151 was isolated in 61% yield. Finally, treatment of 2-151 with aq HCl in THF/water (1:1) at 
room temperature116 gave Uhle’s ketone 2-106 in 74% yield.  
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Scheme 39. Synthesis of Uhle's ketone (2-106) 
Comparing to the previously published protocols for the synthesis of Uhle’s ketone, our 
route provides a high improvement for accessing this building block. In contrast to the 
previously reported Uhle’s and Bowman’s routes, which used several steps to prepare 4-
substituted indoles, our IMDAF strategy offers an opportunity for synthesizing this core in two 
steps, followed by a simple hydrolysis of the ketal. On the other hand, the Teranishi protocol 
suffers from an extensive use of environmentally harmful SOCl2 as well as the large excess of 
AlCl3, which makes the work-up procedure tedious.         
2.2.4 Conclusions 
We have extended the indole synthesis methodology previously developed in our group by 
showing that alkyl groups can also be installed in the 4-position of the indole ring. This protocol 
features a microwave assisted Diels-Alder cyclization of furans, which allows for a convergent 
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and rapid preparation of 4-monosubstituted and 3,4-disubstituted indoles. The cascade process is 
quite tolerant of functional groups and associated substitution patterns. Furthermore, this strategy 
is a convenient alternative to the standard transition metal mediated coupling processes for the 
synthesis of heterocycles, which yield products that are often contaminated with trace metal 
residues that can interfere with biological assays and therapeutic applications. 
Although a similar strategy could, in principle, be used in the synthesis of other related 
heterocycles, we showed that the 7-azaindole core cannot be easily obtained using IMDA. This 
increased stability of thiazoles may be due to the higher bond order uniformity comparing to 
other common dienes, indicating the stronger delocalization of -electrons that are included in 
the [4+2] cascade process. However, we successfully applied the previously developed IMDAF 
protocol in the synthesis of the synthetically valuable building block, Uhle’s ketone, in 4 steps 
starting with the commercially available 1,4-cyclohexanedione monoethyleneketal (2-150). 
2.3 EXPERIMENTAL PART 
General: All moisture-sensitive reactions were performed under an atmosphere of N2. Glassware 
was flame dried prior to use. Reactions carried out at -78 °C employed a dry ice/acetone bath. 
THF and Et2O were dried by distillation over Na/benzophenone ketyl, Et3N was distilled from 
CaH2, and CH2Cl2 and toluene were purified using an alumina filtration system. Unless 
otherwise stated, solvents and reagents were used as received. Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F254 plates (250 m layer thickness, 
particle size 0.040-0.055 mm, 230-240 mesh) and visualization was accomplished with a 254 nm 
UV light and/or by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 
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95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of 
conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O244H2O and 0.2 
g of Ce(SO4)2 in 100 mL of a 3.5 M H2SO4 solution), or a KMnO4 solution (1.5 g of KMnO4 and 
1.5 g of K2CO3 in 100 mL of a 0.1 % NaOH solution). Flash chromatography on SiO2 was used 
to separate and purify the reaction crude mixtures. Microwave reactions were performed on a 
Biotage Initiator microwave reactor. 1H and 13C NMR were recorded on a Bruker Avance 300 
instrument. Chemical shifts () were reported in parts per million with the residual solvent peak 
used as an internal standard. 1H NMR spectra were run at 300, 400 or 500 MHz, and are 
tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, sept = septet, 
m = multiplet, br = broad, app = apparent), number of protons, and coupling constant(s). 13C 
NMR spectra were obtained using a proton-decoupled pulse sequence with a d1 of 3 sec, and are 
tabulated by observed peak. LC/MS analyses were obtained from a Helwett Packard Series 1100 
MSD. RP HPLC was obtained from Gilson Series 215, using C18 column, Bio-rad Laboratoris, 
250 x 4.6 mm. Mass spectra were obtained on a Micromass Autospec double focusing 
instrument. Infrared spectra were measured on a Nicolet AVATAR 360 FT-IR E.S.P. 
spectrometer (KBr or neat) or Smiths Detection IdentifyIR FT-IR spectrometer (ATR). 
O
NHBoc
 
tert-Butyl furan-2-ylcarbamate (2-73).86 To a solution of 2-furoyl chloride (2.00 g, 15.3 mmol) 
in t-BuOH (16 mL) was added sodium azide (1.13 g, 17.5 mmol) and the resulting mixture was 
stirred at room temperature for 24 h, and then 85 °C and stirred for 16 h. The solvent was 
removed under reduced pressure, and the residue was purified by chromatography on SiO2 (10% 
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EtOAc/hexanes) to obtain 2-73 (1.26 g, 45%) as a white solid: IR (ATR) 3252, 3237, 1698, 
1538, 1154 cm-1; 1H NMR (400 MHz, CDCl3)  7.06 (dd, 1 H, J = 2.0, 0.8 Hz), 6.68 (s, 1 H), 
6.34 (dd, 1 H, J = 2.8, 2.0 Hz), 6.04 (s, 1 H), 1.51 (s, 9 H); 13C NMR (100 MHz, CDCl3)  151.9, 
145.4, 136.1, 111.3, 95.1, 81.3, 28.2; HRMS (TOF MS ESI) m/z calcd for C9H14NO3 [M+H]+ 
184.0974, found 1184.1006. 
n-Bu3Sn I  
Tri-n-butyl(iodomethyl)stannane (2-72).86 To a solution of diisopropylamine (1.05 g, 11.1 
mmol) in THF (14 mL) at 0 °C was added a solution of n-BuLi (1.6 M solution in hexane, 6.6 
mL, 11 mmol), stirred for 30 min, and treated with a solution of TBTH (2.81 g, 9.65 mmol) in 
THF (5.8 mL) over 30 min. The reaction mixture was stirred for 30 min at room temperature, 
treated with paraformaldehyde (0.42 g, 14 mmol), warmed to room temperature, and stirred for 3 
h. The resulting clear and colorless solution was diluted with Et2O (60 mL) and washed with 
water (35 mL). The aqueous phase was separated, and extracted with Et2O (3 x 15 mL). The 
combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated in 
vacuo to obtain 2-71 (3.1 g, 97%) as a colorless liquid, which was used in the next step without 
further purification. To a stirred solution of PPh3 (2.57 g, 9.81 mmol) in THF (20 mL) was added 
dropwise a solution of NIS (2.0 g, 9.8 mmol) in THF (20 mL), and stirred at room temperature 
for 10 min. To this solution was added a solution of the alcohol 2-71 (2.1 g, 6.5 mmol) in THF 
(20 mL), and the resultant mixture was stirred at room temperature for 16 h. The reaction 
mixture was then poured into petrol-ether/water, organic layer was separated, dried (Na2SO4), 
and concentrated under reduced pressure. Purification by chromatography on SiO2 (hexanes) 
gave 2-72, which was distilled (bp 110 °C/0.1 mm Hg) to obtain 2-72 (2.1 g, 74%) as a colorless 
oil: IR (ATR) 2934, 2846, 1461, 667 cm-1; 1H NMR (500 MHz, CDCl3)  1.95 (s, 2 H), 1.56-
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1.50 (m, 6 H), 1.33 (app sext, 6 H, J = 7.5 Hz), 1.00-0.97 (m, 6 H), 0.913 (t, 9 H, J = 7.5 Hz); 13C 
NMR (125 MHz, CDCl3)  28.8, 27.2, 13.7, 10.6. 
Alternatively, following the procedure used by Seitz et al.,117 n-BuLi (1.6 M in hexanes, 72.5 
mL, 115 mmol) was added at -78°C to a solution of diisopropylamine (17.7 mL, 127 mmol) in 
THF (230mL). The reaction mixture was stirred at 0 °C for 15 min, treated with tri-n-butyltin 
hydride (31.0 mL, 115 mmol), stirred for 30 min at 0 °C, and treated with paraformaldehyde 
(3.46 g, 115 mmol). The mixture was stirred for 3 h at room temperature, then cooled to -78 °C, 
and treated dropwise with methanesulfonyl chloride (11.8 mL, 152 mmol). The resulting mixture 
was stirred at room temperature for 16 h. THF was removed under reduced pressure and water 
was added. The resulting aqueous phase was extracted with hexanes. The combined organic 
layers were washed with brine and dried (MgSO4), filtered and concentrated under reduced 
pressure. To a solution of crude (chloromethyl)tributylstannane in acetone (209 mL) was added 
NaI (26.9 g, 179 mmol). The resulting mixture was stirred at room temperature for 16 h. Water 
was added and the resulting aqueous phase was extracted with Et2O. The combined organic 
layers were washed with brine, dried (MgSO4), and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (hexanes) furnished 2-72  (44.0 g, 96%) as a colorless 
oil. 
O NBoc
Snn-Bu3  
Tert-butyl furan-2-yl((tri-n-butylstannyl)methyl)carbamate (2-74).86 To a solution of 2-73 
(0.61 g, 3.3 mmol) in DMF (4.5 mL) at 0 °C was added sodium hydride (88.0 mg, 3.67 mmol) 
slowly, until hydrogen gas evolution stopped. The mixture was stirred at 0 °C for 1 h, and then 
treated dropwise with 2-72. The reaction mixture was stirred for 2 h at 0 °C and then partitioned 
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between Et2O and saturated aqueous solution of NH4Cl. The aqueous layer was extracted with 
Et2O, the combined organic layers were washed with water, brine, dried (Na2SO4), and 
concentrated in vacuo. Purification by chromatography on SiO2 (hexanes) gave 2-74 (1.41 g, 
87%) as a colorless liquid, which became yellowish upon storage at room temperature or in the 
freezer. In this case, the material needed another purification by chromatography. 2-74: IR 
(ATR) 2952, 2919, 1694, 1156 cm-1; 1H NMR (400 MHz, CDCl3)  7.14 (dd, 1 H, J = 2.4, 1.2 
Hz), 6.33 (t, 1 H, J = 2.8 Hz), 5.92 (s, 1 H), 3.38 (s, 2 H), 1.50-1.40 (m, 14 H), 1.27 (app sext, 6 
H, J = 7.2 Hz), 0.90-0.88 (m, 16 H); 13C NMR (120 MHz, CDCl3)  154.0, 150.0, 136.8, 111.1, 
99.0, 81.0, 70.0, 29.0, 28.2, 27.4, 13.7, 9.7; HRMS (TOF MS ESI) m/z calcd for C22H42NO3Sn 
[M+H]+ 488.2187, found 488.2185. 
OH
N
Boc
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(E)-tert-Butyl furan-2-yl(2-hydroxy-5-methylhex-3-enyl)carbamate (2-117). To a solution of 
furanyl stannane 2-7490 (0.33 g, 0.60 mmol) in THF (10 mL) under nitrogen atmosphere at -78 
°C was added dropwise a solution of n-BuLi (1.60 M in hexane, 0.43 mL, 0.69 mmol). The 
reaction mixture was stirred for 1 h at -78 °C, treated dropwise with a solution of aldehyde 2-119 
(64.0 mg, 0.652 mmol) in THF (2 mL) over 5 min, stirred for 3 h, and quenched with saturated 
aq NH4Cl (5 mL). The layers were separated, the aqueous layer was further extracted with ether 
(3 x 20 mL), and the combined organic layers were dried (Na2SO4), and concentrated in vacuo. 
Purification by chromatography on SiO2 (10% EtOAc/hexanes) afforded 2-117 (72.3 mg, 36%) 
as a yellowish oil: IR (ATR) 3438, 2958, 1709, 1610, 1364, 1150, 1148 cm-1; 1H NMR (300 
MHz, CDCl3)  7.19-7.18 (m, 1 H), 6.34 (dd, 1 H, J = 3.0, 2.4), 6.02 (bs, 1 H), 5.72 (dd, 1 H, J = 
15.6, 6.6 Hz), 5.39 (ddd, 1 H, J = 15.6, 6.6, 0.9 Hz), 4.26-4.33 (m, 1 H), 3.57-3.71 (m, 2 H), 2.6 
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(bs, 1 H), 2.21-2.33 (m, 1 H), 1.44 (s, 9 H), 0.97 (d, 3 H, J = 6.6 Hz); 13C NMR (75 MHz, 
CDCl3)  148.6, 140.2, 138.2, 126.5, 111.0, 101.4, 81.7, 71.7, 55.0, 30.6, 28.1, 22.1 (2 C); MS 
(EI) m/z 295 (M+, 24), 195 (18), 134 (35), 96 (74), 57 (100); HRMS (TOF MS ESI) m/z calcd for 
C16H25NO4 [M+Na]+ 318.1681, found 318.1678. 
OH
N
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(E)-tert-Butyl furan-2-yl(2-hydroxy-4-(2-methylcyclopropyl)but-3-enyl)carbamate  (2-118). 
To a solution of furanyl stannane 2-74 (0.30 g, 0.62 mmol) in THF (9 mL) under nitrogen 
atmosphere at -78 °C was added dropwise a solution of n-BuLi (1.60 M in hexane, 0.38 mL, 0.62 
mmol). The reaction mixture was stirred for 1 h at -78 °C, treated dropwise over 5 min with a 
solution of aldehyde 2-120 (64.6 mg, 0.586 mmol) in THF (2 mL), stirred for 3 h, and quenched 
with saturated aq NH4Cl (5 mL). The layers were separated and the aqueous layer was further 
extracted with ether (3 x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography on SiO2 (1 to 5% EtOAc/hexanes) 
afforded 2-118 (124.2 mg, 65%) as a colorless oil: IR (ATR) 3437, 2978, 2871, 1713, 1613, 
1391, 1369, 1158 cm-1; 1H NMR (300 MHz, CDCl3)  7.19 (s, 1 H), 6.34 (s, 1 H), 6.02 (s, 1 H), 
5.45 (dd, 1 H, J = 15.3, 6.6 Hz), 5.28 (dd, 1 H, J = 15.3, 8.7 Hz), 4.22-4.31 (m, 1 H), 3.62-3.64 
(m, 2 H), 1.48 (s, 9 H), 1.05 (d, 3 H, J = 5.7 Hz), 0.70-0.80 (m, 1 H), 0.51-0.57 (m, 1 H), 0.46-
0.50 (m, 1 H); 13C NMR (75 MHz, CDCl3)  148.7, 138.2, 137.0, 136.9, 126.5, 111.0, 101.5, 
81.7, 71.8, 55.0, 28.1, 22.3, 18.4, 15.3, 15.2; MS (EI) m/z 307 (M•+, 4), 251 (9), 207 (34), 189 
(93), 134 (49), 96 (91), 69 (42), 57 (100); HRMS (EI) m/z calcd for C17H25NO4 307.1784, found 
307.1809. 
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General procedure for the synthesis of 4-substituted indoles (2-121 and 2-122). A solution of 
the corresponding alcohol in o-dichlorobenzene (2.5 mL) was heated in a microwave reactor for 
30 min at 180 °C. The reaction mixture was poured on a silica-gel column (packed with 
hexanes), and flushed with hexanes until o-dichlorobenzene was completely removed. 
Compounds 2-121 and 2-122 were purified by chromatography on SiO2 (1-5% EtOAc/hexanes). 
N
H  
4-Isopropyl-1H-indole (2-121). According to the General Protocol, alcohol 2-117 (26.3 mg) 
was converted to the colorless oily indole 2-121 (5.1 mg, 36%): IR (ATR) 3401, 2956, 2866, 
1498, 1409, 1340, 743 cm-1; 1H NMR (300 MHz, CD2Cl2)  8.26 (br s, 1 H), 7.25 (d, 1 H, J = 
8.1 Hz), 7.22 (t, 1 H, J = 2.7 Hz), 7.17-7.11 (m, 1 H), 6.98 (d, 1 H, J = 7.2 Hz), 6.65-6.62 (m, 1 
H), 3.38 (sept, 1 H, J = 7.2 Hz), 1.38 (d, 6 H, J = 6.9 Hz); 13C NMR (75 MHz, CD2Cl2)  141.6, 
136.4, 127.1, 124.0, 122.7, 115.9, 109.3, 101.4, 31.9, 23.5; MS (EI) m/z 159 (M•+, 100); HRMS 
(EI) m/z calcd for C11H13N 159.1048, found 159.1047. 
N
H  
4-(2-Methylcyclopropyl)-1H-indole (2-122). According to the General Protocol, alcohol 2-118 
(20.1 mg) was converted to the colorless oily indole 2-122 (5.4 mg, 48%): IR (ATR) 3401, 2948, 
1580, 1500, 1338, 1075, 745 cm-1; 1H NMR (300 MHz, CDCl3)  8.15 (br s, 1 H), 7.23-7.21 (m, 
2 H), 7.11 (app t, 1 H, J = 7.5 Hz), 6.73-6.67 (m, 2 H), 1.99-1.93 (m, 1 H), 1.28 (d, 3 H, J = 5.4 
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Hz), 1.28-1.16 (m, 1 H), 1.10-1.05 (m, 1 H), 0.82-0.76 (m, 1 H); 13C NMR (75 MHz, CDCl3)  
136.1, 135.5, 123.4, 122.2, 114.8, 108.2, 101.1, 22.1, 19.4, 16.6, 16.1; MS (EI) m/z 171 (M•+, 
77), 156 (80), 86 (68), 84 (100); HRMS (EI) m/z calcd for C12H13N 171.1048, found 171.1047. 
OH
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tert-Butyl furan-2-yl((1-hydroxycyclohex-2-enyl)methyl)carbamate (2-124). To a solution of 
stannane 2-74 (250.0 mg, 0.5140 mmol) in THF (7.5 mL) under an atmosphere of nitrogen at -78 
°C was added dropwise a solution of n-BuLi (1.60 M in hexane, 0.32 mL, 0.51 mmol). The 
reaction mixture was stirred for 1 h at -78 °C, treated dropwise over 5 min with a solution of 2-
cyclohexane-1-one (247.1 mg, 2.570 mmol) in THF (1.5 mL), stirred for 1 h, and quenched with 
saturated aq NH4Cl (5 mL). The layers were separated and the aqueous layer was further 
extracted with ether (3 x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated in vacuo. Purification by chromatography on SiO2 (10% EtOAc/hexanes) afforded 
2-124 (75.6 mg, 51%) as a colorless oil: IR (ATR) 3508, 2974, 2931, 1709, 1688, 1366, 1159, 
1150 cm-1; 1H NMR (300 MHz, CDCl3)  7.17 (br s, 1 H), 6.36-6.33 (m, 1 H), 6.00 (br s, 1 H), 
5.82 (app dt, 1 H, J = 9.9, 3.0 Hz), 5.58 (d, 1 H, J = 9.9 Hz), 3.75 (d of AB, 1 H, J = 14.7, 0.9), 
3.69 (d of AB, 1 H, J = 14.7, 1.2 Hz), 2.10-1.56 (m, 6 H), 1.44 (s, 9 H); 13C NMR (75 MHz, 
CDCl3)  149.4, 138.0, 130.4, 130.1, 111.0, 101.5, 81.9, 70.7, 58.5, 33.6, 28.1, 25.2, 19.0; MS 
(TOF MS ES) m/z 316 [M+23]+ (100), 242 (60), 198 (48); HRMS (TOF MS ESI) m/z calcd for 
C16H23NO4 [M+Na]+ 316.1525, found 316.1494. 
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H  
2,6,7,8-Tetrahydrobenzo[cd]indole (2-125). According to the General Protocol, alcohol 2-124 
(25.0 mg) was converted to indole 2-125 (11.2 mg, 84%) which was isolated as a white solid: 
Mp 48.6-50.2 °C; IR (ATR) 3399, 2920, 2833, 1439, 1081, 1025, 745 cm-1; 1H NMR (600 MHz, 
CD2Cl2)  7.92 (br s, 1 H), 7.12 (d, 1 H, J = 4.2 Hz), 7.06 (t, 1 H, J = 3.3 Hz), 6.86 (s, 1 H), 6.78 
(d, 1 H, J = 3.3 Hz), 2.92 (t, 2 H, J = 3.0 Hz), 2.85 (dt, 2 H, J = 3.3, 0.3 Hz), 2.04 (app quint, 2 
H, J = 3.0 Hz); 13C NMR (150 MHz, CD2Cl2)  134.5, 132.8, 127.7, 123.0, 117.7, 116.1, 114.3, 
108.5, 28.0, 25.3, 22.4; MS (EI) m/z 157 (M•+, 100); HRMS (EI) m/z calcd for C11H11N 
157.0891, found 157.0894. 
NH2
S
N  
Thiazol-2-amine (2-138).108 To a solution of thiourea (3.81 g, 50.0 mmol) and 
bromoacetaldehyde diethylacetal (9.85 g, 50.0 mmol) in EtOH (100 mL) was added aq HCl 
(37%, 2.5 mL), reflux for 3 h, cooled to room temperature, and concentrated to ca. 100 mL. The 
mixture was added to ice-water, treated with aq NaOH (10%) to adjust pH to 8-9, extracted with 
DCM (3 x 50 mL), washed with brine, and dried (Na2SO4). Purification by chromatography on 
SiO2 (30% EtOAc/ hexanes) gave 2-138 (2.82 g, 56%) as an off-white solid: Mp 88.4-90.6 °C; 
IR (ATR) 3403, 3282, 3188, 1619, 1487 cm-1; 1H NMR (500 MHz, DMSO-d6)  6.92 (d, 1 H, J 
= 3.5 Hz), 6.87 (br s, 2 H), 6.54 (d, 1 H, J = 3.5 Hz); 13C NMR (125 MHz, DMSO-d6)  168.8, 
138.6, 106.5; HRMS (EI) m/z calcd for C3H5N2S [M+H]+ 101.0173, found 101.0204. 
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tert-Butyl thiazol-2-ylcarbamate (2-135).108 To a solution of 2-aminothiazole 2-138 (2.83 g, 
28.3 mmol) in DCM (100 mL) at room temperature were added Boc2O (6.78 g, 31.1 mmol), 
Et3N (9.9 mL, 71 mmol) and DMAP (cat. amount), stirred at this temperature for 3 h, quenched 
with 0.1 M aq HCl (to pH 5-6), extracted with EtOAc (4 x 20 mL), washed with brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (50% 
EtOAc/hexanes) gave 2-135 (3.20 g, 80%) as a white solid: Mp 87.4-86.0 °C; IR (ATR) 2975, 
2934, 1709, 1566, 1288, 1249, 1152 cm-1; 1H NMR (400 MHz, CDCl3)  12.42 (br s, 1 H), 7.39 
(d, 1 H, J = 3.6 Hz), 6.89 (d, 1 H, J = 3.6 Hz), 1.60 (s, 9 H); 13C NMR (100 MHz, CDCl3)  
161.9, 153.0, 136.7, 112.0, 81.8, 28.3; HRMS (EI) m/z calcd for C8H12N2O2S [M+H]+ 201.0698, 
found 201.0704. 
N
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tert-Butyl thiazol-2-yl((tributylstannyl)methyl)carbamate (2-133). To a solution of 2-135 
(100.0 mg, 0.499 mmol) in DMF (1.0 mL) at 0 °C was added NaH (13.1 mg, 0.549 mmol) 
slowly, stirred at this temperature for 1 h, and then treated with Bu3SnCH2I (0.28 g, 0.65 mmol). 
After 2 h, the reaction mixture was diluted with water, extracted with EtOAc (5 x 10 mL), 
washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by chromatography 
on SiO2 (5% EtOAc/hexanes) gave 2-133 (240.1 mg, 96%) as a colorless oil: IR (ATR) 2952, 
2921, 1694, 1366, 1150 cm-1; 1H NMR (500 MHz, CDCl3)  7.38 (d, 1 H, J = 3.5 Hz), 6.89 (d, 1 
H, J = 4.0 Hz), 3.84 (dd, 1 H, J = 11.0 Hz), 1.60 (s, 9 H), 1.46-1.41 (m, 6 H), 1.25 (dt, 6 H, J = 
15.0, 7.5 Hz), 0.86 (t, 9 H, J = 7.5 Hz), 0.82-0.79 (m, 6 H); 13C NMR (100 MHz, CDCl3)  
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161.3, 153.2, 137.3, 113.8, 82.7, 34.1, 29.0, 28.3, 27.4, 13.7, 10.2; HRMS (ESI) m/z calcd for 
C21H40N2O2SSnNa [M+Na]+ 527.1730, found 527.1748. 
Ph
O
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(E)-1-Bromo-4-phenylbut-3-en-2-one (2-145).110 To a solution of DIPA (2.0 mL, 16 mmol) in 
THF (40 mL) at -78 °C was added n-BuLi (1.6 M in hexane, 10.3 mL, 16.4 mmol), stirred at 0 
°C for 15 min, and then cooled to -78 °C. To this solution was added a solution of benzalacetone 
(2-144) (2.0 g, 14 mmol) in THF (5 mL), stirred at -78 °C for 1.5 h, quenched with TMSCl (1.74 
mL, 13.7 mL), and stirred at room temperature for 2 h. The solvent was removed in vacuo. The 
residual suspension was filtered quickly through a pad of silica-gel, and washed with hexane (3 x 
10 mL). The filtrate was concentrated in vacuo, and the resulting crude silyl enol ether was 
subjected to the next step without further purification or characterization. To a solution of silyl 
enol ether in THF (20 mL) at -40 °C was added NBS (3.0 g, 16 mmol), and stirred overnight at 
this temperature. The mixture was then poured into saturated aq Na2S2O3, extracted with EtOAc 
(4 x 10 mL), washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (10% EtOAc/hexanes) gave 2-145 (2.76 g, 90%) as a dark liquid: IR 
(ATR) 2975, 1681, 1605, 1062 cm-1; 1H NMR (500 MHz, CDCl3)  7.72 (d, 1 H, J = 16.0 Hz), 
7.60 (t, 1 H, J = 1.5 Hz), 7.59 (t, 1 H, J = 2.0 Hz), 7.45-7.41 (m, 3 H), 6.97 (d, 1 H, J = 16.0 Hz), 
4.10 (s, 2 H); 13C NMR (125 MHz, CDCl3)  190.9, 145.3, 133.9, 131.1, 129.0, 128.6, 122.2, 
33.0; HRMS (EI) m/z calcd for C10H9Br 223.9837, found 223.9879. 
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(E)-tert-Butyl 2-oxo-4-phenylbut-3-enyl(thiazol-2-yl)carbamate (2-146). To a solution of 
bromide 2-145 (220.0 mg, 0.9774 mmol) in acetonitrile at room temperature was added thiazole 
2-135 (177.9 mg, 0.8885 mmol), followed by K2CO3 (245.6 mg, 1.777 mmol). The reaction 
mixture was heated to 50 °C for 2 h, diluted with water and EtOAc, extracted with EtOAc (4 x 5 
mL), washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (10% EtOAc/hexanes, dry load) gave 2-146 (241.0 mg, 79%) as a 
yellow solid: Mp 101.0-102.8 °C; IR (ATR) 2986, 2975, 1705, 1364, 1154 cm-1; 1H NMR (400 
MHz, CDCl3)  7.72 (d, 1 H, J = 16.4 Hz), 7.58 (d, 1 H, J = 2.0 Hz), 7.56 (d, 1 H, J = 2.8 Hz), 
7.42-7.41 (m, 3 H), 7.35 (d, 1 H, J = 3.2 Hz), 6.95 (br s, 1 H), 6.84 (d, 1 H, J = 16.0 Hz), 1.53 (s, 
9 H); 13C NMR (125 MHz, CDCl3)  193.0, 161.3, 143.7, 137.1, 134.2, 130.8, 129.0, 128.4, 
122.5, 114.5, 83.6, 82.0, 54.5, 28.0; HRMS (ESI) m/z calcd for C18H20N2O3SNa [M+Na]+ 
376.1092, found 376.1072. 
Ph
OH
N
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(E)-tert-Butyl 2-hydroxy-4-phenylbut-3-enyl(thiazol-2-yl)carbamate (2-140). To a solution of 
2-146 (28.0 mg, 0.0813 mmol) in MeOH (0.5 mL) was added NaBH4 (6.2 mg, 0.16 mmol), and 
stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo, diluted with 
water, extracted with EtOAc (3 x 5 mL), washed with brine, dried (Na2SO4), and concentrated in 
vacuo. Purification by chromatography on SiO2 (20% EtOAc/hexanes) gave 2-140 (20.2 mg, 72 
%) in the form of colorless oil: IR (ATR) 3400, 2975, 2816, 1700, 1152 cm-1; 1H NMR (500 
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MHz, CDCl3)  7.43 (d, 1 H, J = 3.5 Hz), 7.40-7.38 (m, 2 H), 7.32 (dt, 2 H, J = 7.0, 1.5 Hz), 
7.25-7.22 (m, 1 H), 6.99 (d, 1 H, J = 3.5 Hz), 6.72 (d, 1 H, J = 16.0 Hz), 6.29 (dd, 1 H, J = 16.0, 
6.0 Hz), 4.69 (d, 1 H, J = 5.5 Hz), 4.36-4.28 (m, 2 H), 1.55 (s, 9 H); 13C NMR (125 MHz, 
CDCl3)  163.7, 136.7, 130.8, 129.4, 128.5, 128.3, 127.6, 126t5, 125.8, 114.6, 78.0, 72.4, 53.9, 
28.1; HRMS (ESI) m/z calcd for C18H23N2O3S [M+H]+ 347.1429, found 347.1439. 
OO
O  
1,4-Dioxaspiro[4.5]dec-6-en-8-one (2-149).114 To a stirred solution of 1,4-cyclohexadiene 
monoethylene ketal (1.19 g, 7.62 mmol) and triethylamine (3.21 mL, 22.86 mmol) in CH2Cl2 (50 
mL) at 0 °C was added a solution of TMSOTf (1.52 mL, 8.38 mmol) in CH2Cl2 (20 mL) over 10 
min, stirred for 2 h, quenched with saturated aq NaHCO3. Organic layer was separated, dried 
(Na2SO4), and concentrated in vacuo. The residue was dissolved in CH2Cl2, filtered through a 
plug of SiO2, washed with CH2Cl2 (50 mL), and concentrated in vacuo to give the corresponding 
TMS-enol ether, which was used crude, without further purification or characterization: 1H NMR 
(400 MHz, CDCl3)  4.73 (t, 1 H, J = 3.6 Hz), 3.98 (s, 4 H), 2.27 (s, 4 H), 2.22 (t, 2 H, J = 6.4), 
1.81 (t, 2 H, J = 6.4 Hz), 0.19 (s, 9 H).  
The solution of the intermediate TMS-enol ether (1.40 g) in CH3CN (80 mL) was treated with 
Pd(OAc)2 (0.54 g, 2.40 mmol) and stirred at room temperature for 14 h. The reaction mixture 
was then concentrated in vacuo, dissolved in CH2Cl2, washed with saturated aq NaHCO3, 
concentrated in vacuo, and purified by chromatography on SiO2 (50% EtOAc/hexanes) to 
provide 2-149 (0.63 g, 54%) as a yellowish oil: IR (ATR) 2958, 1676, 1217, 1115 cm-1; 1H NMR 
(400 MHz, CDCl3)  6.62 (d, 1 H, J = 10.0 Hz), 6.01 (d, 1 H, J = 10.4 Hz), 4.05 (dd, 4 H, J = 
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6.8, 4.0 Hz), 2.63 (t, 2 H, J = 6.4 Hz), 2.20 (t, 2 H, J = 6.4 Hz); 13C NMR (125 MHz, CDCl3)  
198.7, 146.3, 130.5, 104.0, 65.0, 35.3, 32.9; HRMS (ESI) m/z calcd for C8H11O3S 155.0708, 
found 155.0734. 
O
O OH
N
O
Boc  
tert-Butyl furan─2─yl((8─hydroxy─1,4─dioxaspiro[4.5]dec─6─en─8yl)methyl)carbamate 
(2-148). To a solution of tin reagent 2-74 (315.4 mg, 0.6487 mmol) in THF (2.5 mL) at -78 °C 
was added n-BuLi (1.6 M in hexane, 0.4 mL, 0.6 mmol), stirred at -78 °C for 1 h. To this 
solution was added a solution of 2-149 (100.0 mg, 0.6487 mmol) in THF (2.5 mL), stirred at this 
temp for 1 h, quenched with saturated aq NH4Cl, extracted with EtOAc (4 x 5 mL), dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (30-50% 
EtOAc/hexanes) gave 2-148 (156.6 mg, 69%) as a yellowish oil: IR (ATR) 3482, 2975, 1709, 
1366, 1146 cm-1; 1H NMR (500 MHz, CDCl3)  7.17 (dd, 1 H, J = 1.0 Hz), 6.33 (dd, 1 H, J = 
3.0, 2.0 Hz), 6.00 (br s, 1 H), 5.78 (d, 1 H, J = 10.0 Hz), 5.61 (d, 1 H, J = 10.5 Hz), 3.99-3.91 (m, 
4 H), 3.79 (d, 1 H, J = 15.0 Hz), 3.69 (d, 1 H, J = 15.0 Hz), 2.01-1.96 (m, 1 H), 1.93-1.86 (m, 2 
H), 1.76-1.71 (m, 1 H), 1.44 (s, 9 H); 13C NMR (125 MHz, CDCl3)  149.0, 138.2, 134.5, 129.2, 
111.0, 105.1, 101.7, 82.3, 70.7, 64.6, 64.5, 57.4, 31.7, 30.3, 28.0; HRMS (TOF MS ESI) m/z 
calcd for C18H25NO6Na [M+Na]+ 374.1580, found 374.1585. 
 82 
N
H
O
 
3,4-Dihydrobenzo[cd]indol-5(1H)-one (2-106): A solution of 2-148 (34.0 mg, 0.0968 mmol) in 
trifluorotoluene (3.5 mL) was heated in the microwave oven for 60 min at 180 °C. The solvent 
was removed in vacuo, and the residue was filtered through a plug SiO2 (20% EtOAc/hexanes) to 
provide 2-151 (12.7 mg, 61%) as a colorless oil, which was used in the next step without further 
purification.  
To a solution of crude 2-151 (7.0 mg, 0.033 mmol) in water/THF (1:1; 2 mL) was added 
hydrochloric acid (6 M, 1 drop). The mixture was stirred at room temperature for 30 min, 
extracted with EtOAc, washed with brine, dried (Na2SO4), and concentrated in vacuo. 
Purification by chromatography on SiO2 (20% EtOAc/hexanes) gave Uhle’s ketone 2-106 (5.6 
mg, 74%) as a yellowish solid: Mp 161.2-162.4 °C (lit. mp 162-164 °C);116 IR (ATR) 3224, 
3210, 2924, 1648, 1616 cm-1; 1H NMR (500 MHz, CDCl3)  8.16 (br s, 1 H), 7.62 (d, 1 H, J = 
7.5 Hz), 7.55 (d, 1 H, J = 8.0 Hz), 7.30 (t, 1 H, J = 8.0 Hz), 7.09 (s, 1 H), 3.28 (t, 2 H, J = 7.5 
Hz), 2.94 (t, 2 H, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3)  198.6, 134.7, 132.4, 125.9, 122.8, 
120.2, 115.7, 115.6, 110.8, 39.4, 20.8; HRMS (ESI) m/z calcd for C11H10NO 172.0762, found 
172.0735. 
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3.0  TOTAL SYNTHESIS OF CYCLOCLAVINE AND 5-EPI-CYCLOCLAVINE 
3.1 INTRODUCTION 
3.1.1 Ergot Alkaloids 
Ergot alkaloids comprise a notable class of indole-containing alkaloids. They are produced by 
fungi of the families Clavicipitaceae (e.g., Claviceps and Neotyphodium) and Trichocomaceae 
(including Aspergillus and Penicillium), which affect the seeds of various plants, mostly rye and 
other cerial grains. These natural products are striking for their molecular architecture and wide 
spectrum of physiological activity.118,119 Nowadays, ergot alkaloids have found widespread 
clinical use, and more than 50 formulations contain natural or semisynthetic ergot alkaloids. The 
broad physiological effects are based mostly on their interactions with neurotransmitter 
receptors, resembling some important neurohumoral mediators (e.g., noradrenalin, serotonin, 
dopamine).120 
The ergot alkaloid family consists of two distinct structural types which are distinguished 
by the nature of the functionality present in the six-membered ring D in the common tetracyclic 
core, called ergoline (3-1, Figure 14).121 Thus, while the lysergic acid subclass has oxygenated 
substituents at position C(8) of the ergoline core (D-ring), the clavine subclass alkaloids features 
alkyl chains at that position. 
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Figure 14. Ergot alkaloid sturcture types and representative examples of two subclasses 
(common ergoline core outlined in red) 
The ergoline nucleus has been a challenging target for total synthesis with attempts 
dating back to the classic work of Uhle in 1949 and culminating in the synthesis of lysergic acid 
by Woodward and coworkers in 1954.122,123 The total synthesis of ergot alkaloids received 
increasing attention in the 1980s and 1990s, and the pursuit of synthesizing these alkaloids has 
led to the development of new strategies for the construction of the ergoline core.120 With a vast 
majority of research existing in literature regarding the synthesis of ergot alkaloids, only 
approaches relevant to the material contained in this dissertation will be mentioned. 
3.1.2 Approaches to Ergot Alkaloids 
In 1954 Woodward and coworkers published the first total synthesis of an ergot alkaloid – 
lysergic acid (3-2, Scheme 40).123,124 Their pioneering work commences with N-benzoylated 3-
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(-carboxyetheyl)dihydroindole (3-6), which was converted into tricyclic ketone 3-7 through a 
two-step sequence. Compound 3-7 was brominated and subsequently converted to the 
corresponding -aminoketone 3-8. The synthesis of the D-ring (ergoline numbering) was 
completed through an intramolecular aldol reaction of the ketone derived from 3-8. After several 
functional group manipulations, the necessary carboxylic group was introduced at position 8. 
Finally, the indole moiety was formed through a dehydrogenation step, which provided lysergic 
acid (3-2) in 30% yield.    
N
Bz
CO2H 1. SOCl2
2. AlCl3, CS2
    46 °C, 1 h
77% (2 steps) NBz
O 1. PyrHBr3, AcOH
    60 °C, 30 min; 69%
2.
OO
NHCH3
benzene, 80 °C
21 h; 93%
NBz
O
NCH3
O
O
1. HCl, H2O, 5 d; 77%
2. NaOCH3, EtOH
    -10 °C, 10 min; 69%
NH
NCH3
O
1. Ac2O, benzene,
    80 °C, 21 h; 93% 
2. NaBH4, CH3OH/H2O
    rt, 2 h; 79%
3. SOCl2, SO2(l), autoclave
    rt, 6 h; > 90%
NAc
NCH3
Cl 1. NaCN, HCN(l), 0 °C; 54%
2. CH3OH, H2SO4, 100 °C
    24 h; 53%
3. KOH (aq), Na3AsO4, Ra-Ni
    100 °C, 20 h; 30%
NH
NCH3
HO2C
3-6 3-7 3-8
3-9 3-10 3-2  
Scheme 40. Woodward's approach to lysergic acid (3-2) 
A unique approach by Ninomiya and coworkers features a reductive photocyclization of a 
furan enamide for the construction of the ergoline D-ring, followed by a glycol formation and 
oxidative cleavage of the dihydrofuran ring.125 Initial coupling of 3-11 with furan-3-carbonyl 
chloride afforded enamide 3-12 in 96% yield (Scheme 41). Elaboration of the D-ring was 
achieved by irradiation of enamide 3-12 in the presence of excess of NaBH4, which afforded the 
pentacyclic amide 3-13 in 54% yield. Subsequent functional group transformations led to 3-15, a 
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direct precursor to isofumigaclavine 3-16. Similar to Woodward’s approach, the indole moiety 
was established through a late stage dehydrogenation of the indoline core. 
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Scheme 41. Reductive photocyclization approach to clavine alkaloids by Ninomiya 
The recent synthesis of costaclavine (3-23) reported by Padwa employs the Pummerer 
cyclization-deprotonation-cycloaddition cascade reaction of imidosulfoxides (Scheme 42).126 
Starting with the known amide 3-17, the authors prepared imidosulfoxide 3-18 in 94% yield over 
two steps. When 3-18 was subjected to the Pummerer-deprotonation conditions, tetracyclic 
intermediate 3-21 was isolated in 64% yield. This interesting transformation presumably 
involves the formation of the isomüchnone 3-20, followed by an intramolecular 1,3-dipolar 
cycloaddition, thus allowing the rapid construction of the D-ring. Several additional functional 
group conversions, including the indoline oxidation in the last step, led to the completion of (±)-
3-23. 
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Scheme 42. Padwa's cycloaddition approach to ergot alkaloids 
In the recent synthesis of lysergic acid reported by Szántay,127 the D-ring of the ergoline 
core was formed by an intramolecular aldol reaction, similar to the Woodward’s approach. 
However, the Szántay group employed Uhle’s ketone, possessing the necessary indole moiety, 
thus avoiding the low yielding indoline oxidation in the last step. Elaboration of 3-
indolepropionic acid (3-24) into N-unprotected 4-bromo-Uhle’s ketone (3-26),128 followed by an 
SN2 displacement of the secondary bromide and a ketal deprotection afforded a diketone, a direct 
precursor to 3-28. The enantiomers of (±)-3-28 were further separated using (–)-dibenzoyl-L-
tartaric acid, which, after several additional steps, allowed the completion of (+)-lysergic acid (3-
2). 
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Scheme 43. Szántay's synthesis of lysergic acid 
In 2004, Hendrickson and Wang reported a 10-step synthesis of (±)-lysergic acid (3-2).129 
Following the initial Suzuki coupling of boronic acid 3-29 and m-chloropyridine 3-30, the diester 
3-31 was selectively converted into aldehyde 3-32, which under basic conditions allowed for the 
synthesis of the entire core of the lysergic acid. A few additional manipulations provided the 
desired acid 3-2 in a 6:1 ration with its cis-isomer isolysergic acid. 
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Scheme 44. Hendrickson's approach to the ergoline core 
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3.1.3 Biosynthetic Relationship of Ergot Alkaloids 
Based on the information obtained from gene clusters, significant progress has been made in the 
identification of the biosynthetic pathways towards ergot alkaloids. Functions of six out of seven 
genes found in all known ergot alkaloid clusters have been proven experimentally. Their roles 
were assigned to reaction steps from L-tryptophan to festuclavine (3-40) or agoraclavine (3-
41).119,130 
The biosynthesis of ergot alkaloids begins with the prenylation of L-tryptophan (3-35) at 
position C(4) of the indole ring in the presence of dimethylallyl pyrophosphate (DMAPP). This 
reaction is catalyzed by the prenyltransferase 4-dimethylallyltryptophane synthase (4-DMATS). 
The product of 4-DMATS is further methylated at the amino group by (S)-adenosyl methionine, 
resulting in the formation of N-methyl dimethylallyl tryptophane 3-37. 
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Scheme 45. Proposed biosynthesis of ergot alkaloids 
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The next detected intermediate in the biosynthesis of ergot alkaloids is chanoclavine-I (3-
38). Although no direct proof of this transformation exists, it is believed that it includes at least 
three steps: decarboxylation, stereoselective cyclization, and hydroxylation of one methyl group 
of the dimethylallyl unit. Further oxidation of the primary alcohol by a short-chain 
dehydrogenase/reductase (SDR) in the presence of NAD+ yields chanoclavine-I aldehyde (3-39), 
the presence of which has been proven by feeding experiments with isotopically labeled 
precursors.131 
Chanoclavine-I aldehyde is the branch point in the biosynthesis of ergot alkaloids. While 
in the synthesis of the clavine subclass of ergot alkaloids chanoclavine-I aldehyde undergoes 
reductive cyclization and olefin reduction, the synthesis of the D-ring in the lysergic acid 
subclass is believed to proceed without the reduction of alkene, thus enabling the subsequent 
allylic oxidation and the introduction of the oxygenated substituent at C(8). 
3.1.4 Cycloclavine 
Cycloclavine (3-5, Figure 15) was first isolated in 1969 from the seeds of the African 
morning glory (Ipomea hildebrandtii) by Hoffman and co-workers.132 On the basis of 
spectroscopic data and an X-ray crystallographic analysis of its methobromide salt, these 
investigators were able to establish the absolute configuration of all stereocenters. Later, other 
research groups found cycloclavine among other ergot alkaloids in different Aspergillus and 
Argyrea fungi.133,134 
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Figure 15. Structure of cycloclavine (3-5) 
In spite of its small size (C16H18N2, MW = 238), possessing only sixteen carbon atoms, 
cycloclavine has a very interesting structure. Its compact molecular framework displays three 
contiguous stereogenic centers, two of which are fully substituted and part of a cyclopropane 
ring, thus posing a respectable synthetic challenge.135 
In contrast to other ergot alkaloids of the clavine subclass with a 6-membered D-ring in 
the ergoline core, cycloclavine contains an additional C(8)-C(10) bridge, making this molecule 
unique among other members of this family. Although no significant biological activity has been 
reported to date, the total synthesis of this remarkable ring system is an attractive venture. 
3.1.5 Previous Work on the Total Synthesis of Cycloclavine 
In 2008, Szántay and coworkers reported the first total synthesis of (±)-cycloclavine 
(Scheme 46). 
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Scheme 46. Szántay's approach to (±)-cycloclavine 
The initial SN2 displacement of 4-bromo-Uhle’s ketone (3-26), which was synthesized 
according to the previously mentioned route (Scheme 43) with ethyl 3-N-
methylaminopropanoate (3-42) afforded amine 3-43. An intramolecular aldol reaction under 
basic conditions provided hydroxyester 3-44 as a 65:35 inseparable mixture of isomers, which 
was subsequently subjected to water elimination with POCl3 in pyridine, which gave 3-45, 
isolated as a hydrochloride salt in 25% yield. 
From this intermediate, the construction of the target molecule required the complete 
reduction of the allylic ester, as well as the installation of the necessary cyclopropane moiety. 
Thus, ester reduction followed by an oxidation/reduction sequence, furnished 8-methyl-D-
norergoline 3-46 in 56% yield. The final cyclopropanation, although a straightforward 
transformation, proved to be very challenging and was achieved by using diazomethane in the 
presence of Pd(OAc)2 as a catalyst. (±)-Cycloclavine was isolated as a hydrochloride salt in 22% 
yield (32% brsm). Accordingly, this total synthesis features 14 steps and an overall yield of 0.2% 
for the longest linear sequence. 
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Our group joined this arena shortly before the first total synthesis of cycloclavine was 
published. Dr. Timmons, a former Wipf group member, evaluated a new strategy towards 
cycloclavine, based on two key steps: the oxidative cyclization of a methyl tyramine, and the 
construction of an indole by an intramolecular furan Diels-Alder reaction (Scheme 47).89 
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Scheme 47. Oxidative cyclization/IMDAF approach to cycloclavine 
Since the development of the oxidative cyclization of tyrosine to hydroindoles by Wipf 
and coworkers in 1992,136 it has been used in the total synthesis of three members of the Stemona 
alkaloid family: stenine,137 tuberostemonine,138 and sessilifoliamide C.139 In addition, this 
approach seemed attractive for the possible construction of the hydroindoline part of the 
cycloclavine scaffold. With this in mind, a direct precursor to the hydroindole moiety would be 
methyl tyramine (3-49). 
The requisite methyl tyramine (3-49) was synthesized from 4-benzyloxybenzaldehyde (3-
50) and nitromethane (Scheme 48). The corresponding nitrostyrene 3-51 was isolated in 58% 
yield and subjected to the conjugate addition of methyl magnesium bromide. A hydrogenative 
deprotection of the benzyl ether and a reduction of the nitro group afforded the desired methyl 
tyramine (3-49) in 61% yield over 2 steps. Final Boc-protection of the primary amine gave the 
corresponding carbamate 3-53. 
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Scheme 48. Synthesis of N-Boc protected methyl tyramine (3-53) 
Exposure of methyl tyramine 3-53 to standard oxidative cyclization conditions using 
iodosobenzene diacetate (PIDA) as the oxidant did not provide any desired product. Changing 
the oxidant to iodosobenzene bis(trifluoroacetate) (PIFA) or oxone did not improve the results, 
and in all cases complex reaction mixtures were obtained with no detectable quantities of the 
desired product. 
 After considerable reaction optimization, it was found that N-benzoyl protected methyl 
tyramine (3-54) underwent an oxidative cyclization process, giving the desired hydroindole 3-55 
in 43% yield (Scheme 48). At this stage, elimination of the benzoate group to form the diene 3-
57 would have furnished the required scaffold for the hydroindoline system of cycloclavine. 
Unfortunately, benzoate removal under thermal and -allyl palladium conditions proved to be 
unsuccessful. Although the alcohol could be unmasked quantitatively by treatment of the 
benzoate ester with K2CO3 in methanol, all attempts to dehydrate 3-56 to the resulting diene 3-57 
resulted in the formation of phenol 3-58. 
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Scheme 49. Attempts towards diene 3-57 
In the revised strategy, following the established protocol, hydroindoline 3-60 was 
accessed in one pot from Boc-protected L-tyrosine 3-59. Gratifyingly, the exposure of 3-60 to 
POCl3 in pyridine yielded the desired diene 3-61 in 67%. Unfortunately, all attempts to install 
the necessary methyl group at C(8) (ergot alkaloid numbering) through a 1,6-conjugate addition 
using a variety of copper salts were unsuccessful. Similarly, all trials to decarboxylate the methyl 
ester through a vinylogous Krapcho elimination with LiCl in DMSO, or through an oxidation-
decarboxylation sequence yielded either a very complex mixture of products or an undesired 
phenol 3-63. 
HO
NHBoc
CO2H
1. PhI(OAc)2
    CH3CN/i-PrOH
    (3:1)
2. Na2CO3 (aq)
    CH3OH
    17% (2 steps)
O NBoc
HO
H
3-60
CO2CH3
3-59
POCl3
pyridine
67% O
N
BocH
3-61
CO2CH3
O NBocH
3-61
CO2CH3
O NBocH
3-62
CO2CH3
CH3
1,6-addition
X
decarboxylation
HO NBoc
3-63  
Scheme 50. Oxidative cyclization of Boc-L-tyrosine and elaboration of the diene 3-61 
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3.2 RESULTS AND DISSCUSION 
On the basis of our previous success in indole ring formation summarized in Chapter 2.2, we 
decided to apply the IMDAF strategy to install the indole portion of cycloclavine (Scheme 51). It 
was anticipated that indoline 3-65 should be the precursor for the cascade process. Indeed, as we 
have shown previously, the 1,2-addition of the tin-lithium exchanged product of stannane 3-48 to 
an ,-unsaturated ketone should provide an allylic tertiary alcohol, which under previously 
optimized conditions cyclizes to give an indole. According to our retrosynthetic plan, we 
assumed that the stability of the cyclopropane moiety in the hydroindoline intermediate 3-64 was 
sufficient to allow a thermal [4+2] process,90 leading us to the idea of constructing the indole 
portion of cycloclavine in the last step of our synthesis. 
HN
N
CH3H
CH3
cycloclavine (3-5)
ON
Boc
n-Bu3Sn
3-48
Intramolecular Diels-Alder
reaction of furan
N
CH3H
CH3
HO
BocN
O
N
CH3H
CH3
O3-64
+
3-65  
Scheme 51. Strategy for the indole formation in our synthesis of cycloclavine 
3.2.1 1st Generation Approach: Cascade TBS-Deprotection/Cyclopropanation Process 
Initially, we envisioned that the retrosynthetic disassembly of tricyclic ketone 3-65 furnished the 
reduced and protected intermediate 3-66 as a potential precursor. If successful, this maneuver 
would accomplish the formation of the cyclopropane ring in the late stage of the synthesis and 
allow a quick access to a higher level of molecular complexity starting from a seemingly simple 
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precursor. Although we feared that the strained cyclopropane ring would be difficult to form, we 
also had much confidence in this cyclization method, since the results of numerous experiments 
underscored its utility for the construction of cyclopropanes.140 
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Scheme 52. Retrosynthetic approach to 3-65: tandem TBS-deprotection/cyclopropanation 
 The primary alcohol group, an essential element for the conversion of 3-67 to 3-66, was 
derived from the ester moiety in 3-67. Based on the Vedejs’ procedure, it was anticipated that the 
ester moiety could be stereoselectively introduced in a two-step protocol employing an O-
acylation of lactam 3-68, followed by an enantioselective TADMAP-catalyzed carboxyl 
migration.141 Finally, lactam 3-69 could be further simplified by cleavage of the C(8)-C(10) 
bond, through an intramolecular Friedel-Crafts reaction. Intermediate 3-70, a direct precursor to 
3-69, could be traced retrosynthetically to the commercially available chloroacetyl chloride (3-
72) and TBS-protected 3-aminophenol (3-71). 
Our approach to cycloclavine began with the tert-butyldimethylsilyl protection of 3-
aminophenol and the conversion of aniline 3-71 to its N-acylated analog 3-74 (Scheme 53). 
Intermediate 3-74 was exposed to several standard conditions previously described for an 
intramolecular Friedel-Crafts reaction.142,143 Unfortunately, all attempts to induce cyclization 
were unsuccessful, and instead of cyclized product 3-75, TBS-deprotection was observed. 
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Scheme 53. Attempted formation of 2-indolinone 3-69 
In 2005, Hennessy and Buchwald reported a synthesis of 2-oxindoles via palladium-
catalyzed C-H activation of -chloroacetanilides.144 Although initial attempts to induce 
cyclization of 3-74 following the Buchwald protocol failed, we found that when the N-
methylated amide 3-70, obtained in 95% yield from 3-74, was heated in toluene in the presence 
of a catalytic amount of Pd(OAc)2 and phosphine catalyst 3-77, the desired cyclized product 3-69 
was generated in 77% yield. N-Methylation was certainly a required step in our synthesis, and a 
simple change in order of steps gratifyingly afforded indolinone 3-69, easily prepared in 
multigram quantities following this protocol. 
TBSO NH
O
Cl
3-74
(CH3)2SO4
NaOH, BnEt3NCl
CH2Cl2/H2O
95% TBSO
N
CH3
O
Cl
3-70
Pd(OAc)2 (2 mol%)
3-77 (1 mol%)
Et3N, toluene, 80°C
77%
TBSO NCH3
O
3-69
t-Bu2P
3-77 (JohnPhos)  
Scheme 54. Synthesis of indolinone 3-69 via Pd-catalyzed C-H activation 
We were now in a position to address the installation of methyl and carboxyl groups at 
position C(8). As mentioned before, it was anticipated that this could be achieved by treating the 
anion with methyl iodide, followed by an O-acylation and an acyl-transfer using Vedejs’ 
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protocol.141 When 3-69 was treated with LiHMDS in THF at -78 °C in the presence of HMPA, 
followed by the addition of methyl iodide, 3-68 was isolated in 74% yield (Scheme 55). After 
successful O-acylation of 3-68 with methyl chloroformate, a critical stage of the synthesis had 
been reached. Although the acyl transfer could be performed in a stereoselective fashion, we 
decided to first use (±)-TADMAP (3-79) in this transformation to check its feasibility. Indeed, 
treatment of 3-78 with (±)-TADMAP in the solution of t-AmOH resulted in the formation of 3-
67 in 75% yield. 
TBSO NCH3
O
3-69
LiHMDS, HMPA
THF, -78 °C
then CH3I
-78 °C, 3 h; 74% TBSO
N
CH3
O
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THF, -78 °C; 65%
CH3
TBSO NCH3
O
CH3 O
OCH3
3-78
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t-AmOH, rt; 75% TBSO NCH3
H3CO2C CH3
O
3-67
N
(H3C)2N
CPh3
OAc
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Scheme 55. Introduction of methyl- and methoxycarbonyl groups at C(8) 
As discussed previously, the use of an ester moiety represented an important feature of 
the synthesis, since its conversion to the primary alcohol would lead to the cyclization precursor 
that would enable cyclopropane formation. This tactic would install another quaternary 
stereocenter and allow the formation of the intermediate dienone in an enantioselective fashion. 
Unfortunately, all attempts toward a selective reduction of the ester function led to either loss of 
the ester or a complete reduction to the corresponding indole (Table 3). 
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Table 3. Attempts toward reduction of ester 3-67  
TBSO NCH3
H3CO2C CH3
O
3-67
conditions
TBSO NCH3
OH
CH3
O
3-66
N
CH3
CH3
TBSO NCH3
CH3
TBSO
O++
3-683-80  
Entry Conditions Result 
1 LiAlH4 (1 equiv), THF, -78 °C 3-68 
2 DIBAL (1 equiv), THF, -78 °C 3-80 (6%) + 3-68 (52%) 
3 DIBAL (1.2 equiv), toluene, -78 °C (12 h) 3-68 (34%) 
4 LiBH4 (1 equiv), THF, -78 to 0 °C to rt 3-80 (23%) + 3-68 (43%) 
5 BH3 (2 equiv), THF, -78 to 0 °C; then 66 °C, 2 h Decomposition during heating 
The lack of success in the ester reduction forced us to identify another way to install the 
necessary hydroxymethyl moiety. Hydroxymethylbenzotriazol (3-81), developed by Katrizky’s 
group145 and used as an efficient source of formaldehyde by Bischoff,146 appeared to be 
particularly attractive. Indeed, treating 3-68 with LiHMDS in THF at -78 °C, followed by the 
addition of a suspension of 3-81 in THF, furnished the desired alcohol 3-66 in 90% yield. From 
this intermediate, the construction of the cyclopropane ring required only a hydroxyl group 
activation, followed by a TBS-deprotection. Primary alcohol 3-66 was converted to the 
corresponding mesylate in high yield. Treatment of this mesylate with TBAF in THF (0.1 M) 
resulted in a complex mixture of products. In contrast, under high dilution conditions (0.006 M), 
TBAF promoted a silyl ether cleavage, with a concomitant intramolecular alkylation to give 3-
82.147 
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Scheme 56. Synthesis of 3-82: tandem TBS-deprotection/cyclopropane formation 
We were now at the stage of a very challenging transformation. A selective reduction of 
the cross-conjugated dienone 3-82 would provide the desired enone 3-65, a direct precursor for 
the key IMDAF reaction. Only a few literature reports of selective reductions of this type had 
been reported, but in all cases the starting material did not contain labile moieties as in 3-82. 
Thus, this transformation was a concern, but we hoped that we could effect it by taking 
advantage of Lewis acidic reducing agents and the electron-donating properties of the -amino 
substituent. However, in spite of considerable experimentation, our attempts to regioselectively 
reduce the trisubstituted alkene in 3-82 proved to be unsuccessful (Scheme 57). Hydride 
reductions in the presence of Lewis acids (NH4Br/NaBH3CN, BF3•Et2O/Et3SiH, 
Me3OBF4/NaBH4)148 led only to the recovered starting material. Under hydrogenation conditions 
(H2, Pd/C), formation of the corresponding phenol 3-83 was observed with concomitant opening 
of the cyclopropane ring. When 3-82 was subjected to SmI2/HMPA reduction,149 opening of the 
cyclopropane ring was detected. These observations indicated that the more substituted double 
bond in 3-82 was difficult to reduce chemoselectively, which, on the other hand, was expected, 
given the fact that this olefin is a part of a conjugated enamide moiety. In addition, the cross-
conjugated dienone increases the reactivity of the cyclopropane ring, favoring its opening under 
hydrogenation conditions.  
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The next obvious step was a selective reduction of the less substituted olefin in the cross-
conjugated dienone 3-82, hoping that, after a successful reduction of the intermediate enamide, 
introduction of the unsaturation at C(11)-C(16) would be feasible. Using conditions reported by 
Lipshutz, dienone 3-82 was selectively reduced with Stryker’s reagent and PhSiH3 in toluene, 
and the corresponding enamide 3-84 was isolated in quantitative yield.150 
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Scheme 57. Attempts toward selective reduction of dienone 3-82 
As stated before, partial reduction of dienone 3-82 diminishes the reactivity of the 
cyclopropane ring. This gave us an opportunity to thoroughly investigate conditions for the 
reduction of the alkene present in 3-84 (Scheme 58). Initial attempts towards hydrogenation led 
only to the isolation of starting material.151 A similar result was obtained when Hantzsch ester (3-
85) was used as a hydride source.152 Metal hydrides, on the other hand, led to the reduction of the 
keto-group, giving either a mixture of allylic alcohols with the double bond intact (in the case of 
NaBH4/i-PrOH) or completely reduced 3-87 (in the case of NaBH3CN under acidic conditions). 
To our surprise, when 3-84 was subjected to hydrogenation under high pressure (70 bar), using 
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Raney-Ni as a catalyst, a mixture of diastereomeric alcohols 3-88 was isolated in quantitative 
yield. Oxidation of 3-88 under the Swern conditions provided the desired ketone 3-89 in 79% 
yield as a single diastereomer. 
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Scheme 58. Attempts toward enamide reduction and synthesis of 3-89 
Reduction of the enamide 3-84 to the corresponding alcohol 3-88, and its subsequent 
oxidation to provide 3-89 need an additional comment. Although successful, the reduction-
oxidation sequence from 3-84 to 3-89 provided only one diastereomer, but we were not able to 
ascertain the relative configuration at C(5) in 3-89 at this point. Based on the Newman projection 
of 3-84, we hypothesized that the cyclopropane moiety would shield the -face from hydrogen 
delivery (Figure 16). If our hypothesis was correct, the reduction-oxidation sequence would 
provide the desired diastereomer of 3-89, in which hydrogen atom at C(5) and the methyl group 
at C(8) are on the same face of the hydroindoline core. In other words, the hydrogen delivery 
should occur selectively from the -face, leading to the desired stereochemistry at C(5). Hoping 
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that our rationale was valid and that the stereochemistry at C(5)-C(10) in 3-89 was trans as in 3-
89’, we continued with our journey towards cycloclavine. 
N
CH3
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O
H
H
H3C
H H
 
Figure 16. Newman projection of 3-84 and disfavored hydrogen delivery from the -face 
Following our previously mentioned plan, we next attempted to install the necessary 
unsaturation at C(11)-C(16) (cycloclavine numbering) in 3-89 (Scheme 59). Accordingly, we 
subjected 3-89 to several conditions for the formation of the corresponding silyl enol ether, 
followed by the Pd(OAc)2-assisted oxidation (Saegusa-Ito protocol).115 Treating 3-89 with either 
HMDS153 or LiTMP154 as a base, followed by the addition of a slight excess of TMSI (1.2–1.5 
equiv), and then subjecting the intermediate TMS-enol ether to the Saegusa-Ito conditions 
provided the undesired regioisomer 3-84  as a sole product. On the other hand, heating the 
mixture of 3-89, TMSOTf (5 equiv) and Et3N (5 equiv) in acetonitrile at reflux for 2.5 h,155 
followed by the oxidation with Pd(OAc)2 in DMSO led to the formation of both regioisomers 3-
65 and 3-84 in 1:2 ratio (93% combined yield), favoring the formation of the more substituted 
alkene 3-84. Using Mukaiyama’s reagent156 or IBX in DMSO157 led to the exclusive formation 
of the undesired isomer 3-84 in 45% and 66% yields respectively. 
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Scheme 59. Formation of the ,-unsaturated ketone 3-65 
The strong preference for the formation of the undesired regioisomer 3-84 under kinetic 
conditions could be partly attributed to the rigid nature of 3-89 (i.e. the fused ring system with a 
cyclopropane moiety and a quaternary center), which might prevent the approach of the base 
from the seemingly less hindered side. In addition, the electron-withdrawing nature of the 
nitrogen atom at the -position probably increases the acidity of the -proton at C(4). Under 
thermodynamic conditions, however, the preference for the formation of the undesired 
regioisomer 3-84 probably lies in the fact that the double bond is a part of an extended 
conjugated system, thus favoring the formation of the enamide. 
In order to address the problem associated with the regioselective introduction of the 
alkene, we decided to make a major modification to our synthetic strategy. The successful 
synthesis of dienone 3-82 and the more reactive nature of the less substituted alkene led us to a 
hypothesis that, perhaps, this alkene unit could be protected as an epoxide, which would, after a 
successful reduction of the enamide moiety, provide a handle for the formation of the desired 
enone 3-65 (Scheme 60). 
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Scheme 60. Modification of the initial strategy toward 3-65 
Accordingly, epoxidation of 3-82 with tert-butyl hydroperoxide (TBHP) in THF158 
provided monoepoxide 3-92 as a sole regio- and stereoisomer (Scheme 61). Following the 
procedure of Miyashita and coworkers,159 3-92 was regioselectively opened with 
Na[PhSeB(OEt)3] in EtOH, furnishing -hydroxy ketone 3-93 in 85% yield. Thus, the 
disubstituted alkene in 3-82 was masked as a secondary alcohol. Further protection of the 
secondary alcohol with TBSCl in DMF provided 3-94 in 66% yield. This additional protection 
was necessary since the reduction of the enamide fragment under previously mentioned 
conditions (Raney-Ni, H2 (80 bar), 6 h, rt) also leads to the formation of a secondary alcohol. 
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Scheme 61. Masking the less substituted olefin in 3-82 as an alcohol 
Hydrogenation of 3-94 followed by PCC oxidation afforded 3-95 in quantitative yield. As 
stated before, the hydrogen delivery in this step was assumed to occur from the -face since it 
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was expected that the fused cyclopropane ring would block the -attack. Exposure of 3-95 to a 
TBAF solution in THF promoted the -elimination of the intermediary formed hydroxyketone 
and furnished the ,-unsaturated ketone 3-65’ in 62% yield. 
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Scheme 62. Formation of the desired enone 
After tin-lithium exchange of stannane 3-48 followed by a 1,2-addition to 3-65’ in THF, a 
single isomer of the tertiary alcohol 3-97 was obtained in 63% yield (Scheme 63). When 3-97 
was heated in o-dichlorobenzene at 190 °C for 1 h under microwave irradiation, a cyclized 
product 3-98 was isolated in 60% yield. Finally, after exposure of lactam 3-98 to LiAlH4 in THF 
at reflux, we were pleased to see the formation of the final product 3-99. 
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Scheme 63. Synthesis of 5-epi-cycloclavine (3-99) 
Unfortunately, the analytical data of 3-99 did not match those of cycloclavine. An X-ray 
analysis of 3-99 confirmed the cis-configuration at the C(5)-C(10) ring fusion of the indoline 
substructure. Such a stereochemical outcome, which comes from the hydrogenation step, 
revealed the strong substrate preference for the delivery of hydrogen from the -face. This was 
surprising, since not only the hydrogenation of the TBS-ether 3-95, but also the deoxygenated 
analog 3-84, provided a sole hydrogenation isomer. Comparison of the 1H NMR data for 3-84 
and 3-95 confirmed the same stereochemistry at C(5), which was assigned to be trans with 
respect to the C(8)-CH3 group, based on the X-ray analysis of 5-epi-cycloclavine (3-99).  
These substrate preferences, in addition to the difficulties in reducing the trisubstituted 
alkene in dienone 3-82, required a complete redesign of our retrosynthetic approach. 
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3.2.2 2nd Generation Approach: Formation of the Indoline Core via a [4+2] Cycloaddition 
The main feature of our new strategy is the introduction of the C(5)-C(10) trans-hydroindole by 
an intramolecular methylenecycopropane Diels-Alder reaction, which is presented in a 
retrosynthetic format in Scheme 64. Disconnection of dibromide 3-100, a direct precursor to 3-
65, furnishes intermediate 3-102. Such transformation would be used to set two stereocenters in 
our synthesis of cycloclavine and to construct the hydroindoline core in one step. Although a few 
cases of the intramolecular [4+2] cycloaddition of unsubstituted methylenecyclopropane and 
other simple derivatives (such as perfluoromethylenecyclopropane, 2,2-
difluoromethylenecyclopropane, and methyl 2-chloro-2-cyclopropylidene acetate) have been 
described in literature,160-163 there is only one prior report of an intramolecular, high-pressure 
Diels-Alder reaction with this strain-activated dienophile.164 This intramolecular [4+2] 
cycloaddition of an exocyclic olefin with the diene portion of 3-102 would be expected to afford 
the trans-C(5)-C(10) TMS-enol ether 3-100, which, after conventional functional group 
manipulations, could be converted to the desired enone 3-65. The synthetic problem is now 
reduced to the construction of amide 102, and it was anticipated that this objective could be 
achieved by merging -aminovinyl ketone 3-104165 and the primary bromide derived from the 
TBS-protected alcohol 3-103.  
On the basis of Kuivila’s pioneering work in the 1960s,166 olefin 3-103, the projected 
dienophile component for the Diels-Alder reaction, could conceivably be derived from allene 3-
105 by a selective dibromocyclopropanation of the more electron-rich double bond, which in 
turn could be obtained from propargylic chloride, a process previously described in literature.167  
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Scheme 64. Retrosynthetic analysis of 3-65: cycloaddition approach 
Our cycloaddition approach toward the cycloclavine precursor 3-65 commenced with the 
conversion of acetyl chloride into -chlorovinyl ketone 3-107. In this simple transformation, 
acetylene gas was bubbled through a solution of acetyl chloride in dichloroethane in the presence 
of AlCl3 to furnish 3-107 in 45% yield. Exposure of 3-107 to methylamine resulted in an 
addition-elimination process, which provided 3-104 in 98% yield after overnight extraction using 
diethyl ether. 
The synthesis of fragment 3-103 started with a previously well-established protocol.168 
Treatment of propargylic chloride with stoichiometric amounts of n-BuLi, followed by the 
addition of formaldehyde, provided propargylic alcohol 3-108 in 76% yield. After protection of 
the hydroxyl group in the form of a tert-butyldimethylsilyl ether, propargylic chloride 3-109 was 
converted into the allene 3-105 with MeMgBr in the presence of CuI. However, the allene was 
isolated in variable yields, depending on the scale and the quality of CuI. 
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Scheme 65. Synthesis of intermediates 3-104 and 3-110 
One of the challenging tasks remaining for the synthesis of 3-65 was the chemoselective 
cyclopropanation of the more substituted double bond in the allene intermediate 3-105. Although 
allenes can successfully be cyclopropanated,169-171 only a few chemoselective examples are 
available in the literature. As previously mentioned, using the Kuivila procedure and exposure of 
the allene intermediate to one equivalent of CHBr3 in the presence of t-BuOK in pentane resulted 
in the formation of the desired dibromocyclopropane 3-103 in modest yield.  Finally, TBS-
deprotection of the primary alcohol furnished dibromocyclopropylmethyl alcohol 3-110 with the 
required exocyclic olefin fragment. 
With the two requisite coupling components in hand, the next step was the union of 
fragments 3-110 and 3-104. This seemingly straightforward transformation proved to be very 
difficult. Several conditions, including various leaving groups (OMs, OBs, OTf, Br) in 3-110 as 
well as different bases (NaH, n-BuLi, Et3N), were examined, but none of them gave rise to the 
desired coupling product 3-102. Instead, decomposition of 3-110 was observed. 
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Scheme 66. Attempted coupling of 3-104 and 3-110 
At this stage, another major overhaul of our synthetic strategy was clearly needed. We 
believed that the failure of our previous approach could partly be attributed to the reactive nature 
of the dibromocyclopropyl intermediates (3-111 – 3-114), which decompose under the basic 
conditions used for the attempted coupling. In order to overcome this problem, we decided to 
synthesize the corresponding methylenecyclopropyl derivative 3-118 (Scheme 67). The main 
feature of this route is the transformation of the corresponding dibromocyclopropyl moiety to the 
desired olefin, the necessary dienophile for the Diels-Alder reaction, prior to the coupling with 
the vinylogous amide 3-104. Accordingly, -methallyl alcohol 3-115 was THP-protected and 
converted to dibromocyclopropane 3-116 under phase transfer conditions in 86% overall yield. 
Exposure of 3-116 to n-BuLi (1 equiv) at -95 °C in THF and subsequent treatment of the 
monobromo-monolithiated intermediate with CH3I furnished the tertiary bromide 3-117. When 
3-117 was treated with t-BuOK in DMSO at room temperature, a clean conversion to the 
corresponding dehydrobrominated product 3-118 was observed. Finally, THP-deprotection with 
p-TsOH•H2O in CH3OH provided the desired cyclopropylmethylidene alcohol 3-119. 
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1. DHP, HCl (cat.); 90%
2. CHBr3, Et3N
    cetrimide, NaOH
    CH2Cl2/H2O; 95%
OTHP
Br
Br
n-BuLi (1 equiv)
THF, -95°C
then CH3I (15 equiv)
-95 °C to rt, 2 h; 82%
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t-BuOK
DMSO
rt, 12 h
69%
OTHP
p-TsOH•H2O
CH3OH, rt, 2 h
79%
OH
3-115 3-116 3-117
3-118 3-119  
Scheme 67. Synthesis of cyclopropylmethylidene alcohol 3-119 
Conversion of this alcohol to the corresponding mesylate 3-120, followed by the N-
alkylation of the anion of vinylogous amide 3-104 cleanly provided the desired coupling product 
3-121 in 67% yield from 3-119. As we had hypothesized, the presence of the 
dibromocyclopropane moiety in 3-110 was apparently the cause of the failure of the attempted 
coupling with 3-104 under basic conditions. 
OH
3-119
MsCl, Et3N
CH2Cl2
0 °C to rt, 1 h
OMs
3-120
O
NHCH3
3-104
NaH, DMF, rt, 1 h
then 3-120, rt, 12 h
67% (2 steps)
O
N
CH3
CH3
3-121  
Scheme 68. Coupling between 3-120 and 3-104 
With this coupling product in hand, we set out to convert 3-121 into the corresponding 
TBS-enol ether (Scheme 69). Formation of the silyloxy diene was originally met with some 
problems. Common bases, such as LiHMDS, LDA, or KHMDS gave either no reaction or very 
complex mixtures of products, as evidenced by 1H NMR. Gratifyingly, treatment of 3-121 with 
NaHMDS (1 equiv) in THF, followed by TBSCl trapping of the enolate provided a clean 
conversion of 3-121 to 3-122 in quantitative yield.172 It is worth mentioning that, although 
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several procedures employ an aqueous work-up followed by a TBS-enol ether purification by 
chromatography on SiO2,173-175 3-122 was found to be very easily hydrolyzed, to the extent that 
even a TLC-analysis could not be used to monitor the reaction progress.  
The crude Diels-Alder precursor 3-122 was smoothly converted to the indoline 3-123 by 
microwave irradiation in ,,-trifluorotoluene at 195 °C for 1 h. The tricyclic ketone 3-124 was 
isolated in 85% yield after removal of the TBS group with TBAF. 
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THF, -78 °C, 1 h
then TBSCl (1 equiv)
-78 °C to rt, 2 h; quant.
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Scheme 69. Intramolecular Diels-Alder reaction of TBS-enol ether 3-122 
The configuration of 3-124 could not be assigned from 1H NMR or 2D NMRs due to 
overlap of the indicative proton signals. However, after slow evaporation of the chloroform 
solution of 3-124, a chloroform adduct 3-125 was obtained as a crystalline compound, the X-ray 
crystallographic analysis of which confirmed the desired trans-configuration at the indoline ring 
fusion bond. Thus, the configuration at C(5) in 3-124 was unambiguously assigned to be cis with 
respect to the methyl group at C(8).   
Remarkably, the aforementioned intramolecular Diels-Alder reaction provided, after TBS 
deprotection with TBAF, 3-124 as a sole diastereomer. Although the desired diastereomer was 
isolated and its structure confirmed by an X-ray crystallographic analysis, this reaction needed an 
additional analysis. As shown in Figure 17, there are two possible transition states (exo-3-122 
 115 
and endo-3-122). The exo-3-122 transition state, which would ultimately lead to the undesired 
ketone 3-124’, suffers from the syn-pentane interaction between N-CH3 group and the 
cyclopropane ring. On the other hand, in endo-3-122 N-CH3 group is pointed away from the 
cyclopropane ring, thus avoiding this unfavorable interaction. Furthermore, there is an additional 
steric repulsion between the hydrogen atom at C(5) and one of the hydrogen atoms on the 
cyclopropane fragment in exo-3-122, while in endo-3-122 cyclopropane ring is placed on the 
opposite side of the C(5)-H atom. Indeed, a computational analysis suggests that the energy for 
the endo-transition state endo-3-122 leading to 3-124 is 6.8 kcal/mol lower than the transition 
state exo-3-122 (Figure 18).176 
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Figure 17. Possible transition states for the Diels-Alder reaction 
 
Figure 18. Transition state endo-3-122 
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 Encouraged with this result, we next attempted to install the required unsaturation at 
C(11)-C(16). Once again we were met with less than desirable reactivity issues. The formation of 
the corresponding silyl enol ether, followed by a Pd-catalyzed oxidation (Saegusa-Ito protocol) 
did not provide any isolable product, probably due to competing side reactions involving the 
basic amine moiety. Several conditions (CuBr2 in CHCl3/EtOAc,177 PyrH+Br3- in THF,178 or 
NBS in THF) were screened towards the regioselective -bromination of ketone 3-124. In all 
cases, however, only starting material was recovered. Interestingly, when the corresponding 
TMS-enol ether was exposed to NBS in THF, and then treated with Li2CO3 and LiBr in DMF at 
120 °C, the desired enone was isolated as the sole regioisomer, although only in 17% yield. 
N
CH3H
O
3-124
1. TMSOTf, 2,6-lutidine
    CH3CN, 0 °C, 30 min
    100% (crude)
2. Pd(OAc)2 (1.2 equiv)
    CH3CN, rt, 12 h
complex mixture
CuBr2, CHCl3/EtOAc
or pyrH+Br3-, THF
or NBS, THF
X
N
CH3H
O
3-126
Br
1. TMSOTf, 2,6-lutidine
    CH3CN, 0 °C, 30 min
    100% (crude)
2. NBS, NaHCO3
    THF, -78 °C to rt, 1 h
3. Li2CO3, LiBr
    DMF, 120 °C, 2.5 h
       17% (3 steps)
N
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O
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Scheme 70. Attempts towards the synthesis of 3-65 
As we encountered difficulties in the successful formation of 3-65, we decided to 
elaborate an additional approach by postponing the introduction of the cyclopropane ring. We 
hoped that if a double bond was present at C(8)-C(10), the introduction of an additional 
unsaturation should be facilitated by an extended resonance (Scheme 71). Consequently, a 
mesylation of the allylic alcohol 3-127 and subsequent N-alkylation of the anion of 3-104, 
provided the coupling product 3-129. Following our previously developed strategy, 3-129 was 
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treated with NaHMDS in THF and quenched with TBSCl, which afforded TBS-enol ether 3-130. 
When 3-130 was heated in o-dichlorobenzene for 30 min at 230 °C under microwave irradiation, 
the cyclization product 3-131 was obtained. Finally, TBS deprotection by TBAF in THF 
provided the desired ketone 3-132 in 61% yield. 
•
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Scheme 71. Alternative approach: synthesis of 3-132 
Unfortunately, 3-132 proved to be very unstable, slowly decomposing at room 
temperature even under vacuum. This could partly be attributed to the reactive nature of 3-132 
towards air and oxygen. Furthermore, exposing 3-132 to the same reaction conditions as 
described previously for the preparation of 3-65 (Scheme 70), yielded a complex mixture of 
products. 
Having demonstrated the success in the preparation of 3-124, but faced with a 
problematic dehydrogenation to the corresponding enone 3-65, we investigated an additional 
strategy. We envisioned that a protection of the indolinone nitrogen atom as a carbamate could 
give the desired enone, without obvious side reactions. Accordingly, we decided to circumvent 
the problem by a dealkylative protection of the tertiary amine as a carbamate. Indeed, when 3-
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124 was heated at reflux for 3 h in methyl chloroformate, the corresponding carbamate 3-133 
was isolated in 71% yield.179 Further treatment of 3-133 under Saegusa-Ito oxidation conditions 
(LDA, TMSCl, -78 °C, then Pd(OAc)2) served to cleanly introduce the desired double bond at 
the C(11)-C(16) position of 3-134.  
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O
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    CH3CN, rt, 12 h; 67%
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Scheme 72. Dealkylative protection of 3-124 and the formation of enone 3-134 
Treatment of enone 3-134 with the tin-lithium exchange product of stannane 3-48 led to 
the formation of two diastereomeric tertiary alcohols 3-135 in a 1:1 ratio (Scheme 73). Although 
these two diastereomeric alcohols can be separated by chromatography on SiO2, we did not 
determine their relative configurations. Instead, we subjected both diastereomers separately to 
the microwave-promoted IMDAF cyclization in trifluorotoluene at 190 °C. Surprisingly, only 
one diastereomer (Rf = 0.35, 50% EtOAc/hexanes) exhibited the expected reactivity, furnishing 
indole 3-136 in 44% yield. Another diastereomer (Rf = 0.52, 50% EtOAc/hexanes) was 
unreactive under these conditions. Extended heating under microwave conditions at 210 °C led 
to a complete decomposition of the alcohol, with no detected product of cyclization. The reason 
for such a big difference in reactivities of the two stereoisomeric alcohols is probably due to the 
different steric hindrance of the C(8)-methyl group and the cyclopropyl methylene unit. The 
C(5)-hydrogen atom and the C(8)-methyl group at the -face of 3-134 are not too close to the 
reacting C(11)-C(16) olefinic bond, favoring the furan approach from this side during the Diels-
Alder reaction. On the other hand, fused cyclopropane ring probably blocks the -face of 3-134, 
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disfavoring the furan -approach during the [4+2]-cycloaddition. However, this assumption 
requires more detailed analysis in order to determine the nature of the reacting isomer.        
Finally, reduction of the carbamate with LiAlH4 in THF provided (±)-cycloclavine (3-5) 
in quantitative yield. The spectroscopic data for 3-5 (Tables 4 and 5) were consistent with the 
previously reported data for the natural compound. 
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n-Bu3Sn
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then N
HHO CO2CH3
BocN
O
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99%
N
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O
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µW, trifluorotoluene
180 °C, 30 min
44% (56% brsm)
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N
H
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Scheme 73. Synthesis of (±)-cycloclavine (3-5) 
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Table 4. 1H NMR comparison of Santay's synthetic cycloclavine180 and 3-5 
N
H
N H
H3C
Cycloclavine (3-5)
1
2
3
45
67
8
9
10
11
12
13
14
15
16
18
17
CH3
 
atom # 
Santay’s synthetic cycloclavine 
1H NMR, CDCl3, 300 MHz 
 [ppm], multiplicity (J) 
Our synthetic cycloclavine 
 1H NMR, CDCl3, 700 MHz 
 [ppm], multiplicity (J) 
1 7.95, s (8.4 Hz) 7.92, br s 
2 6.87, d (2.0 Hz) 6.91, s 
4 
3.12, dd (13.2, 4.3 Hz) 
2.58, ddd (13.2, 11.6, 2.0 Hz) 
3.15, dd (14.0, 4.2 Hz) 
2.61, t (12.6 Hz) 
5 2.76, dd (11.6, 4.3 Hz) 2.79, dd (11.2, 3.5 Hz) 
7 
3.14, d (9.0 Hz) 
2.38, d (9.0 Hz) 
3.17, d (9.1 Hz) 
2.42, d (8.4 Hz) 
9 
1.58, d (3.6 Hz) 
0.46, d (3.6 Hz) 
1.61, d (2.8 Hz) 
0.46, d (3.5 Hz) 
12 6.80, d (7.0 Hz) 6.84, d (7.0 Hz) 
13; 14 7.15-7.00, m 
7.15, d (8.4 Hz); 7.10, t (7.7 
Hz) 
17 2.34, s 2.37, s 
18 1.68, s 1.70, s 
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Table 5. 13C NMR comparison of Szantay's synthetic cycloclavine180 and 3-5 
N
H
N H
H3C
Cycoclavine (3-5)
1
2
3
45
67
8
9
10
11
12
13
14
15
16
18
17
CH3
 
atom # 
Santay’s synthetic cyclcoclavine 
13C NMR, CDCl3, 75 MHz 
 [ppm] 
Our synthetic cycloclavine 
13C NMR, CDCl3, 175 MHz 
 [ppm] 
2 118.3 118.1 
3 113.5 113.2 
4 25.1 24.9 
5 69.9 69.9 
7 65.8 65.6 
8 29.9 34.3 
9 24.2 24.2 
10 28.0 27.8 
11 135.6 135.4 
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12 110.6 110.3 
13 123.1 122.9 
14 108.1 107.9 
15 133.8 133.5 
16 129.0 128.7 
17 40.1 39.9 
18 16.7 16.5 
3.2.3 Conclusions 
The Ergot alkaloids have represented important synthetic targets for decades and many creative 
approaches towards the total syntheses of these molecules have been described in literature. 
Herein, we have developed novel synthetic routes to the ergot alkaloid cycloclavine (3-5) as well 
as the unnatural 5-epi-cycloclavine (3-99). The total syntheses proceed in 14 steps and 1.2% 
overall yield for 3-5, and in 17 steps and 2.3% overall yield for 3-99. The main feature of both 
syntheses is a rapid construction of the indole moieties through the allylic alcohol-IMDAF 
reaction. Based on the previous research in our group and the results described in the Chapter 2 
of this thesis, we were able to synthesize the indole portion of cycloclavine and 5-epi-
cycloclavine by the application of the cascade IMDAF reaction in the late stages of these two 
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routes, showing the high tolerance of a usually sensitive cyclopropane unit. In the course of the 
synthesis of 5-epi-cycloclavine we observed the high preference of the tricyclic vinylogous 
amide 3-94 towards the -hydrogen delivery during the Ra-Ni catalyzed hydrogenation, which 
ultimately led to the undesired stereochemistry at C(5). In a different approach we have 
developed a new strategy for the formation of the cycloclavine’s indoline core through a novel 
and highly stereoselective intramolecular Diels-Alder reaction of methylenecyclopropane, which 
led to the formation of only one diastereomeric ketone 3-124 with the desired configuration at 
C(5). In this route, the introduction of a necessary unsaturation at C(11)-C(16) was highly 
regioselective, giving 3-134 as a sole isomer. Finally, the addition of lithiated 3-48 provided two 
stereoisomeric tertiary allylic alcohols, the only one of which underwent the IMDAF cyclization 
and the desired indole ring formation. The carbamate functional group, introduced to protect the 
sensitive tertiary amine, was converted to the required N-methyl amine by LiAlH4 reduction.    
3.3 EXPERIMENTAL PART 
General: All moisture-sensitive reactions were performed under an atmosphere of N2. Glassware 
was flame dried prior to use. Reactions carried out at -78 °C employed a dry ice/acetone bath. 
THF and Et2O were dried by distillation over Na/benzophenone ketyl, Et3N was distilled from 
CaH2, and CH2Cl2 and toluene were purified using an alumina filtration system. Unless 
otherwise stated, solvents and reagents were used as received. Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F254 plates (250 m layer thickness, 
particle size 0.040-0.055 mm, 230-240 mesh) and visualization was accomplished with a 254 nm 
UV light and/or by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 
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95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of 
conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O244H2O and 0.2 
g of Ce(SO4)2 in 100 mL of a 3.5 M H2SO4 solution), or a KMnO4 solution (1.5 g of KMnO4 and 
1.5 g of K2CO3 in 100 mL of a 0.1 % NaOH solution). Flash chromatography on SiO2 was used 
to separate and purify the reaction crude mixtures. Microwave reactions were performed on a 
Biotage Initiator microwave reactor. 1H and 13C NMR were recorded on a Bruker Avance 300 
instrument. Chemical shifts () were reported in parts per million with the residual solvent peak 
used as an internal standard. 1H NMR spectra were run at 300, 400 or 500 MHz, and are 
tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, sept = septet, 
m = multiplet, br = broad, app = apparent), number of protons, and coupling constant(s). 13C 
NMR spectra were obtained using a proton-decoupled pulse sequence with a d1 of 3 sec, and are 
tabulated by observed peak. LC/MS analyses were obtained from a Helwett Packard Series 1100 
MSD. RP HPLC was obtained from Gilson Series 215, using C18 column, Bio-rad Laboratoris, 
250 x 4.6 mm. Mass spectra were obtained on a Micromass Autospec double focusing 
instrument. Infrared spectra were measured on a Nicolet AVATAR 360 FT-IR E.S.P. 
spectrometer (KBr or neat) or Smiths Detection IdentifyIR FT-IR spectrometer (ATR). 
TBSO NH2  
3-(tert-Butyldimethylsilyloxy)benzenamine (3-71).181 To a solution of imidazole (4.00 g, 58.6 
mmol) and 3-aminophenol (4.00 g, 36.6 mmol) in THF (100 mL) was added tert-
butyldimethylsilyl chloride (7.18 g, 47.6 mmol). The reaction mixture was rapidly stirred at 
room temperature overnight, poured into water (150 mL), extracted with ether (3 x 50 mL), 
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washed with brine, dried (MgSO4), and concentrated under reduced pressure. Purification by 
chromatography on SiO2 (30% EtOAc/hexane) gave 3-71 (8.2 g, 100%) as a colorless oil: IR 
(ATR) 3466, 3369, 2926, 2855, 1591, 1489, 1191, 976, 835 cm-1; 1H NMR (300 MHz, CDCl3)  
7.04 (app t, 1 H, J = 8.1 Hz), 6.32 (app dt, 2 H, J = 8.1, 1.8 Hz), 6.24 (app t, 1 H, J = 2.4 Hz), 
3.63 (br s, 2 H), 1.05 (s, 9 H), 0.26 (s, 6 H); 13C NMR (75 MHz, CDCl3)  156.5, 147.6, 129.8, 
110.2, 108.4, 106.9, 25.6, 18.0, -4.5; MS (EI) m/z 223 (M•+, 31), 166 (100), 86 (33), 84 (52); 
HRMS (EI) m/z calcd for C12H21NOSi 223.1392, found 223.1386. 
TBSO NH
O
Cl
 
N-(3-(tert-Butyldimethylsilyloxy)phenyl)-2-chloroacetamide (3-74). To a mixture of 3-71 
(1.00 g, 4.50 mmol) and potassium carbonate (0.74 g, 5.4 mmol) in CH2Cl2 (7 mL) was added 
dropwise chloroacetyl chloride (0.61 g, 5.4 mmol). The reaction mixture was heated to 40 °C for 
4 h, cooled to room temperature, poured into ice water (30 mL), and extracted with CH2Cl2 (4 x 
20 mL). The combined organic layers were washed with brine, dried (Na2SO4), and concentrated 
in vacuo. The crude product was crystallized from ether/hexane to provide 3-71 (1.04 g, 77%) as 
a white solid: Mp 71.8-72.5 °C; IR (ATR) 3286, 2928, 1673, 1554, 1224, 835 cm-1; 1H NMR 
(300 MHz, CDCl3)  8.16 (br s, 1 H), 7.24-7.18 (m, 2 H), 7.06 (d, 1 H, J = 7.8 Hz), 6.67 (dd, 1 
H, J = 7.8, 1.5 Hz), 4.18 (s, 2 H), 1.00 (s, 9 H), 0.23 (s, 6 H); 13C NMR (75 MHz, CDCl3)  
163.6, 156.3, 137.7, 129.7, 116.9, 112.8, 112.0, 42.9, 25.6, 18.2, -4.5; MS (EI) m/z 299 (M•+, 73), 
242 (75), 84 (100), 75 (68); HRMS (EI) m/z calcd for C14H22ClNO2Si 299.1108, found 299.1112. 
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TBSO NCH3
O
Cl
 
N-(3-(tert-Butyldimethylsilyloxy)phenyl)-2-chloro-N-methylacetamide (3-70). To a solution 
of 3-74 (0.70 g, 2.3 mmol) in CH2Cl2 (21 mL) was added Me2SO4 (1.00 mL, 10.0 mmol), 
followed by benzyltriethylammonium chloride (0.22 g, 0.90 mmol). A solution of NaOH (1.7 
mL of 50% in water) was added dropwise over 10 min. The reaction mixture was stirred at room 
temperature overnight, and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (20% EtOAc/hexane) furnished 3-70 (0.69 g, 95%) as a white solid: 
Mp 40.0-42.1 °C; IR (ATR) 2950, 1679, 1584, 1483, 1221, 908, 827 cm-1; 1H NMR (300 MHz, 
CDCl3)  7.28 (t, 1 H, J = 8.1 Hz), 6.84 (app dt, 2 H, J = 7.8, 1.2 Hz), 6.71 (t, 1 H, J = 2.1 Hz), 
3.87 (s, 2 H), 3.28 (s, 3 H), 0.98 (s, 9 H), 0.21 (s, 6 H); 13C NMR (75 MHz, CDCl3)  166.1, 
156.9, 143.6, 130.6, 120.3, 119.8, 118.8, 41.4, 37.8, 25.5, 18.1, -4.5; MS (EI) m/z 313 (M•+, 10), 
199 (80), 150 (57), 122 (100), 65 (75); HRMS (EI) m/z calcd for C15H24NO2SiCl 313.1265, 
found 313.1273. 
TBSO NCH3
O
 
6-(tert-Butyldimethylsilyloxy)-1-methylindolin-2-one (3-69). To a flame-dried flask was added 
palladium acetate (1.4 mg, 0.0062 mmol), followed by 2-(di-tert-butylphosphino)biphenyl (3-77) 
(1.3 mg, 0.0044 mmol) and 3-70 (100.0 mg, 0.3150 mmol). The flask was evacuated and refilled 
with nitrogen three times. Triethylamine (65 L, 4.7 mmol) was added, followed by toluene (0.3 
mL). The mixture was placed into a preheated oil bath (80 °C), stirred for 4 h, quenched with 
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water (10 mL), and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed 
with water (25 mL), brine, dried (Na2SO4), and concentrated under reduced pressure. Purification 
by chromatography on SiO2 (20% EtOAc/hexane) gave 3-69 (67.6 mg, 77%) as a white solid: 
Mp 70.2-72.3 °C; IR (ATR) 2926, 1713, 1700, 1368, 970, 837, 798 cm-1; 1H NMR (300 MHz, 
CDCl3)  7.07 (d, 1 H, J = 8.1 Hz), 6.49 (dd, 1 H, J = 8.1, 2.1 Hz), 6.34 (d, 1 H, J = 2.4 Hz), 3.46 
(s, 1 H), 3.18 (s, 3 H), 1.01 (s, 9 H), 0.22 (s, 6 H); 13C NMR (75 MHz, CDCl3)  175.8, 155.9, 
146.3, 124.7, 116.8, 113.1, 101.4, 35.3, 26.2, 25.7, 18.2, -4.4; MS (EI) m/z 277 (M•+, 37), 220 
(100); HRMS (EI) m/z calcd for C15H23NO2Si 277.1498, found 277.1492. 
TBSO NCH3
O
CH3
 
6-(tert-Butyldimethylsilyloxy)-1,3-dimethylindolin-2-one (3-68). To a solution of 3-69 (2.60 g, 
9.37 mmol) in THF (20 mL), cooled to -78 °C, was added a solution of LiHMDS (1.72 g, 10.3 
mmol) in THF (10 mL), followed by HMPA (5.0 mL). The mixture was stirred at -78 °C for 1 h. 
Methyl iodide (8.70 mL, 140 mmol) was added dropwise. The reaction mixture was stirred at 
this temperature for 3 h, quenched with saturated aqueous NH4Cl and extracted with EtOAc (4 x 
50 mL). The combined organic layers were washed with brine, dried (Na2SO4), and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (5% EtOAc/hexanes) provided 
3-68 as a colorless liquid (2.64 g, 96%): IR (ATR) 2952, 2928, 1713, 1614, 1373, 1249, 831 cm-
1; 1H NMR (300 MHz, CDCl3)  7.04 (d, 1 H, J = 7.8 Hz), 6.49 (dd, 1 H, J = 8.1, 2.1 Hz), 6.32 
(d, 1 H, J = 2.1 Hz), 3.35 (q, 1 H, J = 7.2 Hz); 3.15 (s, 1 H), 1.42 (d, 3 H, J = 7.5 Hz), 0.99 (s, 9 
H), 0.21 (s, 6 H); 13C NMR (75 MHz, CDCl3)  179.3, 155.9, 145.1, 123.8, 123.1, 113.0, 101.2, 
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40.1, 26.1, 25.7, 18.2, 15.6, -4.4; MS (EI) m/z 291 (M•+, 65), 290 (90), 234 (100), 73 (49); 
HRMS (EI) m/z calcd for C16H25NO2Si 291.1655, found 291.1647. 
TBSO NCH3
O
CH3 O
OCH3
 
6-(tert-Butyldimethylsilyloxy)-1,3-dimethyl-1H-indol-2-yl methyl carbonate (3-78). To a 
solution of KHMDS (41.0 mg, 0.206 mmol) in THF (0.25 mL) at -78 °C was added a solution of 
3-68 (50.0 mg, 0.171 mmol) in THF (0.35 mL), stirred at -78 °C for 1 h, and then transferred to a 
solution of methyl chloroformate (20.0 mg, 0.206 mmol) in THF (0.4 mL) at -78 °C. This 
solution was allowed to warm to room temperature, quenched with water, extracted with EtOAc 
(3 x 5 mL), washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (10% EtOAc/hexanes) gave 3-78 (39.1 mg, 65%) as a colorless oil: IR 
(ATR) 2952, 2934, 1772, 1232, 1215 cm-1; 1H NMR (400 MHz, CDCl3)  7.34 (d, 1 H, J = 8.8 
Hz), 6.71 (s, 1 H), 6.69 (d, 1 H, J = 6.0 Hz), 3.98 (s, 3 H), 3.51 (s, 3 H), 2.16 (s, 3 H), 1.03 (s, 9 
H), 0.22 (s, 6 H); 13C NMR (100 MHz, CDCl3)  153.3, 151.5, 138.3, 133.3, 121.1, 119.2, 113.6, 
99.9, 96.1, 56.1, 28.2, 25.8, 18.2, 7.2, -4.4; MS (EI) m/z 350 (M•+, 49), 349 (99), 306 (52), 290 
(100). 
TBSO NCH3
H3CO2C CH3
O
 
Methyl 6-(tert-butyldimethylsilyloxy)-1,3-dimethyl-2-oxoindoline-3-carboxylate (3-67). To a 
solution of 3-78 (34.4 mg, 0.0984 mmol) in t-amyl alcohol (1 mL) was added TADMAP (4.3 
mg, 0.0098 mmol), stirred at room temperature for 36 h, and quenched with methyl iodide (1 
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mL). The solution was concentrated under reduced pressure, and purified by chromatography on 
SiO2 (10% EtOAc/hexanes) to obtain 3-67 (24.7 mg, 75%) as a colorless oil: IR (ATR) 2950, 
2934, 1718, 1612, 1241 cm-1; 1H NMR (300 MHz, CDCl3)  7.09 (d, 1 H, J = 7.8 Hz), 6.50 (dd, 
1 H, J = 7.8, 1.8 Hz), 6.36 (d, 1 H, J = 2.1 Hz), 3.66 (s, 3 H), 3.22 (s, 3 H), 1.64 (s, 3 H), 1.00 (s, 
9 H), 0.23 (s, 3 H), 0.22 (s, 3 H); 13C NMR (100 MHz, CDCl3)  175.7, 170.6, 156.8, 144.7, 
123.6, 122.4, 113.5, 101.6, 54.4, 52.9, 26.5, 25.6, 20.3, 18.1, -4.4 (2C); MS (TOF ESI) m/z 350 
(35), 349 (M+, 31), 290 (100). 
TBSO NCH3
OH
CH3
O
 
6-(tert-Butyldimethylsilyloxy)-3-(hydroxymethyl)-1,3-dimethylindolin-2-one (3-66). A 
solution of LiHMDS (52.0 mg, 0.311 mmol) in THF (0.6 mL) was cooled to -78 °C, treated with 
a solution of 3-68 (30.0 mg, 0.103 mmol) in THF (0.2 mL), and stirred for 1 h. After the addition 
of a suspension of 1H-benzotriazole-1-methanol (3-81) (30.0 mg, 0.201 mmol) in THF (1 mL), 
the reaction mixture was stirred for 2 h, quenched with water, warmed up to room temperature, 
and extracted with Et2O (3 x 10 mL). The combined organic layers were washed with aqueous 
NaOH (10 mL, 1 M solution), brine, dried (Na2SO4), and concentrated under reduced pressure. 
Purification by chromatography on SiO2 (30 to 50% hexane/ EtOAc) afforded 3-66 (30.1 mg, 
91%) as a white solid: Mp 109.3-110.0 °C; IR (ATR) 3423, 2924, 2881, 1687, 1610, 1381, 1247, 
831 cm-1; 1H NMR (300 MHz, CDCl3)  7.04 (d, 1 H, J = 7.8 Hz), 6.52 (dd, 1 H, J = 8.1, 2.1 
Hz), 6.38 (d, 1 H, J = 2.1 Hz), 3.80 (d, 1 H, J = 10.8 Hz), 3.69 (d, 1 H, J = 10.8 Hz),3.18 (s, 3 H), 
1.38 (s, 3 H), 1.00 (s, 9 H), 0.23 (s, 6 H); 13C NMR (75 MHz, CDCl3)  180.5, 156.3, 144.7, 
123.9, 123.2, 113.3, 101.5, 67.7, 49.4, 26.2, 25.6, 19.1, 18.1, -4.4. MS (ESI) m/z 344 ([M+Na]+, 
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100), 304 (90), 290 (48); HRMS (ESI) m/z calcd for C17H27NO3SiNa ([M+Na]+) 344.1658, 
found 344.1652. 
N
CH3
CH3
O
O
 
(1aS*,7aS*)-1a,3-Dimethyl-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (3-82). To a solution 
of 3-66 (200.0 mg, 0.6221 mmol) in CH2Cl2 (5.5 mL) was added triethylamine (0.26 mL, 1.8 
mmol) followed by methanesulfonyl chloride (96 L, 1.2 mmol). The mixture reaction was 
stirred at room temperature for 30 min, quenched with saturated aqueous NaHCO3, and extracted 
with CH2Cl2 (4 x 10 mL). The combined organic layers were dried (Na2SO4), and concentrated 
under reduced pressure to provide crude mesylate, which was used in the next step without 
further purification. A solution of crude mesylate (301.1 mg, 0.7535 mmol) in THF (50 mL) was 
treated with a solution of TBAF (0.68 mL, 1 M solution in THF, 0.68 mmol), stirred at room 
temperature for 1 h, and the reaction mixture was filtered through a pad of SiO2 (pretreated with 
TEA). The filtrate was concentrated in vacuo. Purification by chromatography on SiO2 (10% 
acetone/chloroform) afforded 3-66 (79.1 mg, 83%) as a white crystalline solid: Mp 107.8-108.7 
°C; IR (ATR) 3286, 2933, 1733, 1632, 1569, 1364, 1064, 853 cm-1; 1H NMR (300 MHz, MeOD) 
 6.92 (d, 1 H, J = 9.9 Hz), 6.38 (dd, 1 H, J = 9.9, 1.5 Hz), 5.83 (d, 1 H, J = 1.5 Hz), 2.98 (s, 3 
H), 2.09 (d, 1 H, J = 3.9 Hz), 1.96 (d, 1 H, J = 3.9 Hz), 1.57 (s, 3 H); 13C NMR (75 MHz, 
MeOD)  189.4, 177.5, 165.4, 143.7, 131.7, 103.6, 40.2, 38.8, 35.9, 26.6, 11.3; MS (EI) m/z 189 
(M•+, 100), 161 (47), 132 (56), 63 (77); HRMS (EI) m/z calcd for C11H11NO2 189.0790, found 
189.0789. 
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CH3
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(1aS*,7aR*)-1a,3-Dimethyl-6,7-dihydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (3-84). 
To a solution of Stryker's reagent (156.0 mg, 0.07928 mmol) in toluene (21 mL) was added 
triphenylsilane (0.3 mL, 2.37 mmol), followed by 3-82 (300.0 mg, 1.585 mmol). The reaction 
mixture was stirred for 2 h at room temperature, filtered through Celite, and concentrated in 
vacuo. Purification by chromatography on SiO2 (2% to 30% to 50% EtOAc/hexanes) gave 
vinylogous amide 3-84 (323.6 mg, 100%) as a white solid: Mp 102-104.3 °C; IR (ATR) 2933, 
1720, 1591, 1463, 1075 cm-1; 1H NMR (300 MHz, CDCl3)  5.47 (s, 1 H), 2.92 (s, 3 H), 2.66-
2.61 (m, 2 H), 2.39-2.28 (m, 1 H), 1.76-1.69 (m, 1 H), 1.41 (s, 3 H), 1.32 (d, 1 H, J = 4.2 Hz), 
1.70 (d, 1 H, J = 4.5 Hz); 13C NMR (75 MHz, CDCl3)  197.1, 177.0, 164.3, 101.3, 36.8, 30.0, 
29.8, 29.1, 26.2, 24.4, 10.3; HRMS (EI) m/z calcd for C11H13NO2 191.0946, found 191.0941. 
N
CH3
CH3
O
 
(1aS*,7aR*)-1a,3-Dimethylhexahydro-1H-cyclopropa[c]indol-2(1aH)-one (3-87). To a 
solution of 3-84 (100.0 mg, 0.5229 mmol) in MeOH (5 mL) at room temperature was added a 
solution of HCl in Et2O (5 ml, 2 M HCl in Et2O), followed by sodium cyanoborohydride (150.0 
mg, 2.615), and stirred at room temperature for 2 h. The reaction mixture was quenched with 
water, extracted with Et2O (5 x 20 mL), combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (50% 
EtOAc/hexanes) gave 3-87 (69.3 mg, 74%) as a colorless oil: IR (ATR) 2934, 2928, 2854, 1687 
cm-1; 1H NMR (300 MHz, CDCl3)  3.11 (dd, 1 H, J = 11.4, 3.0), 2.66 (s, 3 H), 2.00-1.88 (m, 3 
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H), 1.77 (dt, 1 H, J = 12.3, 2.7), 1.61 (s, 1 H), 1.56-1.41 (m, 3 H), 1.28 (s, 3 H); 13C NMR (75 
MHz, CDCl3)  179.4, 62.8, 33.2, 29.8, 29.1, 28.0, 26.8, 26.2, 24.9, 23.1, 10.6; HRMS (ESI) m/z 
calcd for C11H18NO ([M+H]+) 180.1388, found 180.1350. 
N
CH3
CH3
O
O
H  
(1aS*,3aS*,7aR*)-1a,3-Dimethyltetrahydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione (3-
89). To a solution of 3-84 (300.0 mg, 1.569 mmol) in CH3OH (15 mL) was added slurry of 
Raney-Ni (600.0 mg of 50% slurry of Raney-Ni in water, rinsed with CH3OH (3 x 10 mL)), and 
subjected to hydrogenation (70 bar) at room temperature for 2.5 h. The reaction was filtered 
through Celite, washed with EtOAc, and concentrated in vacuo. Purification on SiO2 (50% 
EtOAc/hexanes) gave alcohol 3-88 (280.0 mg, 78%) as an inseparable mixture of diastereomers 
in a form of a colorless oil, which was used in the next step without further characterization. To a 
solution of oxalyl chloride (88 µL, 1.0 mmol) in CH2Cl2 (1.5 mL) at -78 ºC was added DMSO 
(110 µL, 1.54 mmol) in CH2Cl2 (0.4 mL), and stirred for 5 min at -78 ºC. To this solution was 
added a solution of 3-88 (100.0 mg, 0.512 mmol) in CH2Cl2 (0.4 mL), and stirred for 1 h. To this 
solution was added Et3N (285 µL, 2.05 mmol), slowly warmed to room temperature, quenched 
with saturated aqueous of NaHCO3, and extracted with CH2Cl2 (3 x 10 mL). Combined organic 
layers were washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification by 
chromatography on SiO2 (5% to 10% CH3OH/CH2Cl2) afforded 3-89 (76.0 mg, 79%) as a 
colorless oil: 1H NMR (300 MHz, CDCl3)  3.71 (t, 1 H, J = 6.6 Hz), 2.80 (dd, 1 H, J = 15.0, 
6.3), 2.68 (s, 3 H), 2.52-2.23 (m, 4 H), 1.81-1.75 (m, 1 H), 1.30 (s, 3 H), 0.89 (d, 1 H, J = 4.5 
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Hz), 0.82 (d, 1 H, J = 4.8 Hz); 13C NMR (75 MHz, CDCl3)  208.5, 175.8, 60.3, 43.6, 38.8, 29.0, 
27.3, 26.8, 25.4, 23.8, 11.5; HRMS (EI) m/z calcd for C11H15NO2 193.1103, found 193.1099. 
N
CH3
CH3
O
O
O
 
(4aS*,5aS*,5bS*,6aS*)-2,6a-Dimethyl-4a,5a,6,6a-tetrahydro-1H-cyclopropa[c]oxireno[2,3-
e]indole-1,4(2H)-dione (3-92). To a solution of dienone 3-82 (25.0 mg, 0.132 mmol) in THF 
(0.5 mL) at 0 °C was added sequentially a solution of TBHP (5-6 M in decane, 26.0 µL, 0.132 
mmol) and Triton-B (40% solution in MeOH, 3 drops). The reaction mixture was warmed to 
room temperature and stirred for 3 days, quenched with saturated aqueous Na2SO3, and extracted 
with EtOAc (3 x 5 mL). The combined organic layers were washed with water, dried (MgSO4), 
and concentrated in vacuo. Purification by chromatography on SiO2 (10% acetone/chloroform) 
gave epoxide 3-92 (15.0 mg, 55%) as a colorless oil: IR (ATR) 1733, 1601, 1591, 1247 cm-1; 1H 
NMR (300 MHz, CDCl3) δ 5.40 (d, 1 H, J = 1.8 Hz), 3.61 (dd, 1 H, J = 3.9, 1.5 Hz), 3.42 (d, 1 
H, J = 3.9 Hz), 2.93 (s, 3 H), 1.67 (s, 3 H), 1.61 (d, 1 H, J = 4.8 Hz), 1.39 (d, 1 H, J = 4.8 Hz); 
13C NMR (125 MHz, CDCl3) δ 192.4, 176.6, 174.9, 158.6, 97.7, 53.6, 50.9, 30.8, 30.4, 26.3, 
11.3; MS (ESI) m/z 205 (42), 176 (33), 86 (87), 84 (100); HRMS (ESI) m/z calcd for C11H11NO3 
205.0739, found 205.0728. 
N
CH3
CH3
O
O
OH
 
(1aS*,7R*,7aS*)-7-Hydroxy-1a,3-dimethyl-6,7-dihydro─1H─cyclopropa[c]indole─2,5(1aH, 
3H)-dione (3-93). Sodium borohydride (55.3 mg, 1.46 mmol) was slowly added, under nitrogen 
 134 
atmosphere, to a suspension of diphenyl diselenide (228.2 mg, 0.7311 mmol) in EtOH (4 mL) at 
room temperature. After a vigorous evolution of hydrogen had ceased and the NaBH4 was 
consumed, the faint yellow solution of Na[PhSeB(OEt)3] was cooled to 0 °C, and glacial acetic 
acid (14 µL, 0.24 mmol) was added. The resulting mixture was stirred for 5 min, and then treated 
with a solution of epoxyketone 3-92 (100.0 mg, 0.4873 mmol) in EtOH (3 mL). The mixture was 
stirred at 0 °C for 75 min, then diluted with EtOAc (10 mL), washed with half-saturated brine (2 
x 10 mL), extracted with EtOAc, and the combined organic layers were concentrated in vacuo. 
Purification by chromatography on SiO2 (5 to 10% acetone/chloroform) gave alcohol 3-93 (84 
mg, 85%) as a white crystalline solid: Mp 161.2-162.4 °C; IR (ATR) 3420, 1731, 1591, 1441, 
1210, 1010 cm-1; 1H NMR (500 MHz, acetone-d6) δ 5.46 (s, 1 H), 4.31 (br s, 1 H), 4.25 (br s, 1 
H), 2.92 (s, 3 H), 2.78 (dd, 1 H, J = 9.9, 1.5 Hz), 2.61 (d, 1 H, J = 10.2 Hz), 1.96 (s, 1 H), 1.48 
(app s, 4 H), 1.36 (d, 1 H, J = 3.6 Hz); 13C NMR (acetone-d6, 125 MHz) δ 195.3, 177.5, 162.5, 
101.7, 69.3, 61.0, 47.3, 36.3, 26.7, 21.3, 15.0, 11.5; MS (ESI) m/z 208 ([M+H]+, 12), 207 (87), 
192 (58), 164 (41), 163 (65), 134 (43); HRMS (EI) m/z calcd for C11H13NO3 207.0895, found 
207.0885. 
N
CH3
CH3
O
O
OTBS
 
(1aS*,7R*,7aS*)-7-((tert-Butyldimethylsilyl)oxy)-1a,3-dimethyl-6,7-dihydro-1H-cyclopropa 
[c]indole-2,5(1aH,3H)-dione (3-94). A solution of tert-butyldimethylsilyl chloride (107.6 mg, 
0.7139 mmol), alcohol 3-93 (74.0 mg, 0.357 mmol) and imidazole (97.2 mg, 1.42 mmol) in 
DMF (1.5 mL) was stirred for 5 h, diluted with water, extracted with EtOAc (5 x 10 mL), dried 
(MgSO4), and concentrated in vacuo. Purification by chromatography on SiO2 (50% 
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EtOAc/hexane) gave 3-94 (76.0 mg, 66%) as a white solid: IR (ATR): 2928, 2853, 1728, 1610, 
1077, 1075 cm-1; 1H NMR (300 MHz, acetone-d6) δ 5.48 (s, 1 H), 4.41 (t, 1 H, J = 3.0 Hz), 2.94 
(s, 3 H), 2.82 (dd, 1 H, J = 16.2, 2.4 Hz), 2.80 (br s, 1 H), 2.63 (dd, 1 H, J = 16.2, 2.4 Hz), 1.52 
(d, 1 H, J = 4.2 Hz), 1.46 (s, 3 H), 1.35 (d, 1 H, J = 4.2 Hz), 0.82 (s, 9 H), 0.09 (s, 3 H), 0.07 (s, 3 
H); 13C NMR (75 MHz, acetone-d6) δ 194.3, 176.9, 161.9, 101.0, 70.7, 47.3, 36.5, 30.2, 28.9, 
26.4, 26.1, 18.4, 11.4, -4.0, -4.5; MS (EI) m/z 322 (18), 306 (32), 266 (50), 264 (76), 265 (88), 
222 (86%), 148 (95), 75 (100); HRMS (EI) m/z calcd for C17H27NO3Si 321.1760, found 
321.1751. 
N
CH3
CH3
O
O
OTBS
H  
(1aS*,3aS*,7R*,7aS*)-7-((tert-Butyldimethylsilyl)oxy)-1a,3-dimethyltetrahydro-1H-cyclop- 
ropa[c]indole-2,5(1aH,3H)-dione (3-95). To a suspension of Raney-Ni (50% slurry in water, 45 
mg, rinsed with MeOH (2 x 3 mL)) in MeOH (0.8 mL), was added TBS-protected alcohol 3-95 
(40.0 mg, 0.123 mmol) in MeOH (1.0 mL). The reaction mixture was subjected to hydrogenation 
for 8 h (room temperature, 80 bar), filtered through Celite, concentrated in vacuo, and used crude 
in the next step without further purification. To a solution of the intermediate alcohol in CH2Cl2 
(3.0 mL) was added PCC (45.0 mg, 0.209 mmol). The mixture was stirred at room temperature 
for 14 h, filtered through Celite, concentrated in vacuo and purified by chromatography on SiO2 
(5% acetone/chloroform) to obtain ketone 3-95 (39.8 mg, 100%) as a colorless liquid: IR (ATR) 
2928, 2950, 1718, 1675, 1098, 1055, 833 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.34 (dd, 1 H, J = 
5.7, 3.3 Hz), 3.62 (dd, 1 H, J = 9.0, 5.4 Hz), 2.82-2.52 (m, 4 H), 2.74 (s, 3 H), 1.46 (s, 3 H), 1.19 
(d, 1 H, J = 3.9 Hz), 0.91 (d, 1 H, J = 4.2 Hz), 0.85 (s, 3 H), 0.08 (s, 3 H), 0.06 (s, 3 H); 13C 
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NMR (75 MHz, CDCl3) δ 206.6, 175.8, 68.4, 58.5, 48.5, 42.5, 33.6, 29.8, 27.6, 25.7, 24.5, 17.8, 
13.5, -4.2, -4.9; MS (ESI) m/z 315 (51), 314 (100), 146 (71), 115 (44), 77 (34); HRMS (ESI) m/z 
calcd for C17H29NO3SiNa ([M+Na]+) 346.1814, found 346.1831. 
N
CH3
CH3
O
O
H  
(1aS*,3aS*,7aS*)-1a,3-Dimethyl-3a,4-dihydro-1H-cyclopropa[c]indole-2,5(1aH,3H)-dione 
(3-65). A solution of TBAF (1 M in THF, 0.40 mL, 0.40 mmol) was added to a solution of 
ketone 3-95 (85.0 mg, 0.263 mmol) in THF (2.5 mL) at room temperature, stirred for 2 h, diluted 
with water, extracted with EtOAc (3 x 5 mL), washed with brine, dried (Na2SO4), and 
concentrated in vacuo. Purification by chromatography on SiO2 (20% acetone/chloroform) gave 
enone 3-65 (31.1 mg, 62%) as an off-white solid: Mp 117.2-119.0 °C; IR (ATR) 3286, 2917, 
1666, 1606, 1401, 842 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.44 (d, 1 H, J = 6.0 Hz), 6.19 (d, 1 
H, J = 6.0 Hz), 3.86 (dd, 1 H, J = 6.9, 3.3 Hz), 3.02 (dd, 1 H, J = 9.0, 3.3), 2.79 (s, 3 H), 2.27 
(dd, 1 H, J = 9.3, 7.2 Hz), 1.45 (s, 3 H), 1.33 (d, 1 H, J = 3.0 Hz), 1.30 (d, 1 H, J = 2.7 Hz); 13C 
NMR (125 MHz, CDCl3) δ 195.9, 173.9, 148.1, 130.2, 58.3, 43.1, 35.0, 30.4, 28.6, 27.3, 12.6; 
MS (EI) m/z 191(M•+, 23), 148 (51), 91 (100), 77 (82); HRMS (EI) m/z calcd for C11H13NO2 
191.0946, found 191.0947. 
N
CH3
CH3
O
HO H
BocN
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tert-Butyl furan-2-yl(((1aS*,3aS*,7aS*)-5-hydroxy-1a,3-dimethyl-2-oxo─1a,2,3,3a,4,5-hexa- 
hydro-1H-cyclopropa[c]indol-5-yl)methyl)carbamate (3-97). To a solution of stannane 3-48 
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(85.7 mg, 0.176 mmol) in THF (1.0 mL) at -78 °C was slowly added a solution of n-BuLi (1.6 M 
in hexane, 110 µL, 0.176 mmol). The reaction mixture was stirred at this temperature for 1 h, 
than treated with a solution of enone 3-65 (67.4 mg, 0.352 mmol) in THF (1.0 mL) over 10 min, 
stirred at -78 °C for 2 h, quenched with saturated aqueous NH4Cl, extracted with EtOAc, washed 
with brine, dried (Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 
(20 to 50% acetone/chloroform) gave recovered enone 3-65 (13.7 mg) and the desired alcohol 3-
97 (43.6 mg, 63%, 82% brsm) in the form of yellow oil, as a single diastereomer: IR (ATR) 
3362, 2972, 2926, 1668, 1364, 1150 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.20 (d, 1 H, J = 1.5 
Hz), 6.37 (dd, 1 H, J = 3.3, 2.1 Hz), 6.03 (d, 1 H, J = 3.0 Hz), 5.78 (dd, 1 H, J = 9.9, 1.2 Hz), 
5.28 (d, 1 H, J = 10.2 Hz), 3.84 (d, 1 H, J = 15.0 Hz), 3.74 (s, 1 H), 3.71 (d, 1 H, J = 15.0 Hz), 
3.37 (dd, 1 H, J = 12.0, 4.2 Hz), 2.66 (s, 3 H), 2.59 (dd, 1 H, J = 12.6, 3.0 Hz), 1.44 (s, 9 H), 1.29 
(s, 3 H), 1.00 (d, 1 H, J = 4.8 Hz), 0.96 (d, 1 H, J = 4.8 Hz); 13C NMR (75 MHz, CDCl3) δ 174.8, 
149.2, 138.2, 134.0, 127.7, 111.3, 101.6, 82.5, 72.8, 57.7, 56.0, 38.1, 32.3, 29.5, 28.0, 27.1, 26.2, 
12.2; MS (EI) m/z 388 (M•+, 29), 288 (45), 270 (46), 193 (91), 192 (100); HRMS (EI) m/z calcd 
for C21H28N2O5 388.1998, found 388.1990. 
HN
N
CH3H
CH3
 
tert-Butyl furan-2-yl(((1aS*,3aS*,7aS*)-5-hydroxy-1a,3-dimethyl-2-oxo─1a,2,3,3a,4,5-hexa- 
hydro-1H-cyclopropa[c]indol-5-yl)methyl)carbamate (5-epi-Cycloclavine, 3-99). A solution 
of alcohol 3-97 (23.0 mg, 0.0592 mmol) in o-dichlorobenzene (1.5 mL) was heated in the 
microwave reactor (190 °C, 30 min), then poured onto a pad of SiO2, eluted with chloroform (to 
remove the solvent), and then with 50% acetone/chloroform to obtain crude 3-98 (8.9 mg, 60%), 
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which was used in the next step without further characterization. To a suspension of LiAlH4 
(12.0 mg, 0.320 mmol) in THF (0.2 mL) was added a suspension of intermediate 3-98 (8.9 mg, 
0.035 mmol) in THF (0.2 mL). The reaction mixture was heated at 66 °C for 2 h, treated with 
water (12 µL), 15% aqueous NaOH (12 µL), and then water (36 µL), extracted with EtOAc (3 x 
4 mL), washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (20 to 50% acetone/chloroform) gave 5-epi-cycloclavine 3-99 (6.4 mg, 
77%) as a white solid: Mp 148-150 °C; IR (ATR) 3286, 3176, 2928, 2915, 1599, 1437, 1014 cm-
1; 1H NMR (600 MHz, CD2Cl2) 8.04 (br s, 1 H), 7.15-7.10 (m, 2 H), 6.92 (dd, 1 H, J = 1.8 Hz), 
6.58 (dd, 1 H, J = 6.6, 0.6 Hz), 3.47 (dd, 1 H, J = 10.8, 6.0 Hz), 3.01 (dd, 1 H, J = 14.4, 6.0 Hz), 
2.98 (d, 1 H, J = 8.4 Hz), 2.66 (d, 1 H, J = 9.0 Hz), 2.59 (ddd, 1 H, J = 16.2, 11.4, 1.8 Hz), 2.48 
(s, 3 H), 1.57 (d, 1 H, J = 3.0 Hz), 1.12 (s, 3 H), 1.11 (d, 1 H, J = 4.2 Hz); 13C NMR (CDCl3, 75 
MHz) δ 133.3, 130.5, 127.4, 122.9, 118.1, 112.9, 111.7, 107.6, 62.9, 59.8, 35.8, 35.4, 33.2, 20.1, 
18.6, 14.9; MS (AP) m/z 239 ([M+H]+, 43), 208 (100); HRMS (AP) m/z calcd for C16H19N2 
([M+H]+) 239.1548, found 239.1540. 
Cl
HO
 
4-Chlorobut-2-yn-1-ol (3-108). To a solution of propargyl chloride (4.85 mL, 65.8 mmol) in 
diethyl ether (125 mL) at -78 °C was added n-BuLi (1.6 M solution in hexane, 47 mL, 65.8 
mmol) dropwise. The reaction mixture was stirred at -78 °C for 2 hours, and then transferred to a 
solution of paraformaldehyde (2.08 g, 65.8 mmol) in diethyl ether (14 mL) via cannula at 0°C. 
The mixture was warmed up to room temperature, stirred for 14 hours, quenched with water (50 
mL), and extracted with diethyl ether (4 x 150 mL). The combined organic layers were washed 
with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure, which gave 3-108 
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(5.32 g, 76%) as a brownish oil, which was used in the next step without further purification: 1H 
NMR (300 MHz, CDCl3) 4.34-4.25 (m, 2 H), 4.16 (dt, 2 H, J = 12.6, 2.4 Hz), 1.90 (t, 1 H, J = 
5.7 Hz). 
Cl
TBSO
 
tert-Butyl(4-chlorobut-2-ynyloxy)dimethylsilane (3-109). A solution of 3-108 (5.32 g, 50.9 
mmol), TBSCl (9.98 g, 66.2 mmol), and imidazole (5.2 g, 76 mmol) in DMF (100 mL) was 
stirred at room temperature for 12 h, poured into water (100 mL), and extracted with EtOAc (4 x 
50 mL). The combined organic layers were washed with brine, dried (Na2SO4), and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (10% EtOAc/hexanes) gave the 
desired chloride 3-109 (10.70 g, 96%) as a colorless liquid: IR (ATR) 2928, 1950, 1260, 1079, 
820 cm-1; 1H NMR (300 MHz, CDCl3)  4.36 (app t, 2 H, J = 2.1 Hz), 4.17 (app t, 2 H, J = 2.1 
Hz), 0.91 (s, 9 H), 0.13 (s, 6 H); 13C NMR (75 MHz, CDCl3)  85.2, 79.4, 51.7, 30.5, 25.8, 18.3, 
-5.2; MS (EI) m/z 218 (M•+, 12), 161 (36), 125 (35), 95 (39), 93 (100), 84 (45); HRMS (EI) m/z 
calcd for C10H19ClOSi 218.0894, found 218.0888. 
• CH3
OTBS  
tert-Butyldimethyl(2-methylbuta-2,3-dienyloxy)silane (3-105). A solution of methyl 
magnesium bromide (3M solution in ether, 11.5 mL, 34.3 mmol) in ether (30 mL) was cooled to 
-30 °C, treated with cuprous iodide (2.60 g, 13.7 mmol), and stirred at -30 °C for 1 h. To the 
black colored mixture was added 3-109 (3.0 g, 13.7 mmol) dropwise over 30 min. The reaction 
mixture was stirred at -30 °C for 1 h, slowly warmed to room temperature, quenched with 
saturated aqueous NH4Cl (30 mL), and extracted with diethyl ether (4 x 75 mL). The combined 
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organic layers were washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification 
by chromatography on SiO2 (5% EtOAc/hexanes) gave 3-105 (1.4 g, 55%) as a colorless oil: IR 
(ATR) 2926, 1962, 1252, 1072, 833 cm-1; 1H NMR (300 MHz, CDCl3)  4.67-4.64 (m, 2 H), 
4.12-4.10 (m, 2 H), 1.71-1.69 (m, 3 H), 0.91 (s, 9 H), 0.07 (s, 6 H); 13C NMR (75 MHz, CDCl3) 
 205.9, 98.7, 74.8, 65.1, 25.9, 18.4, 15.2, -5.3. 
CH3
Br
Br
OTBS  
tert-Butyl((2,2-dibromo-1-methyl-3-methylenecyclopropyl)methoxy)dimethylsilane (3-103). 
To a solution of 3-105 (1.40 g, 7.06 mmol) in pentane (6 mL) was added dropwise bromoform 
(1.78 g, 7.06 mmol). The reaction mixture was cooled to -20 °C, stirred at this temperature for    
3 h, during which time potassium tert-butoxide was added portion wise (0.91 g, 5.80 mmol), 
stirred for additional 2 h, quenched with water, and extracted with diethyl ether (3 x 20 mL). The 
combined organic layers were washed with brine, dried (Na2SO4) and concentrated in vacuo. 
Purification by chromatography on SiO2 (hexanes) gave 3-103 (1.02 g, 38%) as a colorless oil: 
IR (ATR) 2926, 1461, 1250, 1090, 833, 773 cm-1; 1H NMR (300 MHz, CDCl3)  5.87 (s, 1 H), 
5.50 (d, 1 H, J = 0.6 Hz), 3.79, 3.73 (AB, 2 H, J = 18.3 Hz), 1.51 (s, 3 H), 0.93 (s, 9 H), 0.09 (s, 
3 H), 0.07 (s, 3 H); 13C NMR (75 MHz, CDCl3)  142.2, 109.0, 68.9, 36.9, 30.6, 25.8, 20.4, 18.3, 
-5.3. 
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CH3
Br
Br
OH  
((2,2-Dibromo-1-methyl-3-methylenecyclopropyl)methanol (3-110). To a solution of 3-103 
(1.00 g, 2.70 mmol) in THF (8 mL) was added a solution of TBAF (1M solution in THF, 8.1 mL 
8.1 mmol). The reaction mixture was stirred at room temperature for 10 min, quenched with 
water (10 mL), and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(Na2SO4) and concentrated in vacuo. Purification by chromatography on SiO2 (30% 
EtOAc/hexanes) gave 3-110 (0.61 g, 87%) as an colorless oil: IR (ATR) 3285, 2925, 1416, 1017, 
1003, 917 cm-1; 1H NMR (300 MHz, CDCl3)  5.92 (bs, 1 H), 5.55 (app d, 1 H, J = 0.9 Hz), 3.81 
(app d, 2 H, J = 2.4 Hz), 2.04 (bs, 1 H), 1.58 (s, 3 H); 13C NMR (75 MHz, CDCl3)  141.3, 
109.8, 69.0, 37.3, 30.2, 20.2; MS (EI) m/z 241 (16), 227 (37), 67 (100); HRMS (EI) m/z calcd for 
C5H5Br2O 238.8707, found 238.8701. 
O
NHCH3  
(E)-4-(Dimethylamino)but-3-en-2-one (3-104). To acetylacetaldehyde dimethyl acetal (5.30 
mL, 37.8 mmol), freshly distilled prior to use (bp 67 °C, 12 mm Hg), was added a solution of 
methylamine (2 M solution in methanol, 21.0 mL, 42.7 mmol) in one portion. The reaction 
mixture was stirred at room temperature for 12 h, and concentrated under reduced pressure. The 
resulting oil was purified by bulb-to-bulb distillation (0.25 mm, oven temperature 80-95°C) to 
afford 3-104 (3.75 g, 100%) as a light-yellow oil: 1H NMR (300 MHz, CDCl3) δ 9.8-9.6 (br, 1 
H), 6.60 (dd, 1 H, J = 12.9, 7.2 Hz), 4.97 (d, 1 H, J = 7.2 Hz), 2.95 (d, 3 H, J = 13.0 Hz), 2.02 (s, 
3 H). 
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OTHP  
Synhtesis of 2-(2-Methylallyloxy)tetrahydro-2H-pyran. To a stirred solution of alcohol -
methallyl alcohol (30.0 g, 0.416 mol) and 3,4-dihydro-2H-pyran (35.0 g, 0.416 mol) were added 
several drops of concentrated aq HCl. The reaction mixture was stirred at room temperature for 3 
h, quenched with a saturated solution of NaHCO3, extracted with EtOAc, and concentrated in 
vacuo to obtain the title compound (58.4 g, 90%) as a colorless liquid: IR (ATR) 2939, 2868, 
1647, 1200, 1118, 1019 cm-1; 1H NMR (300 MHz, CDCl3) δ 4.98 (br s, 1 H), 4.87 (br s, 1 H), 
4.62 (t, 1 H, J = 3.3 Hz), 4.12 (d, 1 H, J = 12.6 Hz), 3.88 (d, 1 H, J = 12.0 Hz), 3.86-3.83 (m, 1 
H), 3.54-3.47 (m, 1 H), 1.87-1.79 (m, 1 H), 1.74 (s, 3 H), 1.79-1.49 (m, 5 H); 13C NMR (125 
MHz, CDCl3) δ 142.1, 111.6, 97.6, 70.6, 62.0, 30.5, 25.4, 19.6, 19.3. 
OTHP
Br
Br
 
2-((2,2-Dibromo-1-methylcyclopropyl)methoxy)tetrahydro-2H-pyran (3-116). To a solution 
of 2-(2-methylallyloxy)tetrahydro-2H-pyran (10.0 g, 64.0 mmol), bromoform (11.20 mL, 128.0 
mmol), cetrimide (1.10 g, 3.02 mmol) and triethylamine (10 drops) in dichloromethane (20 mL) 
was added a solution of sodium hydroxide (41.0 g, 1.02 mol) in water (41 mL) at -20 °C. The 
reaction mixture was vigorously stirred with a mechanical stirrer for 24 h, dilute with water (150 
mL), and extracted with CH2Cl2 (5 x 50 mL). The combined organic layers were washed with 
brine, dried (Na2SO4), and concentrated in vacuo. The residue was dissolved in hexane (30 mL), 
stirred at room temperature for 15 min, filtered, and concentrated in vacuo. Purification by 
chromatography on SiO2 (2-5% EtOAc/hexane) gave 3-116 (20.0 g, 95%) as a yellowish, oily, 
inseparable mixture of diastereomers: IR (ATR) 2937, 2866, 1446, 1351, 1200, 1120, 1027 cm-1; 
1H NMR (300 MHz, CDCl3) δ 4.68-4.64 (m, 1 H), 3.96-3.86 (m, 2 H), 3.56-3.47 (m, 2 H), 1.91-
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1.46 (m, 11 H); 13C NMR (75 MHz, CDCl3) δ 98.8, 98.6, 73.5, 73.2, 62.3, 61.9, 36.1, 35.7, 32.8, 
32.7, 30.6, 30.4, 29.7, 29.2, 25.4, 21.1 (2 C), 19.5, 19.1; MS (ESI) m/z 331 (33), 329 (68), 327 
(66), 229 (99), 228 (83), 227 (55), 226 (97), 225 (100), 85 (81); HRMS (EI) m/z calcd for 
C10H16O2Br2 325.9517, found 325.9511. 
OTHP
Br
CH3
 
2-((2-Bromo-1,2-dimethylcyclopropyl)methoxy)tetrahydro-2H-pyran (3-117). To a 
magnetically stirred solution of 3-116 (10.0 g, 30.4 mmol) in THF (60 mL) at -95 °C was added 
a solution of n-BuLi (1.6 M in hexane, 19.0 mL, 30.4 mmol). The reaction mixture was stirred 
for 25 min, treated with MeI (5.7 mL, 0.092 mol) over 5 min, warm to room temperature over 2 
h, quenched with water (20 mL), extracted with EtOAc (6 x 20 mL), washed with brine, dried 
(Na2SO4), and concentrated under reduced pressure. Purification by chromatography on SiO2 (5 
% EtOAc/hexanes) gave 3-117 (6.61 g, 82%) in the form of yellowish liquid, as an inseparable 
mixture of diastereomers, which was used in the next step without further purification: 1H NMR 
(300 MHz, CDCl3) δ 4.70-4.50 (m, 1 H), 3.94-3.76 (m, 2 H), 3.62-3.21 (m, 2 H), 1.90-1.84 (m, 4 
H), 1.74-1.49 (m, 6 H), 1.46 (s, 1 H), 1.45 (s, 1 H), 1.32-1.20 (m, 2 H). 
OTHP  
2-((1-Methyl-2-methylenecyclopropyl)methoxy)tetrahydro-2H-pyran (3-118). To a solution 
of potassium t-butoxide (0.96 g, 8.7 mmol) in DMSO (50 mL) at room temperature was added a 
solution of 3-117 (1.80 g, 6.91 mmol) in DMSO (14 mL). The reaction mixture was stirred for 
12 h, quenched with water (50 mL), and extracted with pentane (5 x 20 mL) and EtOAc (5 x 20 
mL). The combined organic layers were washed with water (50 mL), brine, dried (Na2SO4), and 
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concentrated in vacuo. Purification by chromatography on SiO2 (2% to 5% EtOAc/hexanes) gave 
3-118 (0.46 g, 69%) as a colorless, oily mixture of diastereomers: IR (ATR) 2939, 2898, 1446, 
1349, 1118, 1027 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.42 (ddt, 1 H, J = 7.8, 2.7, 0.9 Hz), 5.34 
(br s, 1 H), 4.65 (dt, 1 H, J = 9.6, 3.3 Hz), 3.90-3.83 (m, 1 H), 3.68-3.58 (m, 1 H), 3.53-3.46 (m, 
1 H), 3.33-3.20 (m, 1 H), 1.89-1.51 (m, 6 H), 1.25 (s, 3 H), 1.21-1.12 (m, 1 H), 1.04-0.99 (m, 1 
H); 13C NMR (75 MHz, CDCl3) δ 140.2, 139.6, 102.6, 102.5, 98.4, 97.9, 73.3, 72.6, 62.3, 61.9, 
30.7, 30.6, 25.5 (2 C), 20.2, 20.0, 19.8 (2 C), 19.6, 19.4, 15.7, 15.2. 
OH  
(1-Methyl-2-methylenecyclopropyl)methanol (3-119). To a solution of 3-118 (4.00 g, 21.9 
mmol) in MeOH (60 mL) at room temperature was added p-toluenesulfonic acid monohydrate 
(0.90 g, 4.7 mmol). The reaction mixture was stirred for 18 h. The solvent was slowly distilled 
off (oil bath temp. 80-85 °C), and the residue was separated between water (5 mL) and Et2O (5 
mL), and extracted with diethyl ether (5 x 10 mL). The combined organic layers were washed 
with brine, dried (Na2SO4), and concentrated in vacuo. Purification on SiO2 (2 to 5 to 15% 
Et2O/pentane) gave 3-119 (1.65 g, 79%) as a colorless oil: IR (ATR) 3362 (bs), 2969, 1446, 
1375, 1025, 885 cm-1; 1H NMR (300 MHz, CD2Cl2) δ 5.41 (dt, 1 H, J = 2.4, 0.9 Hz), 5.32 (bs, 1 
H), 3.43 (s, 2 H), 2.14 (s, 1 H), 1.22 (s, 3 H), 1.05 (dt, 1 H, J = 8.7, 2.1 Hz), 0.95 (dt, 1 H, J = 
8.4, 2.1 Hz); 13C NMR (75 MHz, CD2Cl2) δ 140.6, 102.9, 69.1, 23.1, 19.7, 15.3. 
OMs  
(1-Methyl-2-methylenecyclopropyl)methyl methanesulfonate (3-120). To a solution of 3-119 
(0.88 g, 9.0 mmol) in CH2Cl2 (45 mL) at 0 °C was added triethylamine (3.70 mL, 26.3 mmol) 
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and mesyl chloride (1.00 mL, 12.9 mmol). The reaction mixture was stirred for 1 h, quenched 
with saturated aqueous NaHCO3, extracted with CH2Cl2 (5 x 50 mL), washed with brine, dried 
(Na2SO4), concentrated in vacuo, and the resulting mesylate 3-120 was used crude in the next 
step: 1H NMR (300 MHz, CDCl3) δ 5.47 (t, 1 H, J = 2.7 Hz), 5.38 (app s, 1 H), 3.12 (d, 2 H, J = 
0.6 Hz), 2.98 (d, 3 H, J = 0.3 Hz), 1.28-1.24 (m, 1 H), 1.25 (s, 3 H), 1.13-1.10 (m, 1 H). 
O
N
CH3
CH3
 
(E)-4-(Methyl((1-methyl-2-methylenecyclopropyl)methyl)amino)but-3-en-2-one (3-121). To 
a slurry of NaH (120.1 mg, 5.003 mmol) in DMF (10.0 mL) at room temperature was added a 
solution of amide 3-104 (0.23 g, 2.3 mmol) in DMF (10.0 mL). The reaction mixture was stirred 
for 30 min at this temperature, cooled to 0 °C, and a solution of (1-methyl-2-
methylenecyclopropyl)methyl methanesulfonate (0.53 g, 3.0 mmol) in DMF (10.0 mL) was 
added dropwise. The mixture was stirred at room temperature for 24 h, quenched with water, and 
extracted with EtOAc (5 x 25 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (50% 
EtOAc/hexanes) afforded 3-121 (286.3 mg, 67%) as a yellowish oil: IR (ATR) 3531 (bs), 2963, 
1653, 1593, 1552, 1357, 1125 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.47 (d, 1 H, J = 12.9 Hz), 
5.40-5.37 (m, 2 H), 5.04 (d, 1 H, J = 12.6 Hz), 3.28 (d, 1 H, J = 13.8 Hz), 2.96 (d, 1 H, 14.1 Hz), 
2.79 (br s, 3 H), 2.05 (s, 3 H), 1.05 (s, 3 H), 1.03-1.00 (m, 2 H); 13C NMR (75 MHz, CDCl3) δ 
195.2, 152.1, 138.8, 104.0, 96.6, 77.2, 64.5, 35.6, 28.0, 19.6, 15.3; MS (ESI) m/z 202 
([M+Na]+,100), 156 (18), 180 (18); HRMS (ESI) m/z calcd for C11H17NONa [M+Na]+ 202.1208, 
found 202.1209. 
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OTBS
N
CH3
CH3
 
(E)-3-(tert-Butyldimethylsilyloxy)-N-methyl-N-((1-methyl-2-methylenecyclopropyl)methyl) 
buta-1,3-dien-1-amine (3-122). To a solution of NaHMDS (0.42 g, 2.3 mmol) in THF (2.5 mL) 
at -78 °C was added a solution of 3-121 (0.41 g, 2.3 mmol) in THF (1.5 mL) over a period of 30 
min. The resulting clear yellow solution was stirred for 1 h at -78 °C, treated with a solution of 
tert-butylchlorodimethylsilane (0.36 g, 2.4 mmol) in THF (1.5 mL) over a period of 5 min, 
slowly warmed to room temperature, and concentrated under reduced pressure to provide crude 
3-122 (0.67 g, 100%) as an orange thick oil: 1H NMR (300 MHz, CDCl3) δ 6.72 (d, 1 H, J = 13.2 
Hz), 5.40 (d, 1 H, J = 14.4 Hz), 4.79 (d, 1 H, J = 13.2 Hz), 3.92 (s, 1 H), 3.83 (s, 1 H), 3.14 (d, 1 
H, J = 14.1 Hz), 2.86 (d, 1 H, J = 14.1 Hz), 2.73 (s, 3 H), 1.11 (s, 3 H), 0.99 (app s, 11 H), 0.21 
(app s, 6 H); 13C NMR (75 MHz, CDCl3) δ 156.8, 140.6, 140.1, 103.4, 94.1, 85.3, 63.2, 36.2, 
26.0, 20.5, 20.1, 18.3, 15.5, -4.5 (2 C). 
N
CH3
CH3
TBSO H  
tert-Butyl furan-2-yl(((1aS*,3aS*,7aS*)-5-hydroxy-1a,3-dimethyl-2-oxo─1a,2,3,3a,4,5-hexa- 
hydro-1H-cyclopropa[c]indol-5-yl)methyl)carbamate (3-123). A solution of crude 3-122 
(0.67 g, 4.0 mmol) in trifluorotoluene (7 mL) was heated under microwave irradiation at 195 °C 
for 1 h, concentrated in vacuo, and purified by chromatography on SiO2 (30 to 50% 
EtOAc/hexane) to obtain vinylogous amide 3-122 (0.11 g) and the desired silyl enol ether 3-123 
(0.35 g, 52%, 72% brsm) as a light yellow liquid: IR (ATR) 2928, 1646, 1250, 1180, 1159, 865 
cm-1; 1H NMR (300 MHz, CDCl3) δ 5.01 (br s, 1 H), 3.04 (d, 1 H, J = 8.7 Hz), 2.69 (br s, 1 H), 
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2.23 (s, 3 H), 2.21-2.12 (m, 3 H), 1.95 (dt, 1 H, J = 12.0, 6.3 Hz), 1.41-1.34 (m, 1 H), 1.15 (s, 3 
H), 0.92 (app s, 10 H), 0.16 (s, 3 H), 0.15 (s, 3 H), -0.19 (br s, 1 H); 13C NMR (75 MHz, CDCl3) 
δ 152.6, 104.9, 67.2, 66.1, 40.2, 33.5, 30.9, 25.7, 24.8, 24.3, 18.0, 16.4, 15.1, -4.3, -4.7; MS (EI) 
m/z 294 (14), 292 (100), 250 (27), 97 (34), 83 (34), 73 (48), 57 (73); HRMS (EI) m/z calcd for 
C17H31NOSi 293.2175, found 293.2187. 
N
CH3
CH3
O
H  
(1aS*,3aR*,7aR*)-1a,3-Dimethylhexahydro-1H-cyclopropa[c]indol-5(1aH)-one (3-124). To 
a solution of 3-123 (450.0 mg, 1.533 mmol) in THF (11 mL) was added a solution of TBAF (1 
M solution in THF, 1.53 mL, 1.53 mmol). The reaction mixture was stirred for 2 h at room 
temperature, filtered through Celite and concentrated in vacuo. Purification by chromatography 
on SiO2 (50% EtOAc/hexanes) gave 3-124 (234.0 mg, 85%) as a colorless oil: IR (ATR) 2920, 
2851, 1710, 1446, 1256 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.05 (d, 1 H, J = 9.0 Hz), 2.61 (ddd, 
1 H, J = 12.5, 3.5, 1.5 Hz), 2.49-2.39 (m, 2 H), 2.32-2.21 (m, 3 H), 2.19 (s, 3 H), 1.96 (dt, 1 H, J 
= 13.0, 5.0 Hz), 1.52 (ddd, 1 H, J = 13.0, 6.5, 2.0 Hz), 1.19 (s, 3 H), 1.16 (d, 1 H, J = 3.5 Hz), 
0.05 (d, 1 H, J = 3.5 Hz); 13C NMR (125 MHz, CDCl3) δ 211.0, 68.1, 65.0, 45.3, 40.6, 39.3, 
33.3, 25.6, 25.1, 16.6, 15.1; MS (EI) m/z 179 (M•+, 11), 178 (40), 92 (100), 86 (39), 84 (63); 
HRMS (EI) m/z calcd for C17H11NO 179.1310, found 179.1307. 
N
CH3H
O
 
(1aS*,3aR*,7aS*)-1a,3-Dimethyl-2,3,3a,4-tetrahydro-1H-cyclopropa[c]indol-5(1aH)-one (3-
65). To a solution of 3-124 (120.0 mg, 0.6694 mmol) in acetonitrile (4 mL) at 0 °C was added 
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2,6-lutidine (156 µL, 1.34 mmol), followed by TMSOTf (158 µL, 0.870 mmol), warmed to room 
temperature over 2 h, and quenched with saturated aqueous NaHCO3. After extraction with 
CH2Cl2 (5 x 5 mL), the combined organic layers were washed with brine, dried (Na2SO4), 
concentrated in vacuo to obtain the corresponding TMS-enol ether (168.0 mg, 100%), which was 
used crude in the next step, without further purification or characterization. To a solution of 
TMS-enol ether (65.0 mg, 0.294 mmol) in THF (2.0 mL) at -78 °C was added powdered 
NaHCO3 (30.0 mg, 0.310 mmol) followed by NBS (55.0 mg, 0.310 mmol), slowly warmed to 
room temperature over 1 h, quenched with saturated aqueous NaHCO3, extracted with Et2O (4 x 
10 mL) and CH2Cl2 (1 x 10 mL). Combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated in vacuo to give the crude bromide (61.0 mg, 0.23 mmol), which 
was dissolved in DMF (8 mL), and treated with LiBr (60.0 mg, 0.697 mmol) and Li2CO3 (51.2 
mg, 0.697 mmol). The reaction mixture was heated at 120 °C for 2.5 h, poured into brine, and 
extracted with Et2O (3 x 10 mL) and CH2Cl2 (4 x 10 mL). The combined organic layers were 
washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by chromatography 
on SiO2 (50% EtOAc/hexanes) gave 3-65 (7.0 mg, 17%, three steps) as a yellowish oil: IR 
(ATR) 2934, 2846, 1664, 1571, 1165, 1163 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.81 (d, 1 H, J = 
9.5 Hz), 6.07 (d, 1 H, J = 10.0 Hz), 3.07 (d, 1 H, J = 8.5 Hz), 2.71 (dd, 1 H, J = 15.5, 4.0 Hz), 
2.58 (d, 1 H, J = 13.0 Hz), 2.30 (d, 1 H, J = 14.5 Hz), 2.24 (s, 3 H), 2.17 (d, 1 H, J = 8.5 Hz), 
1.31 (s, 3 H), 1.26 (s, 1 H), 0.44 (d, 1 H, J = 4.0 Hz); 13C NMR (125 MHz, CDCl3) δ 199.6, 
150.8, 130.1, 64.9, 64.0, 41.4, 39.0, 35.3, 29.2, 19.5, 15.0; HRMS (EI) m/z calcd for C11H15NO 
177.1154, found 177.1124. 
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(E)-4-(Methyl(2-methylbuta-2,3-dienyl)amino)but-3-en-2-one (3-129). To a stirred solution of 
allenyl alcohol 3-127 (1.6 g, 19 mmol), DMAP (216.0 mg, 1.768 mmol) and triethylamine (4.0 
mL, 28 mmol) in CH2Cl2 (60 mL) at 0 °C was added mesyl chloride (1.50 mL, 20.0 mmol), 
stirred for 60 min, diluted with CH2Cl2 (20 mL), and quenched with aquoeus HCl (1 M solution, 
20 mL). The organic layer was washed saturated aqueous NaHCO3, brine, dried (Na2SO4), and 
concentrated in vacuo, to give mesylate 3-128 (683.5 mg) as a yellowish oil. To a suspension of 
NaH (104.0 mg, 4.333 mmol) in THF (34 mL) was added a solution of vinylogous amide 3-104 
(0.42 g, 4.2 mmol) in THF (4 mL) dropwise at 0 °C, and the resulting mixture was stirred for 1 h. 
To this solution was added a solution of mesylate 3-128 (683.5 mg, 4.210 mmol) in THF (4 mL) 
dropwise, NaI (120.0 mg, 0.8001 mmol) in one portion at 0 °C, and stirred at 50 °C for 5 h. After 
the reaction mixture was cooled to room temperature, a saturated aqueous solution of NH4Cl was 
added, extracted with Et2O (3 x 5 mL), washed with brine, dried (Na2SO4), and concentrated in 
vacuo. Purification by chromatography on SiO2 (50% EtOAc/hexanes) gave the desired coupling 
product 3-129 (1.00 g, 54%, 2 steps) as a yellowish oil: IR (ATR) 2934, 1651, 1558, 1355 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.49 (d, 1 H, J = 12.8 Hz), 5.08 (d, 1 H, J = 12.8 Hz), 4.72 (dd, 2 
H, J = 6.0, 2.8 Hz), 3.73 (s, 2 H), 2.76 (s, 3 H), 2.09 (s, 3 H), 1.61 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 206.7, 195.4, 152.1, 96.8, 94.7, 75.8, 61.1, 34.8, 28.2, 15.7; HRMS (ESI) m/z calcd for 
C10H16NO [M+H]+ 166.1232, found 166.1225. 
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(E)-3-(tert-Butyldimethylsilyloxy)─N─methyl─N─(2-methylbuta-2,3-dienyl)buta-1,3-dien-
1-amine (3-130). To a solution of NaHMDS (1.04 g, 5.70 mmol) in THF (6.5 mL) at -78 °C was 
added a solution of 3-129 (924.0 mg, 5.701 mmol) in THF (6.5 mL) over 30 min. The resulting 
clear yellow solution was stirred for 1 h at -78 °C, treated with a solution of tert-
butylchlorodimethylsilane (902.0 mg, 5.986 mmol) in THF (6.5 mL) over a period of 5 min, 
slowly warmed to room temperature, and concentrated under reduced pressure to provide 3-130 
(1.59 g, 100%) as an orange thick oil: 1H NMR (400 MHz, CDCl3) δ 6.67 (d, 1 H, J = 13.2 Hz), 
4.81 (d, 1 H, J = 13.2 Hz), 4.66 (dd, 2 H, J = 5.6, 2.4 Hz), 3.92 (s, 1 H), 3.84 (s, 1 H), 3.56 (dd, 1 
H, J = 2.0 Hz), 2.67 (s, 3 H), 1.62-1.56 (m, 5 H), 0.98 (s, 3 H), 0.92 (d, 1 H, J = 4.4 Hz). 
N
CH3
TBSO
 
6-(tert-Butyldimethylsilyloxy)-1,3-dimethyl-2,4,5,7a-tetrahydro-1H-indole (3-131). A 
solution of 3-130 (1.59 g, 5.69 mmol) in o-dichlorobenzene (15 mL) was heated in portions (3 
mL) in a microwave oven at 230 °C for 30 min. The reaction mixture was purified by 
chromatography on SiO2, (hexanes, then 50% EtOAc/hexanes) to obtain 3-131 (434.4 mg, 27 %) 
as a yellow oil: IR (ATR) 2952, 2928, 1655, 1172, 867, 839 cm-1; 1H NMR (500 MHz, CDCl3) δ 
4.91 (dd, 1 H, J = 2.5 Hz), 3.63 (d, 1 H, J = 12.5 Hz), 3.62 (s, 1 H), 2.53 (d, 1 H, J = 13.5 Hz), 
2.43 (s, 3 H), 2.22-2.05 (m, 3 H), 1.64 (s, 3 H), 0.90 (s, 9 H), 0.16 (s, 3 H), 0.15 (s, 3 H); 13C 
NMR (125 MHz, CDCl3) δ 152.1, 131.7, 126.2, 104.6, 69.3, 66.4, 40.2, 30.5, 25.6, 21.2, 17.9, 
11.4, -4.3, -4.4; HRMS (ESI) m/z calcd for C16H30NOSi [M+H]+ 280.2097, found 280.2099. 
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1,3-Dimethyl-4,5,7,7a-tetrahydro-1H-indol-6(2H)-one (3-132). To a solution of 3-131 (144.8 
mg, 0.5181 mmol) in THF (3.5 mL) was added a solution of TBAF (1.0 M in THF, 0.52 mL, 
0.52 mmol), and stirred at room temperature for 2 h. The reaction mixture was concentrated in 
vacuo, and then purified by chromatography on SiO2 (25% acetone/chloroform) to give 3-132 
(52.5 mg, 61%) in the form of yellowish oil: IR (ATR) 2918, 1705, 1620, 1359 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 3.74 (dd, 1 H, J = 13.0, 3.5 Hz), 3.46 (m, 1 H), 3.26 (dt, 1 H, J = 12.5, 7.0, 
0.5 Hz), 2.80-2.74 (m, 2 H), 2.44 (s, 3 H), 2.40-2.32 (m, 3 H), 2.20-2.13 (m, 2 H), 1.69 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 210.4, 129.9, 129.1, 71.9, 66.6, 49.1, 40.3, 39.9, 21.9, 11.5; 
HRMS (ESI) m/z calcd for C10H16NO [M+H]+ 166.1232, found 166.1195. 
N
H
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CO2CH3  
(1aS*,3aR*,7aR*)-Methyl 1a-methyl-5-oxohexahydro-1H-cyclopropa[c]indole-3(3aH)-carb- 
oxylate (3-133). A solution of ketone 3-124 (50.0 mg, 0.279 mmol) in methyl chloroformate (3.0 
mL) was heated to 70 °C for 3 h, quenched with water (3 mL), and extracted with CH2Cl2 (4 x 10 
mL). The combined organic extracts were washed with water, brine, and dried (Na2SO4). 
Purification by chromatography on SiO2 (20% hexanes/EtOAc) provided 3-133 (44.2 mg, 71%) 
as a yellow solid: Mp 79.1-81.0 °C; IR (ATR) 2958, 2859, 1696, 1437, 1349, 1122 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 3.71-3.66 (m, 2 H); 3.65 (s, 3 H); 3.37 (d, 1 H, J = 13.2 Hz), 3.27 
(dd, 1 H, J = 10.0, 0.8 Hz), 2.53 (dddd, 1 H, J = 15.2, 5.2, 1.6 Hz), 2.44-2.35 (m, 2 H), 2.04 (ddt, 
1 H, J = 13.2, 5.2, 1.2 Hz), 1.55 (ddd, 1 H, J = 13.2, 7.2, 2.0 Hz), 0.81 (d, 1 H, J = 3.6 Hz), 0.30 
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(d, 1 H, J = 4.4 Hz); 13C NMR (100 MHz, CDCl3) δ 209.3, 157.0, 60.5, 57.1, 52.1, 46.6, 40.2, 
34.5, 25.0, 24.4, 17.9, 14.5; HRMS (ESI) m/z calcd for C12H17NO3Na [M+Na]+ 246.1106, found 
246.1090. 
N
H
O
CO2CH3  
(1aS*,3aR*,7aS*)-Methyl 1a─methyl─5-oxo─1a,2,4,5─tetrahydro-1H-cyclopropa[c]indole-
3(3aH)-carboxylate (3-134). To a solution of diisopropylamine (13 µL, 0.097 mmol) in THF 
(0.4 mL) at 0 °C was added n-BuLi (1.6 M in hexanes, 60 µL, 0.097 mmol). The reaction 
mixture was stirred at this temperature for 15 min, cooled to -78 °C, and treated with a solution 
of 3-133 (18.0 mg, 0.0810 mmol) in THF (0.3 mL). The mixture was stirred for 60 min, treated 
with TMSCl (20.0 µL, 0.158 mmol), stirred at -78 °C for 1.5 h, concentrated in vacuo, diluted 
with hexane, and filtered through a pad of SiO2. The pad was washed with hexanes (4 x 1 mL) 
and EtOAc (1 x 1 mL), and concentrated in vacuo. The crude material was dissolved in 
acetonitrile (1.5 mL), and treated with Pd(OAc)2 (23.5 mg, 0.105 mmol) for 10 h at room 
temperature, filtered through a pad of Celite, washed with EtOAc (3 x 5 mL), and concentrated 
under reduced pressure. Purification by chromatography on SiO2 (50% EtOAc/hexane) provided 
enone 3-134 (12.0 mg, 67%) as a yellow solid: Mp 95.4-97.2 °C; IR (ATR) 2950, 2872, 1709, 
1674, 1661, 1348, 1195 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.83 (d, 1 H, J = 9.6 Hz), 6.10 (d, 1 
H, J = 9.6 Hz), 3.88 (dd, 1 H, J = 13.6, 3.6 Hz), 3.74 (d, 1 H, J = 10.0 Hz), 3.68 (s, 3 H), 3.51 (d, 
1 H, J = 14.4 Hz), 3.20 (d, 1 H, J = 10.0 Hz), 2.49 (dd, 1 H, J = 16.0, 13.6 Hz), 1.36 (s, 3 H), 
1.28 (d, 1 H, J = 4.8 Hz), 0.58 (d, 1 H, J = 4.4 Hz); 13C NMR (120 MHz, CDCl3) δ 198.7, 157.1, 
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148.2, 130.8, 58.0, 55.6, 52.3, 43.3, 35.3, 27.7, 19.3, 14.3; HRMS (AP) m/z calcd for C12H16NO3 
([M+H]+) 222.1130, found 222.1136. 
N
HHO CO2CH3
BocN
O
 
(1aS*,3aR*,7aS*)-Methyl 5-(((tert-butoxycarbonyl)(furan─2─yl)amino)methyl)-5-hydroxy-
1a-methyl-1a,2,4,5-tetrahydro-1H-cyclopropa[c]indole-3(3aH)-carboxylate (3-135). To a 
solution of furanyl stannane 3-48 (114.3 mg, 0.2350 mmol) in anhydrous THF (0.3 mL) at -78 
°C was added a solution of n-BuLi (1.60 M in hexanes, 146 µL, 0.235 mmol) dropwise over 5 
min. The reaction mixture was stirred for an additional 30 min at -78 °C, then a solution of enone 
3-134 (40.0 mg, 0.181 mmol) in THF (0.2 ml) was added dropwise over 2 min. The resulting 
mixture was stirred for 1 h at -78 °C, diluted with EtOAc (3 mL), and quenched with saturated 
aqueous NH4Cl (4 mL). The layers were separated and the aqueous phase was further extracted 
with EtOAc (3 x 5 mL). The combined organic extracts were dried (Na2SO4), concentrated under 
reduced pressure, and purified by chromatography on SiO2 (50% EtOAc/hexane) to obtain 3-
135-a (38.1 mg, 51%) as a colorless oil (single diastereomer), and 3-135-b (36.1 mg, 48%) as a 
colorless oil (single diastereomer). 3-135-a: Rf = 0.52 (50% EtOAc/hexanes); IR (ATR) 3465, 
2977, 1696, 1364, 1150, 1148 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.18-7.17 (m, 1 H), 6.35-6.34 
(m, 1 H), 6.07 (br s, 1 H), 5.69-5.65 (m, 2 H), 3.84-3.58 (m, 4 H), 3.63 (s, 3 H), 3.42 (d, 1 H, J = 
12.5 Hz), 3.07 (d, 2 H, J = 10.0 Hz), 1.85 (app t, 1 H, J = 12.5 Hz), 1.45 (s, 9 H), 1.23 (s, 3 H), 
0.86 (d, 1 H, J = 4.5 Hz), 0.34 (d, 1 H, J = 4.5 Hz); 13C NMR (125 MHz, CDCl3) δ 171.1, 157.2, 
149.1, 138.1, 131.2, 127.8, 111.0, 101.5, 82.3, 74.6, 60.3, 55.9, 52.0, 37.8, 35.2, 28.1, 26.1, 21.0, 
19.5, 14.1; HRMS (ESI) m/z calcd for C22H30N2O6Na ([M+Na]+) 441.2002, found 441.1959. 3-
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135-b: Rf = 0.35 (50% EtOAc/hexanes); IR (ATR) 3463, 2978, 2952, 1700, 1357, 1150 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.17 (s, 1 H), 6.33 (d, 1 H, J = 1.5 Hz), 6.01 (s, 1 H), 5.68 (d, 1 H, J 
= 9.5 Hz), 5.60 (d, 1 H, J = 9.5 Hz), 3.79-3.66 (m, 4 H), 3.65 (s, 3 H), 3.14 (d, 1 H, J = 10.5), 
2.88 (br s, 1 H), 1.67 (t, 1 H, J = 12.0 Hz), 1.43 (s, 9 H), 1.22 (s, 3 H), 0.80 (d, 1 H, J = 4.0 Hz), 
0.24 (d, 1 H, J = 4.0 Hz) ; 13C NMR (125 MHz, CDCl3) δ 149.0, 138.1, 130.0, 129.3, 111.0, 
101.9, 82.0, 73.9, 60.3, 59.0, 56.9, 56.4, 52.0, 38.3, 35.2, 28.0, 25.6, 18.5, 14.2, 14.1. HRMS 
(ESI) m/z calcd for C22H30N2O6Na ([M+Na]+) 441.2002, found 441.2000. 
HN
N
H
CH3
CO2CH3  
(1aS*,3aR*,9bS*)─Methyl 1a─methyl-1a,2,3a,4─tetrahydro─1H─cyclopropa[c]indolo[4,3-
ef]indole-3(6H)-carboxylate (3-136). A solution of alcohol 3-135-b (23.0 mg, 0.0549 mmol) in 
trifluorotoluene (2.5 mL) was heated under microwave irradiation (180 °C, 30 min), 
concentrated in vacuo, and then purified by chromatography on SiO2 (10-15% 
acetone/chloroform) to obtain starting allylic alcohol 3-135-b (4.8 mg), and the desired indole 3-
136 (6.8 mg, 44%, 56% brsm) as colorless oil: IR (ATR) 3324, 2949, 1680, 1441, 1113 cm-1; 1H 
NMR (700 MHz, CDCl3) δ 7.98 (br s, 1 H), 7.17 (d, 1 H, J = 8.4 Hz), 7.09 (dd, 1 H, J = 8.4, 7.0 
Hz), 6.93 (s, 1 H), 6.86 (d, 1 H, J = 7.0 Hz), 4.06 (br d, 1 H, J = 9.8 Hz),  3.80 (br d, 1 H, J = 9.1 
Hz), 3.79-3.70 (br, 1 H), 3.72 (s, 3 H), 3.43 (d, 1 H, J = 9.8 Hz), 2.82-2.78 (m, 1 H), 1.76 (s, 3 
H), 1.16 (d, 1 H, J = 4.2 Hz), 0.62 (d, 1 H,  J = 4.2 Hz); 13C NMR (175 MHz, CDCl3) δ 157.6, 
133.9, 133.3, 128.4, 122.8, 118.5, 112.9, 110.2, 108.5, 62.4, 57.1, 52.2, 35.3, 27.0, 26.5, 24.8, 
16.2; HRMS (APCI) m/z calcd for C17H18N2O2 282.1368, found 282.1398. 
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(1aS*,3aR*,9bS*)─1a,3─Dimethyl─1a,2,3,3a,4,6─hexahydro─1H-cyclopropa[c]indolo[4,3-
ef]indole (Cycloclavine, 3-5). A suspension of LiAlH4 (1.4 mg, 0.041 mmol) in THF (0.2 mL) 
was treated with a solution of carbamate 3-136 (2.5 mg, 0.088 mmol) in THF (0.2 mL), heated to 
66 °C for 30 min, and cooled to room temperature. After sequential addition of water (1.4 µL), 
15% aqueous NaOH (1.4 µL), and water (4.5 µL), the mixture was filtered through Celite, and 
concentrated in vacuo. Purification by chromatography on SiO2 (20% acetone/chloroform) gave 
cycloclavine (3-5, 2.3 mg, 100%) as a white solid: Mp 153.2-155.3 °C (acetone/chloroform); IR 
(ATR) 2921, 2798, 1591, 1590, 1441, 1150 cm-1; 1H NMR (700 MHz, CDCl3) δ 7.92 (bs, 1 H), 
7.15 (d, 1 H, J = 8.4 Hz), 7.10 (app t, 1 H, J = 7.7 Hz), 7.91 (s, 1 H), 6.84 (d, 1 H, J = 7.0 Hz), 
3.17 (d, 1 H, J = 9.1 Hz), 3.15 (dd, 1 H, J = 14.0, 4.2 Hz), 2.79 (dd, 1 H, J = 11.2, 3.5 Hz), 2.61 
(t, 1 H, J = 12.6 Hz), 2.42 (d, 1 H, J = 8.4 Hz), 2.37 (s, 3 H), 1.70 (s, 3 H), 1.61 (d, 1 H, J = 2.8 
Hz), 0.46 (d, 1 H, J = 3.5 Hz); 13C NMR (125 MHz, CDCl3) δ 135.4, 133.5, 128.7, 122.9, 118.1, 
113.2, 110.3, 107.9, 69.6, 65.6, 39.9, 34.3, 27.8, 24.9, 24.2, 16.5; HRMS (APCI) m/z calcd for 
C16H19N2 ([M+H]+) 239.1548, found 239.1572. 
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4.0  PROGRESS TOWARD THE TOTAL SYNTHESIS OF -
CYCLOPIAZONIC ACID 
4.1 INTRODUCTION 
4.1.1 Cyclopiazonic acid: Structure and Biological Activity 
-Cyclopiazonic acid (CPA, 4-1, Figure 19) is an indole-tetramic acid mycotoxin produced by 
the molds of genera Aspergillus and Penicillium.131,182 These molds can grow on many food 
substrates, such as cheese and meat. Therefore, this toxin can contaminate a variety of 
agricultural commodities and food sources.183 CPA was first isolated by Holzapfel in 1968 from 
stored grain and cereal products infected by Penicillium cyclopium Westling.184 The structure of 
cyclopiazonic acid was established by interpretation of its spectroscopic data; while the absolute 
stereochemistry was confirmed by a circular dichroism (CD) analysis. In 1970, two other 
metabolites related structurally to -CPA were isolated: cyclopiazonic acid imine (4-2) and bis-
seco-dehydrocyclopiazonic acid (-cyclopiazonic acid, 4-3).185 
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Figure 19. Cyclopiazonic acid (4-1) and its two related family members 
The most striking feature of -cyclopiazonic acid is a pentacyclic array containing a 3,4-
disubstituted indole and a highly substituted tetramic acid residue, together with a central cis-ring 
fusion. 
The toxicity of -cyclopiazonic acid is attributed to its ability to alter normal intracellular 
calcium flux through the specific inhibition of sarcoplasmic or endoplasmic reticulum Ca2+-
dependent ATPase (SERCA), which are essential for calcium uptake in muscles.186,187 Recent 
evidence shows that -CPA inhibits the calcium pump by blocking the calcium access channel 
and immobilizing four transmembrane helices of the ATPase. Furthermore, CPA induces various 
pathological lesions in test animals.188 
Biosynthetically, cyclopiazonic acid is derived from L-tryptophan (Scheme 74). This was 
established by feeding studies using radiolabeled substrates.189 The first stable intermediate in 
this biosynthetic pathway is cyclo-acetoacetyl-L-tryptophan (cAATrp, 4-7), derived from L-
tryptophan, acetyl-CoA, and malonyl-CoA. After the initial condensation of acetyl-CoA and 
malonyl-CoA, the acetoacetyl moiety becomes tethered on ACP (acyl carrier protein). Further 
substitution at the carbonyl carbon of the ACP-bound acetylacetone 4-4 by PCP-bound indole 4-
5 (PCP – peptidyl carrier protein) leads to the cAATrp precursor 4-6. The tetramic acid portion 
of cAATrp is formed through a Dieckman condensation, a process which ultimately leads to the 
formation of non-petide bound cAATrp (4-7).131  
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Scheme 74. Biosynthesis of -cyclopiazonic acid 4-1 
Conversion of cAATrp to -cyclopiazonic acid involves alkylation of the C(4) position of 
the Trp indole ring by DMAPP (dimethylallyl pyrophosphate, 4-8), a reaction catalyzed by 
dimethylallyl transferase.190 The final step in the biosynthesis of -cyclopiazonic acid is the 
dehydrogenation of -CPA, which results in an intramolecular ring closure. The enzyme 
involved in this conversion is an FAD-dependent oxidoreductase (Mao A).191 
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4.1.2 Previous Work on the Total Synthesis of Cyclopiazonic Acid 
The synthetic community has been intrigued by cyclopiazonic acid’s interesting structural 
features and its biological activity for decades. Although the structure of CPA was known since 
1968, only three racemic and one asymmetric syntheses have been published to date.  
In 1984 Kozikowski and Greco reported the first racemic total synthesis of -
cyclopiazonic acid (Scheme 75).192 
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Scheme 75. Kozikowski's total synthesis of -CPA (4-1) 
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Indole 4-9 was prepared from 4-indolcarbaldehyde in 5 steps. Subsequent Vilsmeier-
Haack reaction with POCl3 and DMF, followed by a condensation with 2-acetamidomalonic acid 
monoethyl ester provided indole 4-10, which was after an indole protection-acetal deprotection 
transformed to ketone 4-11. In order to obtain tricyclic indole 4-13, ketone 4-11 was first -
sulfenylated via its thermodynamic silyl enol ether, and then subjected to an intramolecular 
Michael reaction with DBU. Interestingly, while an X-ray analysis of 4-13 revealed that the two 
carbon appendages are trans, a subsequent Raney-Ni desulfurization led exclusively to the cis 
product 4-14. This intermediate was further treated with Mg(OTf)2 and thiophenol to effect D-
ring formation and the synthesis of the -phenylthio amide 4-15. When 4-15 was exposed to the 
excess of dimethylzinc in chloroform, the thiophenyl substitution provided 4-16 in 73% yield. 
Finally, the N-acetyl deprotection with Meerwein’s reagent, followed by the treatment of the free 
amine with diketene provided 4-17, a direct precursor to -cyclopiazonic acid. This intermediate 
was exposed to methanolic sodium methoxide, which resulted in the formation of iso--
cyclopiazonic acid (4-18). To complete the synthesis, the authors isomerized 4-18 to 4-1 with 
Et3N in chloroform, which provided a 2.5:1 mixture of 4-1 and the iso-compound 4-18. 
Similar to Kozikowski’s approach, Natsume’s synthesis utilizes a Michael addition for 
the construction of C-ring (Scheme 76).193 However, due to the higher temperature for the 
cyclization reaction, a mixture of tricyclic stereoisomers 4-20, 4-21, and 4-22 was obtained in 
8.7:4.5:1 ratio. Exposure of 4-20 to aqueous HCl, 2-methyl-1-pyrroline 4-23 was formed in 65% 
yield. The necessary gem-dimethyl moiety was introduced through an addition of CH3Li in the 
presence of BF3•Et2O. After the tosyl group deprotection, the tetramic acid was elaborated using 
diketene, thus completing the synthesis of -cyclopiazonic acid (4-1). 
 161 
N
Ts
H3C
4-19
O
N
CO2Et
OHC CH2OCH3
N
Ts
H
OH3C
N
HH
DBU
benzene
80 °C
CO2Et
CHO
CH2OCH3
N
Ts
H
OH3C
N
CO2EtH
H
CHO
CH2OCH3
4-20 (52%) 4-21 (27%)
N
Ts
H
OH3C
N
CO2EtH
H
CHO
CH2OCH3
4-22 (6%)
+ +
N
Ts
H
OH3C
N
HH
CO2Et
CHO
CH2OCH3
4-20
HCl 
EtOH/H2O (4:1)
100 °C; 65% N
Ts
4-23
N
H3C
H
H CO2Et
H BF3•Et2O
THF, 0 °C
then CH3Li
-80 to -65 °C
4%
N
Ts
4-24
NH
H3C
H
H CO2Et
H
CH3
KOH
EtOH/H2O (3:1)
100 °C, 3 h; 67%
N
H
4-25
NH
H3C
H
H CO2Et
H
CH3
1. diketene
    CH2Cl2, 45 °C, 1 h
2. t-BuOK
    THF/EtOH (5:1)
    0 °C to rt, 15 h
      89% (2 steps)
N
H
N
H3C
H3C
H
H
H
O
O
CH3
OH
-Cyclopiazonic acid (4-1)  
Scheme 76. Natsume's approach to 4-1 
In 2005, Haskins and Knight reported a synthesis of -cyclopiazonic acid through an 
implementation of an interesting cationic cascade reaction (Scheme 77).194 Starting with indole-
4-methanol 4-26, aldehyde 4-27 was synthesized through an O-TBDPS protection, formylation 
under standard Vilsmeier conditions, and protection of the indole nitrogen by tosylation. 
Aldehyde 4-27 was further homologated by a Horner-Wadsworth-Emmons reaction, which 
yielded unsaturated ester 4-28. Exposure of this ester to a Michael addition of 2-
methylpropenylmagnesium bromide in the presence of phenylthiocopper, followed by a 
treatment with KHMDS and trisyl azide, engendered introduction of the necessary nitrogen 
functionality. Conversion into the corresponding free amino-ester was achieved under Staudinger 
conditions. Finally, N-nosylation gave the desired precursor 4-29. 
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Scheme 77. Haskins and Knight's synthesis of 4-1 
Exposure of 4-29 to triflic acid in CHCl3 cleanly provided the advanced tetracyclic 4-31, 
presumably through an intermediate 4-30, with the desired stereochemistry. Final deprotection of 
the secondary amine, followed by the previously reported procedure for the formation of the 
tetramic acid (diketene in CH2Cl2, and the subsequent exposure to t-BuOK) led smoothly to -
CPA (4-1). 
Improvement of the Knight synthesis by Beyer and coworkers led to the first asymmetric 
total synthesis of -CPA (Scheme 78).195 1,4-Addition of isopropenylcuprate to the chiral 
indolyl acrylic acid 4-32, followed by a 1,2-addition of trisyl azide (dr 98:2), provided the 
bicyclic intermediate 4-29 in enantiomerically pure form. Further elaboration according to the 
Knight route led to the formation of 4-1. 
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4.2 RESULTS AND DISCUSSION 
4.2.1 Retrosynthetic Analysis of Cyclopiazonic acid (4-1) 
After our success in the formation of the tricyclic indole 4-39 through an intramolecular furan 
Diels-Alder reaction (IMDAF), described in Chapter 2 of this thesis, and the successful 
implementation of this methodology in the synthesis of cycloclavine (Chapter 3), our attention 
turned to the related alkaloid cyclopiazonic acid (4-1).  
Retrosynthetically, we envisioned that the formation of the tricyclic indole 4-39 through 
an IMDAF cascade could provide the part of the core structure of cyclopiazonic acid (Scheme 
79). As in previous syntheses of this alkaloid, the initial disconnection was the tetramic acid 
formation, which could be accessed via a coupling of 4-33 with diketene. The requisite 
dimethylamine could be derived from the corresponding lactam 4-34. The required 
stereochemistry at the C-D ring junction could be revealed following a stereoselective 1,4-
addition of the camphor-derived t-butylglycine imine 4-37 to the ,-unsaturated ester 4-36, 
which could be synthesized from the corresponding ketone 4-38. This ketone could further be 
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simplified to 2-cyclohexen-1-one (4-40) and stannane 4-41, through an IMDAF cascade reaction 
followed by a regioselective oxidation of the tricyclic intermediate 4-39. 
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Scheme 79. Retrosynthetic analysis of cyclopiazonic acid (4-1) 
4.2.2 Progress towards the Total Synthesis of Cyclopiazonic Acid 
Our synthetic approach commences with the previously described coupling of 2-cyclohexene-1-
one (4-40) and the lithiated analog of stannane 4-41 (Scheme 80). Alcohol 4-42 was cyclized 
under microwave conditions in o-dichlorobenzne or trifluorotoluene at 180 °C to provide 4-39 in 
84% yield. Regioselective oxidation of the tricyclic indole 4-39 with DDQ in a mixture of water 
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and THF at room temperature,196 followed by an N-Boc protection of the indole provided desired 
ketone 4-38. When 4-38 was exposed to basic conditions (LDA, THF, -78 °C), and then treated 
with methyl cyanoformate (4 equiv), a formation of the enol 4-44 was observed in 75% yield. It 
is interesting to note that 4-44 exists in the enol form, and no ketone tautomer was observed by a 
1H NMR analysis at room temperature. 
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Scheme 80. Synthesis of the tricyclic ester 4-44 
Attempts towards the preparation of 4-36 through a three-step sequence (enol reduction, 
secondary alcohol mesylation, elimination)197 from 4-44 failed, probably due to the inherent 
reactivity of the intermediary formed mesylate, which could not be isolated. Alternatively, 
triflation of the enol 4-44 with N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide) in the 
presence of NaH, followed by the Pd(PPh3)4-assisted reduction with Et3SiH in DMF provided 4-
36 in 53% yield (2 steps).198 
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Scheme 81. Reduction of the enol 4-44 
With 4-36 in hand, we were now in a position to explore the construction of the D-ring 
through a stereoselective Michael addition followed by lactamization.  In 1991, Kanemasa and 
coworkers reported a highly diastereoselective Michael addition of lithiated camphor imines of 
glycine esters to ,-unsaturated esters to synthesize optically pure 5-oxopyrrolidine-2-
carboxylates.199,200 In order to test the viability of this approach, we first synthesized the 
oxopyrrolidine carboxylate on model system 4-48 (Scheme 82). Accordingly, indole-3-
carbaldehyde (4-47) was N-protected and homologated to 4-48 through the Horner-Wadsworth-
Emmons reaction. Michael addition of the lithium enolate, formed in situ by treating 4-37 with 
LDA at -78 °C, to the ,-unsaturated ester 4-48 resulted in the formation of 4-49 in 67% yield. 
The camphor chiral auxiliary was readily removed by heating the adduct 4-49 at reflux with 
hydroxylamine hydrochloride and sodium acetate in EtOH, which provided 4-50 in 70% yield. 
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Scheme 82. Diastereoselective Michael addition of 4-49 to model system 4-48 
1H NMR analysis of 4-50 revealed a discrepancy with regard to the configuration at the 
pyrrolidinone ring (Figure 20). The H-atom at C(2) of the pyrrolidinone moiety in 4-50 appeared 
as dublet ( 4.30 ppm) with J = 4.4 Hz. However, in t-butyl (2R)-3-phenyl-5-oxopyrrolidine-2-
carboxylate (4-51), synthesized by Kanemasa and coworkers using the same method, the 
corresponding C(2)-H appears as dublet ( 4.03 ppm) with a coupling constant J = 7.3 Hz, 
indicating the desired trans-stereochemistry.  
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Figure 20. Comparison of the coupling constant JH2-H3 in 4-50 and 4-51 
Having succeeded in the synthesis of the required pyrrolidinone ring in the model system, 
but keeping in mind the previously mentioned inconsistency with regard to the stereochemical 
outcome of this process, we decided to subject 4-36 to the same reaction conditions for the 
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Michael addition. Treatment of 4-37, prepared from (S)-camphor and t-butyl glycinate,201 with 
LDA at -78 °C in THF, followed by the addition of 4-36 and t-BuOH provided 4-52 (Scheme 
83). Again, the camphor chiral auxiliary was removed by heating the adduct 4-52 at reflux with 
hydroxylamine hydrochloride and sodium acetate in EtOH, providing 4-53 in 76% yield. 
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Scheme 83. Enolate addition to 4-36 and formation of the tetracyclic 4-53 
Comparison of the 1H NMR data for 4-53 with 4-31 (an advanced intermediate in the 
Knight synthesis of cyclopiazonic acid),194 as well as with iso-cyclopiazonic acid (4-18, 
synthesized by Beyer et al)195 indicated a cis-relationship between H(4) and H(5) in 4-53 (Figure 
21; cyclopiazonic acid numbering). 
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Figure 21. Comparison of the JH4-H5 coupling constant in 4-53, 4-31, and 4-18 
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This inconsistency with the previously reported data could reflect the effect of the -
substituent as a part of the ring in the starting ,-unsaturated ester, which enforces a Z-
geometry of the olefin. Although the Kanemasa model suggests the formation of the desired 
trans-configuration between H(4) and H(5) (Figure 22), it is possible that the -substituent 
introduces an additional strain in the transition state, thus favoring a disruption of the chelation 
between Li and imine N-atom (Figure 21). Or, perhaps more importantly, the steric hindrance 
introduced by the -substituent might disfavor the coordination of the ,-unsaturated ester from 
the -face of the camphor-auxiliary, thus exposing the re-face of the enolate to the reaction with 
the electrophile. 
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Figure 22. Kanemasa's transition state for the Michael addition 
Although the configuration at the pyrrolidinone ring was not correctly set in the Michael 
addition step, we surmised that it would be possible to change the configuration at C(5) in the 
later stage of the synthesis through a thermodynamic equilibration with t-BuOK/t-BuOH. 
According to our earlier plan, we were now in a position to convert the previously synthesized 
lactam into a 2,2-dimethylamine.  
In 2008, Renaud and coworkers developed an efficient method for the synthesis of gem-
2,2-disubstituted tertiary amines from the corresponding lactams or amides.202 This protocol is 
based on the reaction of thioiminium ions, easily prepared from lactams and amides with 
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organometallic reagents such allylmagnesium, benzylmagnesium, and primary alkylcerium 
reagents. Following this protocol, we converted 4-53, after a benzyl protection, to the 
corresponding thiolactam 4-54 (Scheme 84). Unfortunately, when 4-54 was exposed to CH3I, no 
S-methylation was observed, and only starting material was recovered in this reaction. Similarly, 
the exposure of 4-56, derived form 4-50 in a two-step sequence (N-benzylation followed by the 
lactam conversion to the thiolactam) to the methylation conditions did not give rise to desired 
thioiminium salt 4-57. Instead, starting thiolactam was the only observed material. 
N
Boc
NH
H
H
CO2t-Bu
H
4-53
O
1. NaH, THF, rt
    BnBr
    60 °C, 12 h; 68%
2. Lawesson's reagent
    toluene, 100 °C, 2 h
    79%
N
Boc
NBn
H
H
CO2t-Bu
H
4-54
S
N
Boc
NBn
H
H
CO2t-Bu
H
4-55
S
CH3I
CH3
+ I-
not observed
4-50
H
N
O
t-BuO2C
H
H
N
Boc
1. NaH, THF, rt
    BnBr
    60 °C, 12 h; 66%
2. Lawesson's reagent
    toluene, 100 °C, 2 h
    99%
4-56
Bn
N
S
t-BuO2C
H
H
N
Boc
CH3I
4-57
Bn
N
SCH3
t-BuO2C
H
H
N
Boc
+
I-
not observed  
Scheme 84. Attempts towards the formation of the thioiminium salts 4-55 and 4-57 
Another procedure for reductive alkylation of lactams with Grignard or organolithium 
reagents was reported by Huang and coworkers.203 In this direct one pot transformation, a lactam 
is activated with triflic anhydride, and then treated with an appropriate Grignard or 
organolithium reagent. Following this procedure, N-benzyl protected 4-53 was first treated with 
Tf2O in the presence of 2,6-di-tert-butyl-4-methylpyridine (DTBMP), and then with a solution of 
CH3MgBr (Scheme 85). After a lot of experimentation, we found that 4-58 could be converted to 
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the corresponding amine 4-59 following this protocol, and warming the reaction mixture to room 
temperature over 12 h. Seemingly successful, this transformation provided amine 4-59 in only 
17% yield, as confirmed by 1H NMR and HRMS analyses. However, the reaction conditions 
were found to be irreproducible, and this protocol was finally abandoned. 
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Scheme 85. One-pot conversion of 4-53 to 2,2-dimethylamine 4-59 
We also explored an alternative route, which relied on a cyclopropanation of the amide 
carbonyl moiety.204,205 Once installed, the cyclopropane ring could generate the required gem-
dimethyl amine through a hydrogenolysis step. However, several protocols aimed at the 
cyclopropanation of the amide carbonyl failed, and only starting material was observed and 
recovered.  
This inherent stability of the amide carbonyl in 4-53 or the thioamide thiocarbonyl in 4-
54 might originate from steric hindrance. The amide group of the tetrasubstituted pyrrolidinone 
ring in 4-53 could be difficult to access by nucleophiles, such as Grignard or organotitanium 
reagents, thus leading to either no reaction or very low yielding process. 
4.2.3 Future Directions 
To complete the synthesis of -cyclopiazonic acid, we propose using 4-53 as a key advanced 
intermediate (Scheme 86). Protection of the amide nitrogen atom, followed by a basic hydrolysis 
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of the lactam would provide aminoester 4-60. Addition of the CH3MgBr to this intermediate 
should lead to tertiary alcohol 4-61, with the gem-dimethyl moiety installed. If 4-61 is subjected 
to acidic conditions, double N-Boc-deprotection is expected, with a concomitant pyrrolidine 
formation.206 At this point, we propose the ester group isomerization at C(5), in order to decrease 
the steric hindrance on the -face of the pyrrolidinone ring in 4-62. Finally, treatment of 4-63 
with diketene, followed by t-BuOK-induced tetramic acid formation, as previously shown, would 
lead to desired -cyclopiazonic acid (4-1).  
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Scheme 86. Proposed route for the completion of cyclopiazonic acid 
4.3 EXPERIMENTAL PART 
General: All moisture-sensitive reactions were performed under an atmosphere of N2. Glassware 
was flame dried prior to use. Reactions carried out at -78 °C employed a dry ice/acetone bath. 
THF and Et2O were dried by distillation over Na/benzophenone ketyl, Et3N was distilled from 
CaH2, and CH2Cl2 and toluene were purified using an alumina filtration system. Unless 
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otherwise stated, solvents and reagents were used as received. Analytical thin layer 
chromatography was performed on pre-coated silica gel 60 F254 plates (250 m layer thickness, 
particle size 0.040-0.055 mm, 230-240 mesh) and visualization was accomplished with a 254 nm 
UV light and/or by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 
95% EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of 
conc. H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O244H2O and 0.2 
g of Ce(SO4)2 in 100 mL of a 3.5 M H2SO4 solution), or a KMnO4 solution (1.5 g of KMnO4 and 
1.5 g of K2CO3 in 100 mL of a 0.1 % NaOH solution). Flash chromatography on SiO2 was used 
to separate and purify the reaction crude mixtures. Microwave reactions were performed on a 
Biotage Initiator microwave reactor. 1H and 13C NMR were recorded on a Bruker Avance 300 
instrument. Chemical shifts () were reported in parts per million with the residual solvent peak 
used as an internal standard. 1H NMR spectra were run at 300, 400 or 500 MHz, and are 
tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
dd = doublet of doublet, ddd = doublet of doublet of doublet, dt = doublet of triplet, sept = septet, 
m = multiplet, br = broad, app = apparent), number of protons, and coupling constant(s). 13C 
NMR spectra were obtained using a proton-decoupled pulse sequence with a d1 of 3 sec, and are 
tabulated by observed peak. LC/MS analyses were obtained from a Helwett Packard Series 1100 
MSD. RP HPLC was obtained from Gilson Series 215, using C18 column, Bio-rad Laboratoris, 
250 x 4.6 mm. Mass spectra were obtained on a Micromass Autospec double focusing 
instrument. Infrared spectra were measured on a Nicolet AVATAR 360 FT-IR E.S.P. 
spectrometer (KBr or neat) or Smiths Detection IdentifyIR FT-IR spectrometer (ATR). 
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4,5-Dihydrobenzo[cd]indol-3(1H)-one (4-38).207 To a solution of tricyclic indole 4-39 (378.1 
mg, 2.404 mmol) in THF/water (21 mL THF + 3 mL water) at 0 °C under Ar, was added a 
solution of DDQ (1.09 g, 4.81 mmol) in THF (5 mL). The reaction mixture was stirred at room 
temperature for 2 h, concentrated under reduced pressure, diluted with EtOAc (10 mL), and 
extracted with EtOAc (6 x 20 mL). The combined organic layers were washed with saturated 
aqueous Na2CO3, brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (20% acetone/chloroform) gave 4-38 (257.2 mg, 62 %) as an off-white 
solid: Mp 189-190 °C; IR (ATR) 3086, 3037, 1629, 1599, 1521 cm-1; 1H NMR (CDCl3, 400 
MHz) δ 9.78 (br s, 1 H), 7.74 (d, 1 H, J = 2.8 Hz), 7.32 (d, 1 H, J = 8.0 Hz), 7.25 (app t, 1 H, J = 
8.0 Hz), 7.12 (dd, 1 H, J = 6.8, 0.8 Hz), 3.38 (app t, 2 H, J = 6.8 Hz), 2.91 (app t, 2 H, J = 7.2 
Hz); 13C NMR (CDCl3, 125 MHz) δ 194.9, 133.7, 129.1 (2), 124.2 (2), 118.5, 114.0, 109.3, 39.8, 
27.6; HRMS (TOF ESI) m/z calcd for C10H18NO [M+H]+ 172.0762, found 172.0766. 
N
Boc
O
 
tert-Butyl 3-oxo-4,5-dihydrobenzo[cd]indole-1(3H)-carboxylate.207 To a solution of 4-38 
(257.1 mg, 1.502 mmol) in THF (15 mL) were added DMAP (183.5 mg, 1.502 mmol), pyridine 
(121 µL, 1.50 mmol) and Boc2O (393.3 mg, 1.802 mmol), and stirred at room temperature for 13 
h. The reaction mixture was diluted with EtOAc (15 mL), washed with 1.0 M aqueous HCl, and 
extracted with EtOAc (4 x 15 mL). The combined organic layers were washed with brine, dried 
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(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (CHCl3) gave 
tert-butyl 3-oxo-4,5-dihydrobenzo[cd]indole-1(3H)-carboxylate (398.5 mg, 98%) as a white 
solid: Mp 109.4-110.6 °C; IR (ATR) 3286, 1728, 1676, 1556, 1247, 1137 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.07 (s, 1 H), 7.86 (d, 1 H, J = 8.0 Hz), 7.33 (t, 1 H, J = 7.2 Hz), 7.16 (dd, 1 
H, J = 7.2, 0.4 Hz), 3.33 (app t, 2 H, J = 6.8 Hz), 2.86 (app t, 2 H, J = 6.8 Hz), 1.69 (s, 9 H); 13C 
NMR (CDCl3, 100 MHz) δ 194.6, 149.3, 133.5, 129.8, 129.3, 125.9, 124.3, 120.7, 116.6, 113.0, 
85.1, 40.0, 28.0, 27.4; HRMS (TOF ESI) m/z calcd for C16H18NO3 [M+H]+ 272.1297, found 
272.1287. 
N
Boc
OH
CO2CH3
 
1-tert-Butyl 4-methyl 3-hydroxybenzo[cd]indole-1,4(5H)-dicarboxylate (4-44). To a stirred 
solution of diisopropylamine (0.109 mL, 0.774 mmol) in THF (2 mL) at -10 °C was added n-
BuLi (1.6 in hexanes, 0.461 mL, 0.737 mmol), stirred for 20 min, and cooled to -78 °C. To this 
solution was added a solution of tert-butyl 3-oxo-4,5-dihydrobenzo[cd]indole-1(3H)-carboxylate 
(100.0 mg, 0.3686 mmol) in THF (2 mL), stirred for 30 min, treated with methyl cyanoformate 
(100.0 µL, 1.260 mmol), and stirred at -78 °C for 45 min. The reaction was quenched with 
saturated aqueous NH4Cl, and extracted with EtOAc (4 x 15 mL). The combined organic layers 
were washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification by 
chromatography on SiO2 (10% EtOAc/hexanes) gave 4-44 (78.2 mg, 75%) as a white solid: Mp 
156.6-158.2 °C; IR (ATR) 2975, 2950, 1728, 1374, 1245, 1105 cm-1; 1H NMR (CDCl3, 400 
MHz) δ 12.51 (s, 1 H), 7.70-7.60 (br s, 1 H), 7.67 (s, 1 H), 7.26 (t, 1 H, J = 8.0 Hz), 7.02 (d, 1 H, 
J = 7.2 Hz), 3.96 (s, 2 H), 3.86 (s, 3 H), 1.69 (s, 9 H); 13C NMR (CDCl3, 75 MHz) δ 172.9, 
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162.0, 149.5, 133.7, 129.0, 128.4, 126.2, 120.8, 120.3, 113.3, 112.4, 97.5, 84.1, 51.7, 28.7, 28.1; 
HRMS (TOF ESI) m/z calcd for C18H19NO5Na [M+Na]+ 352.1161, found 352.1199. 
N
Boc
OTf
CO2CH3
 
1-tert-Butyl 4-ethyl 3-(((trifluoromethyl)sulfonyl)oxy)benzo[cd]indole-1,4(5H)-dicarboxyla-
te (4-46). To a suspension of NaH (291.7 mg, 12.16 mmol) in THF (2 mL) at 0 °C was added a 
solution of 4-44 (727.9 mg, 2.210 mmol) in THF (6 mL), and stirred at room temperature for 2 h. 
The reaction mixture was cooled to 0 °C, treated with a solution of Comins reagent (2.13 g, 5.41 
mmol) in THF (5 mL), and stirred at room temperature for 2.5 h. The reaction mixture was 
slowly transferred to a cold saturated aqueous NH4Cl (25 mL), and extracted with EtOAc (4 x 20 
mL). The combined organic layers were washed with brine, dried (Na2SO4), and concentrated in 
vacuo. Purification by chromatography on SiO2 (5% EtOAc/ hexanes) gave 4-46 (1.01 g, 99%) 
as an off-white solid: IR (ATR) 2975, 1735, 1718, 1232, 1197 cm-1; 1H NMR (500 MHz, CDCl3) 
 7.69 (s, 1 H), 7.54 (s, 1 H), 7.32 (t, 1 H, J = 8.0 Hz), 7.06 (dd, 1 H, J = 7.5, 0.5 Hz), 4.36 (s, 2 
H), 3.89 (s, 3 H), 1.69 (s, 9 H); 13C NMR (CDCl3, 125 MHz) δ 164.9, 149.2, 144.9, 133.7, 128.6, 
127.3, 126.8, 120.8, 120.4, 119.9, 118.5 (q, J = 318 Hz), 113.1, 112.1, 84.9, 52.3, 33.5, 28.1; 
HRMS (ESI) m/z calcd for C19H19NO7SF3 [M+H]+ 462.0834, found 462.0802. 
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1-tert-Butyl 4-methyl benzo[cd]indole-1,4(5H)-dicarboxylate (4-36). To the solution of 4-46 
(370.0 mg, 0.8019) in DMF (5.7 mL) were added Pd(PPh3)4 (43.7 mg, 0.0379 mmol) and Et3SiH 
(250 µL, 1.56 mmol), heated to 60 °C for 2 h, diluted with water, and extracted with EtOAc (6 x 
10 mL). The combined organic layers were washed with water, brine, dried (Na2SO4), and 
concentrated in vacuo. Purification by chromatography on SiO2 (10% EtOAc/hexanes) gave 4-36 
(133.1 mg, 53%) as colorless oil: IR (ATR) 3286, 2982, 2947, 1724, 1702, 1364, 1128 cm-1; 1H 
NMR (CD2Cl2, 400 MHz) δ 7.67 (d, 1 H, J = 2.0 Hz), 7.66 (d, 1 H, J = 2.0 Hz), 7.46 (br s, 1 H), 
7.26 (app t, 1 H, J = 7.6 Hz), 7.05 (dd, 1 H, J = 7.2, 0.4 Hz), 4.02 (s, 2 H), 3.80 (s, 3 H), 1.66 (s, 
9 H); 13C NMR (CD2Cl2, 75 MHz) δ 167.3, 129.6, 129.5, 128.7, 126.9, 121.8, 121.0, 116.3, 
113.0, 84.3, 52.1, 29.6, 28.2. 
N
Boc
CHO
 
tert-Butyl 3-formyl-1H-indole-1-carboxylate.208 To a stirred solution of 3-indolecarbaldehyde  
(2.00 g, 13.8 mmol) in acetonitrile (25 mL) were added Boc2O (3.91 g, 17.9 mmol) and DMAP 
(168.3 mg, 1.378 mmol), and stirred at room temperature for 12 h. The reaction mixture was 
diluted with EtOAc (10 mL), sequentially washed with 1.0 M aqueous HCl (5 mL), water, brine, 
dried (Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (10 
EtOAc/hexanes) gave the tert-Butyl 3-formyl-1H-indole-1-carboxylate (3.28 g, 97%) as a white 
solid: IR (ATR) 3059, 2816, 1741, 1676, 1357, 1131, 759 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
 178 
10.12 (s, 1 H), 8.30 (d, 1 H, J = 6.8 Hz), 8.25 (s, 1 H), 8.16 (d, 1 H, J = 7.6 Hz), 7.43 (dt, 1 H, J 
= 7.6, 1.6 Hz), 7.39 (dt, 1 H, J = 7.6, 1.2 Hz), 1.72 (s, 9 H); 13C NMR (CDCl3, 100 MHz) δ 
185.7, 148.7, 136.5, 135.9, 126.0 (2C), 124.5, 122.1, 121.5, 115.1, 85.6, 28.0; HRMS (TOF ESI) 
m/z calcd for C14H15NO3 245.1052, found 245.1041. 
N
Boc
CO2CH3
 
(E)-tert-Butyl 3-(3-methoxy-3-oxoprop-1-enyl)-1H-indole-1-carboxylate (4-48).209 To a 
solution of LiCl (112.3 mg, 2.650 mmol) in CH3CN (15 mL) at room temperature was added 
trimethyl phosphonoacetate (0.38 mL, 2.6 mmol), followed by DBU (0.39 mL, 2.6 mmol). To 
this mixture was added a solution of tert-butyl 3-formyl-1H-indole-1-carboxylate (0.50 g, 2.0 
mmol) in acetonitrile (2 mL), stirred at room temperature for 1 h, and diluted with Et2O (20 mL). 
The organic layer was washed with 10% aqueous HCl, saturated aqueous NaHCO3, brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (15% EA/ 
hexanes) gave 4-48 (0.48 g, 78%) as a white solid: Mp 82.4-85.6 °C; IR (ATR) 3059, 2975, 
1713, 1359, 1142, 1090 cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.20 (d, 1 H, J = 8.0 Hz), 7.82-7.87 
(m, 3 H), 7.39 (t, 1 H, J = 7.2 Hz), 7.34 (t, 1 H, J = 7.6 Hz), 6.56 (d, 1 H, J = 16.4 Hz), 3.83 (s, 3 
H), 1.69 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 167.8, 149.1, 136.6, 136.2, 128.7, 127.8, 125.2, 
123.6, 120.2, 116.9, 116.7, 115.5, 84.7, 51.6, 28.1; HRMS (TOF ESI) m/z calcd for 
C17H19NO4Na [M+Na]+ calcd 324.1212, found 324.1215. 
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(Z)-1-tert-Butyl 5-methyl 3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)-2-(1,7,7-trimethylbicy-
clo[2.2.1]heptan-2-ylideneamino)pentanedioate (4-49). To a solution of DIPA (151 µL, 1.07 
mmol) in THF (1 mL) at 0 °C was added n-BuLi (1.6 M in hexanes, 667 µL, 1.07 mmol), stirred 
at room temperature for 15 min, and cooled to -78 °C. To this solution were added imine 4-37 
(300.0 mg, 1.130 mmol) as a solution in THF (1 mL), then t-BuOH (100 µL, 1.07 mmol) as a 
solution in THF (0.5 mL), and indole 4-48 (321.5 mg, 1.067 mmol) as a solution in THF (1 mL), 
in this order. The reaction mixture was stirred at -78 °C for 3.5 h, quenched with water, and 
extracted with EtOAc (5 x 5 mL). The combined organic layers were washed with brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by chromatography on SiO2 (20% 
EtOAc/hexanes) gave 4-49 (429.2 mg, 67%) as a colorless oil: IR (ATR) 3027, 2934, 1728, 
1366, 1148 cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.11 (br s, 1 H), 7.68 (d, 1 H, J = 7.2 Hz), 7.38 
(br s, 1 H), 7.32-7.22 (m, 3 H), 4.23-4.12 (m, 1 H), 4.13 (d, 1 H, J = 6.0 Hz), 3.54 (s, 2 H), 3.53 
(s, 1 H), 2.97-2.84 (m, 2 H), 2.22 (dt, 1 H, J = 16.8, 4.0 Hz), 1.90-1.73 (m, 3 H), 1.65 (s, 9 H), 
1.36 (s, 3 H), 1.32 (s, 9 H), 1.02 (s, 3 H), 0.89 (s, 3 H), 0.74 (s, 3 H); 13C NMR (CDCl3, 100 
MHz) δ 186.3, 172.8, 170.1, 149.6, 135.2, 129.9, 124.3, 123.1, 122.4, 120.8, 119.3, 115.1; 
HRMS (TOF ESI) m/z calcd for C33H47N2O6 [M+H]+ 567.3434, found 567.3427. 
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Nt-BuO2C  
tert-Butyl 2-((Z)-((1R,4S)-1,7,7─trimethylbicyclo[2.2.1]heptan─2─ylidene)amino)acetate (4-
37). To a solution of (S)-camphor (2.00 g, 13.1 mmol) in DME (20 mL) at room temperature was 
added a mixture of P2S5 (5.8 g, 26 mmol) and NaHCO3 (5.8 g, 71 mmol) slowly (in 1.5 g 
portions), and stirred at room temperature for 30 min. The solution was heated to 90 °C slowly, 
and then the rest of the P2S5/NaHCO3 mixture was added at 90 °C. The mixture was stirred at 
this temperature for 1 h, then cooled to room temperature, poured into ice-water (70 mL), stirred 
for 30 min, and filtered off. The residue (yellowish thick liquid) was dissolved in toluene, 
concentrated in vacuo. This procedure was repeated 3 times, to obtain crude (S)-thiocamphor 
(1.23 g, 56%), which was used in the next step without further purification or characterization. 
To a solution of t-butyl glycinate (1.0 g, 7.6 mmol) in toluene (12.5 mL) was added thiocamphor 
(1.23 g, 7.31 mmol) in one portion. The mixture was heated to 110 °C for 14 h, concentrated in 
vacuo, and purified by column chromatography on SiO2 (20% EtOAc/hexanes) to obtain 4-37 
(1.28 g, 70%) as a yellowish oil: IR (ATR) 2956, 2885, 1735, 1146 cm-1; 1H NMR (CDCl3, 500 
MHz) δ 4.03 (d, 1 H, J = 16.5 Hz), 3.96 (d, 1 H, J = 16.5 Hz), 2.30 (dt, 1 H, J = 17.0, 3.5 Hz), 
1.95 (t, 1 H, J = 4.5 Hz), 1.88-1.83 (m, 1 H), 1.80 (d, 1 H, J = 17.0 Hz), 1.68 (dt, 1 H, J = 12.5, 
4.5 Hz), 1.48-1.40 (m, 1 H), 1.45 (s, 9 H), 1.21 (ddd, 1 H, J = 13.0, 9.5, 4.5 Hz), 1.01 (s, 3 H), 
0.93 (s, 3 H), 0.79 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ 187.0, 169.5, 80.9, 54.7, 54.1, 47.2, 
43.8, 35.6, 31.9, 28.1, 27.4, 19.6, 18.9, 11.2; HRMS (TOF ESI) m/z calcd for C16H28NO2 
[M+H]+ 266.2120, found 266.2115. 
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tert-Butyl 3-(2-(tert-butoxycarbonyl)-5-oxopyrrolidin-3-yl)-1H-indole-1-carboxylate (4-50). 
To a solution of 4-49 (200.0 mg, 0.3529 mmol) in EtOH (1 mL) were added hydroxylamine 
hydrochloride (49.0 mg, 0.706 mmol) and sodium acetate trihydrate (96.0 mg, 0.706 mmol), 
heated to reflux for 12 h, cooled to room temperature, and then concentrated in vacuo. 
Purification by chromatography on SiO2 (20% EtOAc/hexanes) gave 4-50 (98.6 mg, 70%) as a 
white solid: IR (ATR) 3301, 2975, 1713, 1702, 1698, 1359, 1146 cm-1; 1H NMR (CDCl3, 400 
MHz) δ 8.20 (d, 1 H, J = 7.2 Hz), 7.62 (d, 1 H, J = 7.6 Hz), 7.53 (s, 1 H), 7.38 (t, 1 H, J = 7.6 
Hz), 7.29 (t, 1 H, J = 7.2 Hz), 6.30 (br s, 1 H), 4.30 (d, 1 H, J = 4.4 Hz), 3.98-3.93 (m, 1 H), 2.92 
(dd, 1 H, J = 17.6, 9.6 Hz), 2.65 (dd, 1 H, J = 17.2, 5.6 Hz), 1.69 (s, 9 H), 1.51 (s, 9 H); 13C 
NMR (CDCl3, 100 MHz) δ 176.8, 170.4, 149.4, 135.9, 128.6, 124.8, 122.7, 122.4, 120.9, 118.8, 
115.6, 83.9, 82.8, 61.8, 36.0, 35.4, 28.1, 27.9; HRMS (TOF ESI) m/z calcd for C22H29N2O5 
[M+H]+ 401.2076, found 401.2079. 
Bn
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tert-Butyl 3-(1-benzyl-2-(tert-butoxycarbonyl)-5-oxopyrrolidin-3-yl)-1H-indole-1-carboxyla-
te. To a suspension of NaH (1.5 mg, 0.062 mmol) in THF (0.2 mL) at room temperature was 
added 4-50 (25.0 mg, 0.0624 mmol), stirred at room temperature for 15 min, and then treated 
with benzyl bromide (7.4 µL, 0.062 mmol). The mixture was heated to reflux for 5 h, cooled to 
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room temperature, diluted with EtOAc (5 mL), and slowly quenched with water. After extraction 
with EtOAc (4 x 5 mL), the combined organic layers were washed with brine, dried (Na2SO4), 
and concentrated in vacuo. Purification on SiO2 (30% EtOAc/hexanes) gave tert-butyl 3-(1-
benzyl-2-(tert-butoxycarbonyl)-5-oxopyrrolidin-3-yl)-1H-indole-1-carboxylate (20.1 mg, 66%) 
as a white solid: IR (ATR) 2973, 1724, 1696, 1146 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.13 (d, 
1 H, J = 7.8 Hz), 7.42-7.16 (m, 9 H), 5.04 (d, 1 H, J = 14.7 Hz), 4.09 (d, 1 H, J = 14.7 Hz), 3.95 
(d, 1 H, J = 3.0 Hz), 3.75 (dt, 1 H, J = 9.3, 3.0 Hz), 3.08 (dd, 1 H, J = 17.1, 9.3 Hz), 2.68 (dd, 1 
H, J = 17.1, 3.9 Hz), 1.67 (s, 9 H), 1.47 (s, 9 H); 13C NMR (CDCl3, 100 MHz) δ 174.0, 170.2, 
149.4, 135.5, 128.6 (2C), 128.5, 127.8, 124.8, 122.6, 121.9, 121.2, 118.7, 115.5, 83.9, 82.7, 65.6, 
45.8, 36.1, 33.1, 28.2, 27.9. 
Bn
N
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Boc  
tert-Butyl 3─((2R)─1─benzyl-2-(tert-butoxycarbonyl)-5-thioxopyrrolidin-3-yl)-1H-indole-1-
carboxylate (4-56). To a solution of tert-butyl 3-(1-benzyl-2-(tert-butoxycarbonyl)-5-
oxopyrrolidin-3-yl)-1H-indole-1-carboxylate (20.0 mg, 0.0408 mmol) in toluene (1.5 mL) was 
added Lawesson's reagent (10.7 mg, 0.0265 mmol), heated to 100 °C for 2 h, and cooled to room 
temperature. The reaction mixture was concentrated in vacuo, and purified by column 
chromatography (15% EtOAc in hexanes) to obtain 4-56 (19.0 mg, 92%) as a white solid: IR 
(ATR) 3059, 2978, 1726, 1452, 1146 cm-1; 1H NMR (CDCl3, 400 MHz) δ 8.12 (d, 1 H, J = 8.0 
Hz), 7.39-7.17 (m, 10 H), 4.41 (d, 1 H, J = 14.8 Hz), 4.23 (d, 1 H, J = 3.2 Hz), 3.81 (dt, 1 H, J = 
8.4, 2.8 Hz), 3.63 (dd, 1 H, J = 17.6, 8.4 Hz), 3.35 (dd, 1 H, J = 17.6, 3.2 Hz), 1.68 (s, 9 H), 1.48 
(s, 9 H); 13C NMR (CDCl3, 100 MHz) δ 202.4, 168.5, 149.4, 135.7, 134.2, 128.7, 128.6, 128.4, 
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128.1, 124.8, 122.6, 122.1, 120.3, 118.5, 115.5, 84.0, 83.3, 72.2, 50.7, 49.4, 35.2, 28.1, 27.9; 
HRMS (TOF ESI) m/z calcd for C29H35N2O4S [M+H]+ 507.2318, found 507.2333. 
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(6aR,9S,9aR)-Di-tert-butyl 7-oxo-6,6a,7,8,9,9a-hexahydro-2H-isoindolo[4,5,6-cd]indole-2,9-           
dicarboxylate (4-53). To a solution of diisopropylamine (8.9 µL, 0.064 mmol) in THF (0.1 mL) 
at 0 °C was added n-BuLi (1.6 M in hexanes, 39.5 µL, 0.063 mmol), stirred for 15 min, and 
cooled to -78 °C. To this solution was added a solution of imine 4-37 (16.7 mg, 0.063 mmol) in 
THF (0.1 mL), t-BuOH (6.0 µL, 0.063 mmol), and a solution of 4-36 (19.8 mg, 0.063 mmol) in 
THF (0.1 mL). This mixture was stirred at -78 °C for 3 h, warmed to -30 °C for 45 min, 
quenched with saturated aqueous NH4Cl, extracted with EtOAc (4 x 10 mL), dried (Na2SO4), 
and concentrated in vacuo. Purification by chromatography on SiO2 (10-15% EtOAc/hexanes) 
gave the corresponding indole 4-35 (21.8 mg, 84%) as colorless oil, which was subjected to the 
next step directly, without further characterization. To a solution of 4-35 (48.9 mg, 0.0845 
mmol) in EtOH (0.3 mL) were added hydroxylamine hydrochloride (11.7 mg, 0.169 mmol) and 
sodium acetate trihydrate (23.0 mg, 0.169 mmol), heated 80 °C for 12 h, and then concentrated 
in vacuo. Purification by chromatography on SiO2 (20% EtOAc/hexanes) gave 4-53 (26.6 mg, 
76%) as a white solid: Mp 97.8-98.9 °C; []D –29.2 (c 0.59, CHCl3); IR (ATR) 3107, 3059, 
2975, 1717, 1700, 1146 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.79 (br s, 1 H), 7.54 (s, 1 H), 7.27 
(t, 1 H, J = 8.0 Hz), 7.07 (d, 1 H, J = 7.5 Hz), 6.10 (s, 1 H), 4.14 (C(5)-H, d, 1 H, J = 4.0 Hz), 
3.93 (C(4)-H, ddd, 1 H, J = 7.0, 4.5, 1.0 Hz), 3.28, 3.22 (C(12)-H and C(12)-H’, d of AB, 2 H, J 
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= 17.0, 6.5 Hz), 3.10 (C(11)-H, app q, 1 H, J = 6.5 Hz), 1.68 (s, 9 H), 1.58 (s, 9 H); 13C NMR 
(CDCl3, 100 MHz) δ 177.9, 170.1, 149.9, 133.0, 128.0, 127.6, 125.3, 121.3, 120.3, 115.7, 112.9, 
83.7, 82.9, 61.6, 40.3, 36.4, 28.1, 28.0, 25.1; HRMS (TOF ESI) m/z calcd for C23H28N2O5 
[M+H]+ 413.2076, found 413.2070. 
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(6aR,9S,9aR)-Di-tert-butyl 7-oxo-6,6a,7,8,9,9a-hexahydro─2H-isoindolo[4,5,6-cd]indole-2,9-
dicarboxylate (4-58). To a suspension of NaH (0.7 mg, 0.03 mmol) in THF (0.3 mL) at room 
temperature was added a solution of 4-53 (11.9 mg, 0.0288 mmol) in THF (0.3 mL), stirred at 
room temperature for 15 min, and then treated with benzyl bromide (3.5 µL, 0.029 mmol). The 
mixture was heated to 66 °C for 2 h, cooled to room temperature, diluted with EtOAc (5 mL), 
and slowly quenched with water. After extraction with EtOAc (4 x 5 mL), the combined organic 
layers were washed with brine, dried (Na2SO4), and concentrated in vacuo. Purification on SiO2 
(30% EtOAc/hexanes) gave 4-58 (11.4 mg, 79%) as a white solid: Mp 62.4-64.0 °C; 1H NMR 
(CDCl3, 500 MHz) δ 7.95 (s, 1 H), 7.28 (t, 1 H), 7.20-7.10 (m, 5 H), 6.77 (d, 1 H, J = 7.5 Hz), 
4.96 (d, 1 H, J = 14.5 Hz), 3.96 (d, 1 H, J = 15.0 Hz), 3.80 (s, 1 H), 3.80-3.79 (m, 1 H), 3.47 (dd, 
1 H, J = 16.5, 3.0 Hz), 3.33-3.29 (m, 1 H), 3.16 (dd, 1 H, J = 17.0, 6.5 Hz), 1.68 (s, 9 H), 1.51 (s, 
9 H); 13C NMR (CDCl3, 125 MHz) δ 174.8, 169.7, 149.8, 135.4, 133.0, 128.2, 127.9, 127.5, 
125.5, 120.6, 116.0, 112.8, 83.6, 82.7, 65.2, 45.8, 40.4, 35.2, 28.2, 28.0, 24.9; HRMS (TOF ESI) 
m/z calcd for C30H35N2O5 [M+H]+ 503.2546, found 503.2562. 
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N
Boc
NBn
H
H
CO2t-Bu
H
S
 
(6aR,9S,9aR)-Di-tert-butyl 7-thioxo-6,6a,7,8,9,9a─hexahydro─2H-isoindolo[4,5,6-cd]indole-
2,9-dicarboxylate (4-54). To a solution of 4-58 (11.0 mg, 0.0219 mmol) in toluene (1.0 mL) was 
added Lawesson's reagent (5.7 mg, 0.014 mmol), heated to 100 °C for 12 h, and cooled to room 
temperature. The reaction mixture was concentrated in vacuo, and purified by column 
chromatography (15% EtOAc/hexanes) to obtain 4-54 (8.8 mg, 77%) as a white solid: IR (ATR) 
2975, 2934, 1726, 1146 cm-1; 1H NMR (CDCl3, 500 MHz) δ 7.79 (br s, 1 H), 7.30 (t, 1 H, J = 7.5 
Hz), 7.23 (t, 1 H, J = 7.5 Hz), 7.17-7.13 (m, 3 H), 7.10 (br s, 1 H), 6.85 (s, 1 H), 6.83 (s, 1 H), 
5.78 (d, 1 H, J = 14.5 Hz), 4.28 (d, 1 H, J = 15.0 Hz), 4.10 (d, 1 H, J = 2.5 Hz), 3.91 (dt, 1 H, J = 
6.0, 2.0 Hz), 3.79 (17.0, 4.0 Hz), 3.59 (ddt, 1 H, J = 5.5, 4.5, 1.5 Hz), 3.30 (dd, 1 H, J = 16.5, 6.0 
Hz), 1.69 (s, 9 H), 1.54 (s, 9 H); 13C NMR (CDCl3, 125 MHz) δ 205.1, 168.1, 149.7, 134.1, 
132.9, 128.3 (2C), 128.1 (2C), 128.0, 125.6, 120.8, 120.7, 115.2, 112.7, 83.6, 83.4, 70.5, 51.4, 
50.9, 37.2, 28.2, 28.1, 28.0; HRMS (TOF ES) m/z calcd for C30H35N2O4S [M+H]+ 519.2318, 
found 519.2301. 
N
Boc
NBn
H
H
CO2t-Bu
H
CH3H3C
 
(6aR,9S,9aR)-Di-tert-butyl 8-benzyl─7,7-dimethyl─6,6a,7,8,9,9a─hexahydro─2H-isoindolo-
[4,5,6-cd]indole-2,9-dicarboxylate (4-59). A solution of amide 4-58 (20.0 mg, 0.0398 mmol) 
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and 2,6-di-tert-butyl-4-methylpyridine (9.8 mg, 0.048 mmol) in CH2Cl2 (0.4 mL) at -78 °C was 
treated with Tf2O (7.9 µL, 0.048 mmol), and stirred at -78 °C for 45 min. A solution of 
CH3MgBr (1.0 M in ether, 120 µL, 0.119 mmol) was added dropwise to the resultant mixture, 
warmed slowly to room temperature, and stirred for 13 h. The reaction mixture was quenched 
with saturated aqueous NH4Cl, extracted with CH2Cl2 (5 x 2 mL), washed with brine, dried 
(Na2SO4), and concentrated in vacuo. Purification by preparative TLC (20% EtOAc/hexanes) 
gave 4-59 (3.4 mg, 17%) as colorless oil, along with the recovered starting material 4-58 (18.7 
mg). 4-59: 1H NMR (400 MHz, CDCl3): 7.55 (s, 1 H), 7.32-7.22 (m, 6 H), 7.18 (d, 1 H, J = 2.8 
Hz), 7.02 (d, 1 H, J = 7.2 Hz), 3.98 (d, 1 H, J = 14.4 Hz), 3.65 (d, 1 H, J = 14 Hz), 3.58-3.51 (m, 
2 H), 3.45 (dt, 1 H, J = 6.4, 3.2 Hz), 3.15 (dd, 1 H, J = 16.8, 6.8 Hz), 2.95 (dd, 1 H, J = 16.8, 4.8 
Hz), 2.58 (dd, 1 H, J = 12.4, 6.4 Hz), 1.67 (s, 9 H), 1.35 (s, 9 H), 1.30 (s, 3 H), 0.80 (s, 3 H); 
HRMS (ESI) m/z calcd for C32H41N2O4 [M+H]+ 517.3066, found 517.3052. 
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Figure 23. X-ray structure of 3-99 
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Table 6. Crystal data and structure refinement for 3-99 
Identification code fp1215s 
Empirical formula  C16 H18 N2 
Formula weight  238.32 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 7.871(5) Å a= 90°. 
 b = 18.239(11) Å b= 101.954(11)°. 
 c = 8.966(5) Å g = 90°. 
Volume 1259.2(13) Å3 
Z 4 
Density (calculated) 1.257 Mg/m3 
Absorption coefficient 0.074 mm-1 
F(000) 512 
Crystal size 0.18 x 0.14 x 0.03 mm3 
Theta range for data collection 2.23 to 25.00°. 
Index ranges -9<=h<=9, -21<=k<=21, -10<=l<=10 
Reflections collected 9489 
Independent reflections 2225 [R(int) = 0.1244] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9978 and 0.9867 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2225 / 0 / 164 
Goodness-of-fit on F2 1.015 
Final R indices [I>2sigma(I)] R1 = 0.0745, wR2 = 0.1806 
R indices (all data) R1 = 0.1336, wR2 = 0.2023 
Extinction coefficient 0.010(4) 
Largest diff. peak and hole 0.286 and -0.262 e.Å-3 
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Table 7. Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) for 3-99   
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
N(1) -1045(3) -6393(2) -3037(3) 42(1) 
C(1) 238(4) -6988(2) -2862(4) 48(1) 
N(2) -505(3) -5960(2) 3762(3) 46(1) 
C(2) 1839(4) -6688(2) -1818(4) 45(1) 
C(3) 2241(4) -5890(2) -2096(4) 46(1) 
C(4) 1165(4) -6064(2) -914(3) 40(1) 
C(5) 1871(4) -5907(2) 738(3) 38(1) 
C(6) 3512(4) -5689(2) 1450(4) 47(1) 
C(7) 3919(4) -5552(2) 3043(4) 48(1) 
C(8) 2703(4) -5626(2) 3955(4) 47(1) 
C(9) 1032(4) -5838(2) 3251(4) 41(1) 
C(10) 622(4) -5977(2) 1674(4) 40(1) 
C(11) -1803(4) -6161(2) 2533(4) 45(1) 
C(12) -1133(4) -6179(2) 1215(4) 39(1) 
C(13) -1861(4) -6403(2) -414(4) 42(1) 
C(14) -799(4) -6027(2) -1506(3) 41(1) 
C(15) -2828(4) -6623(2) -3691(4) 53(1) 
C(16) 3258(4) -7218(2) -1111(4) 57(1) 
________________________________________________________________________________ 
 191 
 
Table 8. Bond lengths [Å] and angles [°] for 3-99 
N(1)-C(15)  1.466(4) 
N(1)-C(1)  1.470(4) 
N(1)-C(14)  1.503(4) 
C(1)-C(2)  1.508(5) 
C(1)-H(1A)  0.9800 
C(1)-H(1B)  0.9800 
N(2)-C(11)  1.388(4) 
N(2)-C(9)  1.398(4) 
N(2)-H(2A)  0.8700 
C(2)-C(16)  1.513(5) 
C(2)-C(3)  1.522(5) 
C(2)-C(4)  1.553(5) 
C(3)-C(4)  1.521(4) 
C(3)-H(3A)  0.9800 
C(3)-H(3B)  0.9800 
C(4)-C(5)  1.498(4) 
C(4)-C(14)  1.528(5) 
C(5)-C(6)  1.375(4) 
C(5)-C(10)  1.424(4) 
C(6)-C(7)  1.420(5) 
C(6)-H(6A)  0.9400 
C(7)-C(8)  1.389(5) 
C(7)-H(7A)  0.9400 
C(8)-C(9)  1.390(5) 
C(8)-H(8A)  0.9400 
C(9)-C(10)  1.406(5) 
C(10)-C(12)  1.407(5) 
C(11)-C(12)  1.391(5) 
C(11)-H(11A)  0.9400 
C(12)-C(13)  1.510(4) 
C(13)-C(14)  1.571(4) 
C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
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C(14)-H(14A)  0.9900 
C(15)-H(15A)  0.9700 
C(15)-H(15B)  0.9700 
C(15)-H(15C)  0.9700 
C(16)-H(16A)  0.9700 
C(16)-H(16B)  0.9700 
C(16)-H(16C)  0.9700 
 
C(15)-N(1)-C(1) 114.2(3) 
C(15)-N(1)-C(14) 115.1(3) 
C(1)-N(1)-C(14) 106.0(2) 
N(1)-C(1)-C(2) 105.4(3) 
N(1)-C(1)-H(1A) 110.7 
C(2)-C(1)-H(1A) 110.7 
N(1)-C(1)-H(1B) 110.7 
C(2)-C(1)-H(1B) 110.7 
H(1A)-C(1)-H(1B) 108.8 
C(11)-N(2)-C(9) 109.1(3) 
C(11)-N(2)-H(2A) 125.5 
C(9)-N(2)-H(2A) 125.5 
C(1)-C(2)-C(16) 118.5(3) 
C(1)-C(2)-C(3) 114.9(3) 
C(16)-C(2)-C(3) 121.3(3) 
C(1)-C(2)-C(4) 105.0(3) 
C(16)-C(2)-C(4) 123.5(3) 
C(3)-C(2)-C(4) 59.3(2) 
C(4)-C(3)-C(2) 61.4(2) 
C(4)-C(3)-H(3A) 117.6 
C(2)-C(3)-H(3A) 117.6 
C(4)-C(3)-H(3B) 117.6 
C(2)-C(3)-H(3B) 117.6 
H(3A)-C(3)-H(3B) 114.7 
C(5)-C(4)-C(3) 120.2(3) 
C(5)-C(4)-C(14) 118.4(3) 
C(3)-C(4)-C(14) 114.7(3) 
C(5)-C(4)-C(2) 124.0(3) 
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C(3)-C(4)-C(2) 59.3(2) 
C(14)-C(4)-C(2) 106.4(3) 
C(6)-C(5)-C(10) 116.7(3) 
C(6)-C(5)-C(4) 129.4(3) 
C(10)-C(5)-C(4) 113.9(3) 
C(5)-C(6)-C(7) 120.8(3) 
C(5)-C(6)-H(6A) 119.6 
C(7)-C(6)-H(6A) 119.6 
C(8)-C(7)-C(6) 122.4(3) 
C(8)-C(7)-H(7A) 118.8 
C(6)-C(7)-H(7A) 118.8 
C(7)-C(8)-C(9) 117.5(3) 
C(7)-C(8)-H(8A) 121.2 
C(9)-C(8)-H(8A) 121.2 
C(8)-C(9)-N(2) 134.2(3) 
C(8)-C(9)-C(10) 120.3(3) 
N(2)-C(9)-C(10) 105.5(3) 
C(9)-C(10)-C(12) 110.4(3) 
C(9)-C(10)-C(5) 122.3(3) 
C(12)-C(10)-C(5) 127.4(3) 
N(2)-C(11)-C(12) 109.5(3) 
N(2)-C(11)-H(11A) 125.2 
C(12)-C(11)-H(11A) 125.2 
C(11)-C(12)-C(10) 105.5(3) 
C(11)-C(12)-C(13) 133.9(3) 
C(10)-C(12)-C(13) 120.5(3) 
C(12)-C(13)-C(14) 109.9(3) 
C(12)-C(13)-H(13A) 109.7 
C(14)-C(13)-H(13A) 109.7 
C(12)-C(13)-H(13B) 109.7 
C(14)-C(13)-H(13B) 109.7 
H(13A)-C(13)-H(13B) 108.2 
N(1)-C(14)-C(4) 103.1(2) 
N(1)-C(14)-C(13) 113.0(3) 
C(4)-C(14)-C(13) 113.3(3) 
N(1)-C(14)-H(14A) 109.1 
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C(4)-C(14)-H(14A) 109.1 
C(13)-C(14)-H(14A) 109.1 
N(1)-C(15)-H(15A) 109.5 
N(1)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
N(1)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
C(2)-C(16)-H(16A) 109.5 
C(2)-C(16)-H(16B) 109.5 
H(16A)-C(16)-H(16B) 109.5 
C(2)-C(16)-H(16C) 109.5 
H(16A)-C(16)-H(16C) 109.5 
H(16B)-C(16)-H(16C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 9. Anisotropic displacement parameters  (Å2x103) for 3-99 
The anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
N(1) 45(2)  51(2) 34(2)  -5(1) 15(1)  -1(1) 
C(1) 55(2)  55(2) 40(2)  -3(2) 20(2)  -4(2) 
N(2) 42(2)  65(2) 35(2)  1(1) 17(1)  2(1) 
C(2) 44(2)  54(2) 41(2)  -2(2) 20(2)  -3(2) 
C(3) 49(2)  62(2) 34(2)  -1(2) 21(2)  -10(2) 
C(4) 43(2)  46(2) 35(2)  1(2) 18(2)  -2(2) 
C(5) 42(2)  44(2) 32(2)  0(1) 16(2)  1(2) 
C(6) 43(2)  59(2) 43(2)  1(2) 19(2)  -1(2) 
C(7) 41(2)  62(2) 41(2)  -2(2) 12(2)  -6(2) 
C(8) 52(2)  60(2) 32(2)  0(2) 13(2)  0(2) 
C(9) 40(2)  53(2) 36(2)  0(2) 19(2)  2(2) 
C(10) 42(2)  47(2) 33(2)  0(2) 15(2)  0(2) 
C(11) 38(2)  56(2) 45(2)  1(2) 16(2)  -4(2) 
C(12) 40(2)  46(2) 34(2)  0(2) 16(2)  3(2) 
C(13) 36(2)  51(2) 41(2)  7(2) 13(2)  -1(2) 
C(14) 50(2)  46(2) 32(2)  -1(2) 15(2)  -3(2) 
C(15) 51(2)  71(3) 38(2)  -6(2) 13(2)  -3(2) 
C(16) 50(2)  65(3) 61(3)  -5(2) 24(2)  4(2) 
______________________________________________________________________________ 
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Table 10. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 103) 
                                                     x                        y                          z                               U(eq) 
H(1A) 492 -7123 -3852 58 
H(1B) -191 -7422 -2413 58 
H(2A) -629 -5917 4700 55 
H(3A) 3436 -5720 -1726 56 
H(3B) 1643 -5666 -3056 56 
H(6A) 4373 -5629 874 56 
H(7A) 5054 -5406 3497 57 
H(8A) 2998 -5536 5009 57 
H(11A) -2958 -6268 2584 54 
H(13A) -3083 -6257 -702 50 
H(13B) -1799 -6937 -509 50 
H(14A) -1155 -5507 -1650 50 
H(15A) -2865 -6855 -4671 79 
H(15B) -3586 -6198 -3826 79 
H(15C) -3215 -6969 -3009 79 
H(16A) 3487 -7553 -1886 86 
H(16B) 2890 -7494 -309 86 
H(16C) 4307 -6947 -686 86 
________________________________________________________________________________  
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Figure 24. X-ray structure of 3-125   
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Table 11. Crystal data and structure refinement for 3-125 
Identification code fp12411s 
Empirical formula  C12 H18 Cl3 N O 
Formula weight  298.62 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.816(3) Å α 90° 
 b = 10.136(3) Å β 97.281(7)° 
 c = 17.731(6) Å γ 90° 
Volume 1393.4(8) Å3 
Z 4 
Density (calculated) 1.424 Mg/m3 
Absorption coefficient 0.642 mm-1 
F(000) 624 
Crystal size 0.39 x 0.06 x 0.03 mm3 
Theta range for data collection 2.32 to 27.49°. 
Index ranges -9<=h<=10, -13<=k<=13, -23<=l<=23 
Reflections collected 13105 
Independent reflections 3200 [R(int) = 0.0473] 
Completeness to theta = 27.49° 100.0 %  
Absorption correction Multi-scan (Sadabs) 
Max. and min. transmission 0.9810 and 0.7879 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3200 / 0 / 226 
Goodness-of-fit on F2 0.995 
Final R indices [I>2sigma(I)] R1 = 0.0474, wR2 = 0.1034 
R indices (all data) R1 = 0.0736, wR2 = 0.1143 
Largest diff. peak and hole 0.372 and -0.291 e.Å-3 
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Table 12. Atomic coordinates  (x 104) and equivalent  isotropic displacement parameters (Å2 x 103) 
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
  ________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O 8363(2) 5206(2) 1907(1) 36(1) 
N 6947(2) 2807(2) 3705(1) 35(1) 
Cl(1) 7121(1) 1936(1) 703(1) 58(1) 
C(1) 5507(4) 3269(3) 4109(2) 44(1) 
Cl(2) 7786(1) 4545(1) 182(1) 50(1) 
C(2) 4084(3) 3694(2) 3494(1) 42(1) 
Cl(3) 10370(1) 3190(1) 1175(1) 55(1) 
C(3) 3786(4) 2724(3) 2846(2) 44(1) 
C(4) 4966(3) 3895(2) 2799(1) 35(1) 
C(5) 4613(4) 4881(2) 2167(1) 38(1) 
C(6) 5454(3) 4389(3) 1487(1) 38(1) 
C(7) 7378(3) 4079(2) 1687(1) 31(1) 
C(8) 7709(3) 3127(2) 2367(1) 32(1) 
C(9) 6856(3) 3665(2) 3025(1) 31(1) 
C(10) 2682(5) 4571(4) 3716(2) 60(1) 
C(11) 8111(3) 3467(2) 982(1) 39(1) 
C(12) 8593(4) 2901(3) 4190(2) 43(1) 
________________________________________________________________________________ 
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Table 13. Bond lengths [Å] and angles [°] for 3-125 
O-C(7) 1.405(2) 
O-H(1O)  0.80(3) 
N-C(12)  1.457(3) 
N-C(9)  1.480(3) 
N-C(1)  1.485(3) 
Cl(1)-C(11)  1.776(2) 
C(1)-C(2)  1.517(4) 
C(1)-H(1A)  0.90(3) 
C(1)-H(1B)  0.97(2) 
Cl(2)-C(11)  1.783(2) 
C(2)-C(4)  1.501(3) 
C(2)-C(3)  1.508(4) 
C(2)-C(10)  1.501(4) 
Cl(3)-C(11)  1.777(3) 
C(3)-C(4)  1.513(3) 
C(3)-H(3A)  0.92(2) 
C(3)-H(3B)  0.97(2) 
C(4)-C(9)  1.499(3) 
C(4)-C(5)  1.500(3) 
C(5)-C(6)  1.528(3) 
C(5)-H(5A)  0.92(2) 
C(5)-H(5B)  0.94(3) 
C(6)-C(7)  1.534(3) 
C(6)-H(6A)  0.88(2) 
C(6)-H(6B)  0.96(3) 
C(7)-C(8)  1.540(3) 
C(7)-C(11)  1.568(3) 
C(8)-C(9)  1.516(3) 
C(8)-H(8A)  0.95(2) 
C(8)-H(8B)  0.91(2) 
C(9)-H(9)  0.97(2) 
C(10)-H(10A)  0.92(4) 
C(10)-H(10B)  0.99(3) 
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C(10)-H(10C)  0.97(4) 
C(12)-H(12A)  0.99(2) 
C(12)-H(12B)  0.95(3) 
C(12)-H(12C)  0.95(3) 
 
C(7)-O-H(1O) 115(2) 
C(12)-N-C(9) 112.96(18) 
C(12)-N-C(1) 111.2(2) 
C(9)-N-C(1) 104.25(18) 
N-C(1)-C(2) 106.0(2) 
N-C(1)-H(1A) 107.9(16) 
C(2)-C(1)-H(1A) 112.0(15) 
N-C(1)-H(1B) 111.5(14) 
C(2)-C(1)-H(1B) 110.4(14) 
H(1A)-C(1)-H(1B) 109(2) 
C(4)-C(2)-C(3) 60.34(16) 
C(4)-C(2)-C(1) 104.9(2) 
C(3)-C(2)-C(1) 112.9(2) 
C(4)-C(2)-C(10) 124.1(2) 
C(3)-C(2)-C(10) 122.6(3) 
C(1)-C(2)-C(10) 118.3(3) 
C(4)-C(3)-C(2) 59.60(15) 
C(4)-C(3)-H(3A) 114.9(15) 
C(2)-C(3)-H(3A) 116.6(15) 
C(4)-C(3)-H(3B) 121.2(14) 
C(2)-C(3)-H(3B) 121.6(14) 
H(3A)-C(3)-H(3B) 113(2) 
C(2)-C(4)-C(9) 107.38(19) 
C(2)-C(4)-C(3) 60.06(16) 
C(9)-C(4)-C(3) 116.7(2) 
C(2)-C(4)-C(5) 130.1(2) 
C(9)-C(4)-C(5) 112.67(19) 
C(3)-C(4)-C(5) 120.6(2) 
C(4)-C(5)-C(6) 108.4(2) 
C(4)-C(5)-H(5A) 111.1(15) 
C(6)-C(5)-H(5A) 110.3(15) 
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C(4)-C(5)-H(5B) 111.9(14) 
C(6)-C(5)-H(5B) 108.8(14) 
H(5A)-C(5)-H(5B) 106(2) 
C(7)-C(6)-C(5) 113.03(19) 
C(7)-C(6)-H(6A) 107.5(15) 
C(5)-C(6)-H(6A) 110.1(15) 
C(7)-C(6)-H(6B) 108.7(14) 
C(5)-C(6)-H(6B) 108.7(15) 
H(6A)-C(6)-H(6B) 109(2) 
O-C(7)-C(6) 112.57(18) 
O-C(7)-C(8) 105.12(17) 
C(6)-C(7)-C(8) 111.83(19) 
O-C(7)-C(11) 107.49(18) 
C(6)-C(7)-C(11) 110.06(18) 
C(8)-C(7)-C(11) 109.56(17) 
C(9)-C(8)-C(7) 109.29(18) 
C(9)-C(8)-H(8A) 112.8(12) 
C(7)-C(8)-H(8A) 106.7(12) 
C(9)-C(8)-H(8B) 109.1(15) 
C(7)-C(8)-H(8B) 109.8(14) 
H(8A)-C(8)-H(8B) 109.1(18) 
N-C(9)-C(4) 104.70(17) 
N-C(9)-C(8) 115.74(18) 
C(4)-C(9)-C(8) 111.38(18) 
N-C(9)-H(9) 110.2(12) 
C(4)-C(9)-H(9) 107.9(12) 
C(8)-C(9)-H(9) 106.7(12) 
C(2)-C(10)-H(10A) 113(2) 
C(2)-C(10)-H(10B) 110.1(16) 
H(10A)-C(10)-H(10B) 105(3) 
C(2)-C(10)-H(10C) 112(2) 
H(10A)-C(10)-H(10C) 109(3) 
H(10B)-C(10)-H(10C) 107(3) 
C(7)-C(11)-Cl(1) 112.16(16) 
C(7)-C(11)-Cl(3) 111.27(15) 
Cl(1)-C(11)-Cl(3) 107.61(12) 
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C(7)-C(11)-Cl(2) 111.26(15) 
Cl(1)-C(11)-Cl(2) 107.56(12) 
Cl(3)-C(11)-Cl(2) 106.72(13) 
N-C(12)-H(12A) 111.5(14) 
N-C(12)-H(12B) 112.1(14) 
H(12A)-C(12)-H(12B) 112(2) 
N-C(12)-H(12C) 110.7(17) 
H(12A)-C(12)-H(12C) 108(2) 
H(12B)-C(12)-H(12C) 102(2) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 14. Anisotropic displacement parameters (Å2x103) for 3-125 
The anisotropic displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 ______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O 47(1)  26(1) 34(1)  3(1) -1(1)  -3(1) 
N 42(1)  31(1) 30(1)  3(1) 0(1)  -8(1) 
Cl(1) 91(1)  38(1) 43(1)  -12(1) -2(1)  -3(1) 
C(1) 51(2)  45(2) 39(1)  3(1) 9(1)  -13(1) 
Cl(2) 67(1)  53(1) 32(1)  10(1) 6(1)  11(1) 
C(2) 43(2)  42(1) 43(1)  4(1) 11(1)  -8(1) 
Cl(3) 51(1)  75(1) 41(1)  1(1) 5(1)  21(1) 
C(3) 40(2)  37(1) 52(2)  5(1) -5(1)  -8(1) 
C(4) 37(1)  30(1) 37(1)  0(1) 2(1)  -3(1) 
C(5) 37(1)  32(1) 44(1)  4(1) 1(1)  2(1) 
C(6) 44(2)  34(1) 34(1)  6(1) -3(1)  1(1) 
C(7) 40(1)  26(1) 28(1)  -1(1) 3(1)  -2(1) 
C(8) 37(1)  26(1) 32(1)  2(1) -1(1)  1(1) 
C(9) 39(1)  23(1) 31(1)  2(1) 3(1)  -6(1) 
C(10) 52(2)  65(2) 68(2)  7(2) 24(2)  -3(2) 
C(11) 49(2)  34(1) 31(1)  1(1) -1(1)  4(1) 
C(12) 49(2)  41(2) 35(1)  3(1) -6(1)  -7(1) 
______________________________________________________________________________ 
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Table 15. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) for 3-125 
x y z U(eq) 
H(1A) 5180(30) 2590(30) 4385(14) 41(7) 
H(1B) 5860(30) 4000(20) 4446(14) 46(7) 
H(3A) 2750(30) 2780(20) 2542(14) 39(7) 
H(3B) 4240(30) 1830(20) 2892(13) 42(7) 
H(5A) 5040(30) 5700(20) 2316(13) 40(7) 
H(5B) 3420(30) 4990(20) 2016(13) 39(7) 
H(6A) 5360(30) 4990(20) 1127(13) 36(6) 
H(6B) 4870(30) 3610(30) 1294(13) 44(7) 
H(8A) 8930(30) 3048(18) 2484(12) 24(5) 
H(8B) 7250(30) 2320(20) 2234(13) 40(7) 
H(9) 7390(30) 4510(20) 3158(11) 25(5) 
H(10A) 1870(50) 4790(30) 3310(20) 95(13) 
H(10B) 2020(40) 4100(30) 4077(16) 65(9) 
H(10C) 3150(50) 5370(40) 3970(20) 90(12) 
H(12A) 8840(30) 3820(20) 4363(13) 42(6) 
H(12B) 9510(30) 2530(20) 3956(14) 41(7) 
H(12C) 8590(30) 2360(30) 4629(17) 57(8) 
H(1O) 8160(40) 5830(30) 1637(16) 59(9) 
________________________________________________________________________________ 
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Table 16. Hydrogen bonds for 3-125 [Å and °] 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O-H(1O)...N#1 0.80(3) 2.09(3) 2.849(3) 159(3) 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y+1/2,-z+1/2       
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